# CURRICULUM VITAE

**Lisa M. Coussens, Ph.D., M.D. (*h.c.),* FAACR, FAIO**
Professor and Chairwoman, Cell, Developmental & Cancer Biology Department
Hildegard Lamfrom Endowed Chair in Basic Science
Deputy Director for Basic & Translational Research, Knight Cancer Institute

Oregon Health & Science University
Knight Cancer Research Bldg., Room 3030
2720 S Moody Ave., #KC-CDCB
Portland, OR 97201-5042

Voice: (503) 494-7811
Fax: (503) 494-4253
Email: coussenl@ohsu.edu
Web: https://www.ohsu.edu/cdcb/coussens

## I. EDUCATION:

| | | | |
|---|---|---|---|
| 1976 - 1980 | San Francisco State University | B.A. | Biology |
| 1988 - 1993 | University of California, Los Angeles | Ph.D. | Biological Chemistry |

## II. PRINCIPAL POSITIONS HELD:

| | | | |
|---|---|---|---|
| 1981 - 1988 | Research Associate | Molecular & Developmental Biology | Genentech, Inc., South San Francisco |
| 1993 - 1997 | Post-Doctoral Fellow | Cancer Biology | University of California, San Francisco |
| 1997 - 1999 | Assistant Research Biochemist | Hormone Research Inst. | Univ. of California, San Francisco |
| 1999 - 2004 | Assistant Professor, *(In Residence)* | Cancer Research Inst. & Dept. of Pathology | Univ. of California, San Francisco |
| 2004 - 2006 | Associate Professor, *(In Residence)* | Cancer Research Inst. & Dept. of Pathology | Univ. of California, San Francisco |
| 2006 - 2007 | Associate Professor, *(Ladder-rank; tenured)* | Dept. of Pathology & Cancer Research Inst. | Univ. of California, San Francisco |
| 2007 - 2012 | Professor *(Ladder-rank; tenured)* | Dept. of Pathology & Cancer Research Inst. | Univ. of California, San Francisco |
| 2012 - 2015 | Adjunct Professor | Dept. of Pathology | Univ. of California, San Francisco |
| 2011 - present | Professor and Chair (*tenured*) | Cell, Developmental & Cancer Biology | Oregon Health & Science University |
| 2011 - present | Hildegard Lamfrom Endowed Chair in Basic Research | School of Medicine | Oregon Health & Science University |
| 2011 - present | Associate Director for Basic Research | Knight Cancer Institute | Oregon Health & Science University |
| 2022 - present | Deputy Director for Basic & Translational Research | Knight Cancer Institute | Oregon Health & Science University |

## OTHER PROFESSIONAL APPOINTMENTS:

| | | | |
|---|---|---|---|
| 1989 - 1992 | Lecturer | Biology Dept. | Whittier College, Whittier, CA |
| 1992 | Consultant | Dept. of Legal Affairs | Genentech, San Francisco CA |
| 2000 - 2012 | Co-Director | Mouse Pathology Core | Helen Diller Family Comp. Cancer Center, UCSF |
| 2007 - 2009 | Senior and Deputy Editor | *Tumor Microenvironment* Section | *CANCER RESEARCH (AACR)* |
| 2009 - 2012 | Co-Leader | Program in *Cancer Immunity & Microenvironment* | Helen Diller Family Comprehensive Cancer Center, UCSF |
| 2009 - 2012 | Deputy Editor | *Breaking Advances* | *CANCER RESEARCH (AACR)* |
| 2013 - present | Senior Editor | General | *Cancer Immunology Research* |
| 2012 - 2018 | Co-Leader | Program in Cancer Biology | Knight Cancer Institute, OHSU |
| 2017 - 2020 | Scientific consultant | Antibody development | Cell Signaling Technologies |

| | | | |
|---|---|---|---|
| 2019 - 2020 | Endowed Professor, TEFAF Oncology Chair | School for Oncology and Developmental Biology | Maastricht University Medical Center, The Netherlands |
| 2020 | Scientific consultant | Clinical study strategy and design | AbbVie Inc |
| 2020 - present | Scientific consultant | Translational R&D guidance | Shasqi, Inc. |

## III. HONORS, AWARDS, FELLOWSHIPS, AND LECTURESHIPS

### Honors, Awards and Fellowships

| | | |
|---|---|---|
| 1985 | Recognition Award | Genentech, Inc., |
| 1986 | Recognition Award | Genentech, Inc., |
| 1988 | Recognition Award | Genentech, Inc. |
| 2000 - 02 | Hellman Family Award for Early Career Faculty | Univ. of Calif., San Francisco |
| 2000 - 01 | V Foundation Scholar | The V Foundation for Cancer Research |
| 2000 - 03 | Edward Mallinckrodt, Jr. Foundation Award for Medical Research | Edward Mallinckrodt, Jr. Foundation |
| 2002 | Gertrude B. Elion Cancer Research Award | American Association for Cancer Research |
| 2006 - 11 | Era of Hope Scholar Award | Dept. of Defense, Breast Cancer Research Program |
| 2011 - 16 | Era of Hope Scholar Expansion Award | Dept. of Defense, Breast Cancer Research Program |
| 2011 - 16 | KOMEN Promise Award | Susan G Komen Foundation |
| 2012 | AACR-Women in Cancer Research, Charlotte Friend Lectureship | American Association for Cancer Research – Women in Cancer Research |
| 2012 | Mildred Scheel Memorial Lectureship (Inaugural) | German Cancer Aid and Deutsches Krebsforschungszentrum |
| 2013 | American Cancer Society/SSO Basic Science Lecture | Society for Surgical Oncology (SSO) |
| 2015 | 13th Rosalind E. Franklin Award | NIH, National Cancer Institute |
| 2015 - 18 | Top Industry Collaboration Award | Oregon Health & Science University |
| 2017 | Distinguished Women in Science Lecture | Barts Cancer Institute, Queen Mary University of London |
| 2017 | Doctor in Medicine (*honoris causa*) | University of Buenos Aires, Argentina |
| 2018 | 12th AACR-Princess Takamatsu Memorial Lectureship | American Association for Cancer Research |
| 2018 | Brinker Award for Scientific Distinction in Basic Science | Susan G. Komen Foundation |
| 2018 | Career Award | European Academy of Tumor Immunology |
| 2019 - 20 | TEFAF Oncology Chair | Maastricht University, The Netherlands |
| 2018 | AAAS Fellow (Lifetime) | American Association for the Advancement of Science (AAAS) |
| 2019 | Fellow of the AACR Academy (Lifetime) | American Association for Cancer Research (AACR) |
| 2019 - 22 | 2019, 2020, 2021, 2022 Highly Cited Researcher | Web of Science™ |
| 2020 - 24 | Komen Scholar (invited) | Susan G Komen Foundation |
| 2021 - 24 | President-Elect (’21-’22), President (’22-’23), Past-President (’23-’24). Elected | American Association for Cancer Research (AACR) |
| 2022 | Fellow of the Academy of Immuno-Oncology (Lifetime) | Society of Immunotherapy of Cancer (SITC) |
| 2023 | 15th Margaret L. Kripke Legend Award | Univ. of Texas, MD Anderson Cancer Center |
| 2023 | Elected Member, National Academy of Sciences | National Academy of Sciences, USA |

**Named and Keynote Lectureships**

2002 **KEYNOTE ADDRESS**; *Dutch Cancer Society Annual Symposium*, Luntern, The Netherlands
2002 **KEYNOTE ADDRESS**; *Cancer: Genome, Signal & Environment, Takeda Genome Urology International*, Kyoto, Japan
2004 **KEYNOTE ADDRESS**; Vanderbilt University Digestive Disease Research Center Retreat, Vanderbilt University, Nashville, TN, USA
2006 **KEYNOTE ADDRESS**; *Vanderbilt-Ingram Cancer Center Annual Retreat*, Vanderbilt University, Nashville TN, USA
2006 **TUMOR BIOLOGY PLENARY LECTURE**; *Advances in Neuroblastoma Research*, Los Angeles, CA, USA
2007 **KEYNOTE ADDRESS**; *7th International Symposium on Hodgkin Lymphoma*, Cologne, GERMANY
2007 **CANDLELIGHT LECTURE**; *Inflammation and Cancer: From molecular links to bed side*; Inaugural meeting for the *Instituto Clinico Humanitas*, Milan ITALY
2008 **CANCER RESEARCH UK LECTURE**; National Cancer Research Institute Annual Conference, Birmingham UNITED KINGDOM
2008 **THE JOHN F. ANDERSON MEMORIAL LECTURE IN MEDICINE**; '*The Linkage between Inflammation and Cancer*', University of Virginia, Charlottesville VA, USA
2008 **KEYNOTE ADDRESS**; Fox Chase Cancer Center 13th Annual Postdoctoral Fellow and Graduate Student Symposium, Philadelphia, PA USA
2008 **ANNUAL KEYNOTE ADDRESS**; Dept of Cancer Biology, Meharry Medical College, Nashville, TN USA
2009 **STATE-OF-THE-ART LECTURE**; International Cancer Conference, *CANCER 2009*, Dublin IRELAND
2009 **KEYNOTE ADDRESS**; European Association of Cancer Research, Special Conference on *Inflammation and Cancer*, Berlin GERMANY
2009 **PRESIDENT'S PLENARY LECTURE**; Italian Cancer Society Annual Meeting, Milano ITALY
2010 **DISTINGUISHED GUEST LECTURE**; Institute of Cancer, Barts & London School of Medicine. London UNITED KINGDOM
2010 **PLENARY LECTURE**; CHUV Research Day, University Hospital (CHUV) and the Faculty of Biology and Medicine, Lausanne, SWITZERLAND.
2010 **PLENARY LECTURE**; *Annual Meeting of the American Association for Cancer Research*, Washington DC USA
2010 **J. WALTER JUCKETT DISTINGUISHED LECTURE**; University of Vermont Cancer Center Clinical and Translational Research Symposium, *Inflammation & Cancer*, Burlington VT, USA
2010 **KEYNOTE ADDRESS**; Saban Research Institute *Annual Symposium, Honoring Yves DeClerck*, University of Southern California and Children's Hospital Los Angeles, Los Angeles CA, USA
2010 **PLENARY LECTURE**; American College of Veterinary Pathologists and American Society for Veterinary Clinical Pathology, Concurrent Annual Meetings, Baltimore MD, USA
2011 **KEYNOTE ADDRESS;** 11th Annual Meeting of NANT Consortium Investigators. Biology and Therapy of High Risk Neuroblastoma, Redondo Beach CA, USA
2011 **PLENARY LECTURE**; San Antonio Breast Cancer Conference, San Antonio, Texas USA
2011 **BORNTREE DISTINGUISHED LECTURE**; Immunology and Infectious Disease Program, Dept of Veterinary and Biomedical Sciences, Pennsylvania State Univ. University Park, PA USA
2011 **HUCK DISTINGUISHED LECTURE**; The Huck Institute, University Park, Pennsylvania State Univ. University Park, PA USA
2011 **CHARLES I. SIEGAL MEMORIAL LECTURE**; Dana-Farber Cancer Institute and the Dana-Farber Cancer Institute, Boston MA, USA
2012 **PLENARY LECTURE;** "Tumor Heterogeneity: Challenges and Therapeutic Opportunities" *103rd Annual Meeting of the AACR*, Chicago, IL USA
2012 **MILDRED SCHEEL LECTURESHIP (INNAUGURAL)**; German Cancer Aid, and Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, GERMANY
2013 **AMERICAN CANCER SOCIETY BASIC SCIENCE LECTURE**; Society of Surgical Oncology Annual Meeting, Washington D.C., USA
2013 **KEYNOTE ADDRESS**; 3rd Annual Women's Cancer Research Center Retreat, University of Pittsburgh Cancer Institute, Pittsburgh PA USA
2013 **SOSNOVSKY DISTINGUISHED LECTURESHIP;** University of Wisconsin, Milwaukee, WI USA
2014 **ASHLEY DUNN ORATION: PLENARY LECTURE**; 26th Lorne Cancer Conference, Lorne, AUSTRALIA
2014 **Lola and John Grace DISTINGUISHED LECTURE in Cancer Research**; Institute Suisse de Recherche

Experenentale sur le Cancer (ISREC), Lausanne SWITZERLAND

2014 **KATHLEEN ROBISON HUNTSMAN DISTINGUISHED LECTURE**; Huntsman Cancer Center, Salt Lake City UT, USA

2014 **GRAND ROUNDS**; Moffit Cancer Center, Tampa FL, USA

2014 **KEYNOTE ADDRESS**; 2014 Breast Cancer Issues Conferences, Susan G. Komen, Oregon and Washington. Portland OR USA

2014 **KEYNOTE ADDRESS**; 2014 Betty Hise Foundation for Cancer Research Annual Convention. Clackamas, OR, USA

2014 **KEYNOTE ADDRESS**; Kearney Breast Center's 5th Anniversary, in honor of Breast Cancer Awareness Month, PacificHealth Southwest Medical Center Foundation, Vancouver, WA, USA

2015 **SENATOR GEORGE MITCHELL LECTURE**; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, N. Ireland

2015 **KEYNOTE ADDRESS;** Cell Symposia; *Cancer, Inflammation, and Immunity*, Sitges, SPAIN

2015 **13th Rosalind E. Franklin Award Lecture**; National Cancer Institute Intramural Program Retreat, Washington DC, USA

2015 **PLENARY LECTURE;** AACR 106th Annual Meeting, "*Oncology Meets Immunology: Not Just Another Hallmark"*, Philadelphia, PA USA

2015 **KEYNOTE ADDRESS;** 6th Annual Meeting of the American Pancreatic Association, San Diego CA USA

2016 **KEYNOTE ADDRESS**; Towards Predictive Cancer Models, ICREA and VHIO Symposium, Barcelona SPAIN

2017 **KEYNOTE ADDRESS**; 1st Crick Cancer Meeting, Francis Crick Institute, London UNITED KINGDOM

2017 **KEYNOTE ADDRESS;** Keystone Symposia, "*Inflammation Driven Cancer: Mechanisms to Therapy/Microbiome in Health and Disease*, Keystone, Colorado USA

2017 **DISTINGUISHED WOMEN IN SCIENCE LECTURE**; Barts Cancer Institute, London UK.

2017 **SIDNEY H. SACHS LECTURE**; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH USA

2017 **MARGUERETTE VOGT LECTURE IN CANCER BIOLOGY**; The Salk Institute, La Jolla CA, USA.

2018 **CAREER AWARD LECTURE**; European Academy of Tumor Immunology (EATI), Centre de Recherche de Cordeliers, Paris, FRANCE.

2018 **KEYNOTE ADDRESS**; Joint Montagna Symposium & Annual PanAmerican Society for Pigment Cell Research Conference, "Melanoma to Vitiligo: The Melanocyte in Biology & Medicine". Glenenden Beach, Oregon USA

2019 **KEYNOTE ADDRESS;** TEFAF Oncology Symposia, Maastricht University, Maastricht, The Netherlands

2019 **KEYNOTE ADDRESS**; '*Stress and inflammation in Tumor Progression and Metastasis Conference*', Weizmann Institute of Science, Rehovot, ISRAEL

2019 **KEYNOTE ADDRESS**; Immunology LA Symposium, Los Angeles CA USA

2019 **KEYNOTE ADDRESS**; 2nd Triannual Symposium Highlighting Parnassus Campus Cancer Research in the HDFCCC, Univ., of California, San Francisco, CA., USA

2019 **EDWARD J SARCIONE EXCELLENCE IN IMMUNOLOGY LECTURE**; Roswell Park Cancer Center, Buffalo NY. USA

2019 **FRANK AND SHIRLEY FITCH LECTURESHIP IN TUMOR IMMUNOLOGY;** Dept of Cancer Research, Ben May Cancer Center, University of Chicago, Chicago IL. USA

2021 **KEYNOTE LECTURE**; CRUK Grand Challenge Key Concepts, 'STORMing Cancer'. Virtual.

2021 **KEYNOTE ADDRESS***, 6th Meeting on the Biology of Cancer: Microenvironment & Metastasis,* Cold Spring Harbor Laboratory Symposium, New York USA

2021 **KEYNOTE ADDRESS,** *Moving Breast Cancer Treatments Forward*, Jayne Koskinas Ted Giovanis Foundation for Health and Policy, Bethesda MS USA

2021 **KEYNOTE ADDRESS,** Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting 2021, Washington DC, USA

2022 **15TH MARGARET L. KRIPKE LEGEND AWARD LECTURE,** Univ. of Texas., MD Anderson Comprehensive Cancer Center, Houston TX, USA

2023 **KEYNOTE ADDRESS,** 2023 Internal Medicine Research Retreat, University of Texas, MD Anderson Comprehensive cancer Center 2023 Internal Medicine Research Retreat. Virtual

## IV. PROFESSIONAL ACTIVITIES

**External Scientific Advisory Boards and Councils (EAB/SAB/SAC) and Scientific Review Board (SRB) Membership**

| | | |
|---|---|---|
| 2007 - 2014 | Member, EAB | (P30) Masonic Cancer Center, University of Minnesota, Minneapolis MN, USA |
| 2007 - 2011 | Member, EAB | (U54) *Aging, Tumor Microenvironment and Prostate Cancer*; PI: S. Plymate; Univ. of Washington, Seattle WA USA |
| 2007 - 2011 | Member, EAB | (U54), *Novel Methods for Detection Cell Interactions in the Tumor Microenvironment*; P.I. J Condeelis. Albert Einstein College of Medicine of Yeshiva University, New York, NY USA |
| 2009 - 2013 | Member, EAB | (P01), *Neuroblastoma*; P.I. R Seeger, Children's Hospital Los Angeles, Univ. of Southern California, Los Angeles, CA USA |
| 2009 - 2014 | Member, EAB | (P01) *Motility and Invasion*, PI: J Condeelis; Albert Einstein College of Medicine, NY, NY USA |
| 2011 - 2021 | Member, SRB | STARR Cancer Consortium: 5th, 8th, 9th, 10th, 13th grant competitions |
| 2012 - 2019 | Member, EAB | (P30) Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis IN, USA |
| 2012 - present | Member, EAB | (P30) Koch Institute for Integrated Cancer Research, Massachusetts Inst. of Tech. Cambridge, MA USA |
| 2013 - 2015 | Member, EAB | Biodesign Institute at Arizona State University, Tempe, AZ USA |
| 2013 | Member, SRB | LabEx, Paris France |
| 2013 - present | Member, SAC | Cancer Research Institute (CRI) |
| 2013 - 2021 | Member, SRB | The V Foundation for Cancer Research |
| 2015 - present | Member, SAB | Genenta Sciences, Milan Italy |
| 2016 - 2024 | Member, EAB | NIH/NCI-Frederick National Laboratory Advisory Committee (FNLAC) |
| 2016 - 2017 | Member | GlaxoSmithKline (GSK), External Immunology Board (EIB) |
| 2016 - 2017 | Member | Jansen Research & Development, LLC; ImmunoOncology Board |
| 2016 - present | Member, EAB | Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore MD. USA |
| 2016 - 2020 | Member, EAB | (P30) Salk Institute Cancer Center, La Jolla CA. USA |
| 2016 - present | Member | Pharmacyclics, Inc: Advisory committee (NCT02436668) |
| 2017 | SAB, ad hoc | AstraZeneca Oncology External IO Science Panel, Waltham, MA. USA |
| 2017 - present | Member, EAB | (P50) Breast Cancer SPORE, Dana Farber Cancer Center, Boston MA. USA |
| 2016 - present | Member, EAB | Syndax Pharmaceutical, Inc. Boston MA. USA |
| 2018 - present | Member, SAB | Carisma Therapeutics Inc. Philadelphia, PA. USA |
| 2018 - 2022 | Member, SAB | Verseau Therapeutics, Inc. Boston, MA. USA |
| 2017 - 2019 | Member, SRB | Cancer Research United Kingdom (CRUK); Early Detection (EDx) Research Committee. London, England |
| 2019 - present | Member, SAB | Zymeworks, Inc. Vancouver, British Columbia, CANADA |
| 2019 - present | Member, EAB | (P30) University of California, San Diego Moores Cancer Center, San Diego, CA. USA |
| 2019 - present | Member, SAB | Cytomix Therapeutics, Inc., S. South Francisco, CA. USA |
| 2019 - present | Member | Lustgarten Foundation, Therapeutics Working Group. NY, NY. USA |
| 2019 - 2022 | Ad hoc Member, EAB | (P30) Dana Farber/Harvard Cancer Center. Boston, MA. USA |
| 2023 - 2025 | Standing Member, EAB | (P30) Dana Farber/Harvard Cancer Center. Boston, MA. USA |
| 2020 - present | Member, SAB | Kineta Inc, Seattle, WA, USA |
| 2020 – present | Member, SAB | HiberCell, Inc., New York, NY, USA |
| 2021 – present | Member – Immuno SAB | Cell Signaling Technologies, Danvers, MA, USA |
| 2021 – present | Member, EAB | (P30) The Jackson Laboratory Cancer Center, Bar Harbor, ME, USA |
| 2021 – present | Member, SAB | Alkermes, Inc., Waltham, MA, USA |
| 2021 – present | Member, EAB | Prostate P01 (M. Shen, PI), Columbia University Medical Center, NY, |

| | | |
|---|---|---|
| | | NY, USA |
| 2022 – present | Member, EAB | MD Anderson Cancer Center GI SPORE (P50; S. Kopetz and A Maitra, coPI), Houston, TX, USA |
| 2022 – present | Member, EAB | PDX Pharmaceuticals, Inc., Portland OR, USA |
| 2022 – present | Member, EAB | Pio Therapeutics Pty Ltd, Parkville VIC, AUSTRALIA |
| 2022 – present | Member, EAB | NextCure, Beltsville MD, USA |
| 2023 – present | Member, EAC | (P30) Mayo Clinic Comprehensive Cancer Center, Rochester, MN USA |

**Editorial Board Activities:**

| | |
|---|---|
| 2003 - 2005 | Associate Editor, ***Cancer Research*** |
| 2005 – 2007 | Editorial Board, ***Carcinogenesis*** |
| 2004 – 2007 | Senior Editor, ***Cancer Research (****Cell, Tumor and Stem Cell Biology* Section) |
| 2007 – 2009 | Senior Editor, ***Cancer Research (****Tumor Microenvironment* Section) |
| 2007 – 2009 | Deputy Editor, ***Cancer Research*** |
| 2007 | Guest Editor, PNAS Editorial Board |
| 2008 | Guest Editor (with Tyler Jacks), *Current Opinion in Genetics & Development* |
| 2008 – 2010 | Editorial Board, ***Cancer Microenvironment*** |
| 2009 – 2012 | Deputy Editor for Breaking Advances, ***Cancer Research*** |
| 2012 – present | Editorial Board, ***Cancer Cell*** |
| 2012 – present | Senior Editor, ***Cancer Immunology Research*** |
| 2013 – 2017 | Editorial Board, ***Cancer Immunology, Immunotherapy*** |
| 2013 | Guest editor, Editorial Committee, ***Annual Reviews of Pathology*** |
| 2016 – 2019 | Board of Reviewing Editors, ***Science*** |
| 2017 – present | Scientific Editor, ***Cancer Discovery*** |

**Local, National and International Meetings Organized:**

2005 Keystone Symposia, *Inflammation and Cancer*, Co-organizer with Dr. Ray DuBois (Vanderbilt Univ, TN), Breckinridge, CO, USA

2006 5th Annual Timberline Symposium on Epithelial Cell Biology, '*Intrinsic and Microenvironmental Regulation of Epithelial Cancer',* Co-Organizer with Dr. Harold Moses (Vanderbilt University, TN, USA), Timberline, OR, USA

2006 Co-Organizer (with Dr. Lewis Lanier), UCSF HDFCCC Annual Symposium, *'Inflammation & Cancer: Bench to Bedside'.*

2007 Keystone Symposia, *Inflammation and Cancer*, Co-Organizer with Drs. Fran Balkwill (Cancer Research UK) and Glenn Dranoff (Beth Israel Cancer Center, Harvard, MA); Santa Fe, New Mexico, USA

2008 AACR Special Conference: *Inflammation and Cancer*, Co-organizer with Drs. Michael Karin (UCSD) and Larry Marnett (Vanderbilt UNiv.). Oahu, Hawaii, USA.

2008 International Society for Biological Therapy of Cancer (ISBTc), *2008 Workshop on Inflammation in Cancer Development,* Co-Organizer with Drs. Michael Karin, (UCSD), Steven Dubinett (UCLA), and George Weiner (WU); San Diego CA USA

2010 Co-Organizer (with Dr. Lewis Lanier), UCSF HDFCCC Program in *Cancer Immunity and Microenvironment* Symposium

2011 AACR Special *Conference: Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy*, Co-Organizer with Drs. Yves DeClerck (USC, Children's Hospital) and Melody Swartz (EPFL). Miami, FL USA

2014 Keystone Symposia, *Immune Evolution in Cancer*, Co-Organizer with Drs. Suzanne Ostrand-Rosenberg (Univ. Maryland) and Olja Finn (Univ. of Pittsburgh). Whistler, British Columbia, CANADA

2014 *3rd International Conference on Tumor Microenvironment and Cellular Stress: Signaling, Metabolism, Imaging and Therapeutic Targets*, Mykonos, Greece. Co-organizer with Drs Amato Giacci (Stanford Univ) and Alexia Ileana-Zaromytidou (Nature Cell Biology).

2016 Keystone Symposia, *Cancer Pathophysiology: Integrating the Host and Tumor Environments,* Co-Organizer with Drs. Sheila Stewart (Washington Univ. St Louis), Sandra McAllister (Brigham Women's Hospital, Harvard Medical School). Breckenridge, CO USA

2017 Cell Symposium: *Cancer, Inflammation and Immunity*. Co-organizer with Drs. Catano Reis e Sousa (Crick Institute, UK), Laurie H Glimcher (Dana Farber Cancer Center). San Diego, CA USA.

2017-present *26th, 27th, 28th, 29th Annual Short Course on Experimental Models of Human Cancer*, sponsored by *The Jackson Laboratory*, Co-organizer with Drs. Carol Bult (The Jackson Laboratory), Karolina Palucka (The Jackson Laboratory), and Charles Wray (The Jackson Laboratory). Bar Harbor, Maine, USA

2018 Keystone Symposium, *Cancer Immunotherapy: Combinations*. Co-organizer with Drs. Chris Boshoff (Pfizer Pharma) and Lieping Chen (Yale Medical), Montreal, Quebec. CANADA

2018 8th AACR Special Conference on *Tumor Immunology and Immunotherapy*. Co-organizer with Drs. Drew Pardol (Johns Hopkins), Ira Mellman (Genentech) and James Allison (MDACC). Miami, FL, USA

2018 Forbeck Foundation Meeting: 'Tumor Microenvironment'. Co-organizer with Dr. Rakesh Jain (Harvard). Colorado, USA

2020 EACR-AACR-ASPIC Basic and Translational Research Conference, '*Tumor Microenvironment'*, AACR Co-Chair organizer with Drs. C Caldas (EACR), L Costa (ASPIC). Lisbon, PORTUGAL.

2020 Keystone Symposium, *Myeloid Cells and Innate Immunity in Solid Tumors*. Co-organizer with Drs. Judith Varner (UC San Diego) and Dmitry Gabrilovich (Wister Institute), Virtual meeting due to COVID-19.

2020 AACR *Translational Cancer Research for Basic Scientists Workshop*. Course Co-Director with RB Corcoran (Mass. General Hospital), SB Horwitz (Albert Einstein College of Medicine), GR Oxnard (Dana-Farber Cancer Institute). Virtual meeting due to COVID-19.

2021 Founding co-organizer '*The Myeloid Network'*, a virtual international seminar series <https://themyeloidnetwork.eng.ucsd.edu>, with Drs. J Varner (UCSD), J Guerriero (BWH/Harvard), D Gabrilovich (AstraZeneca), J Joyce (UNIL).

2021 AACR *Translational Cancer Research for Basic Scientists Workshop*. Course Co-Director with RB Corcoran (Mass. General Hospital), GR Oxnard (Dana-Farber Cancer Institute). Virtual meeting due to COVID-19.

2022 AACR Special Conference on '*Carcinoma in situ', Co-Chair organizer with Drs. K. Polyak (DFCC/Harvard), L. Esserman (UCSF), Reis-Filho (MSKCC).*

2022 AACR *Translational Cancer Research for Basic Scientists Workshop*. Course Co-Director with RB Corcoran (Mass. General Hospital), G Demetri (Dana-Farber Cancer Institute). Boston MA, USA.

## V. RESEARCH PROGRAM AND ACCOMPLISHMENTS

**Research Program:** The Coussens' lab focuses on elucidating the roles of immune cells and their mediators as critical regulators of solid tumor (squamous cancer of the skin, mesothelioma, breast and pancreas cancer) development. During the early development of cancer, many physiological processes occur in the vicinity of 'young tumor cells' that are similar to processes that occur during embryonic development and to healing of wounds in adult tissue, e.g., leukocyte recruitment and activation (inflammation), angiogenesis (development of new blood supply) and tissue remodeling. During tumor development however, instead of initiating a 'healing' response, activated leukocytes provide growth-promoting factors that aid tumor progression, in combination with factors that inhibit cytotoxic activities of $CD8^+$ T cells. We are interested in understanding the molecular mechanisms regulating leukocyte recruitment into neoplastic tissue, how the tumor microenvironment programs recruited and resident leukocytes, and how leukocytes in turn regulate subsequent aspects of tumorigenesis. To address these issues, we have taken several innovative approaches to investigate mechanisms involved in: ***i.*** induction and maintenance of chronic inflammatory microenvironments in premalignant, malignant and metastatic tissues; ***ii.*** role of leukocytes in regulating tissue remodeling, angiogenesis, immune suppression, cancer development and response to cytotoxic/targeted/immune therapy; ***iii.*** development of novel non-invasive imaging reagents and discovery of tumor-derived and soluble biomarkers of tumor and immune response to therapy in tissues/tumors/blood; ***iv.*** Investigate preclinical therapeutic efficacy of "drugs" that inhibit protumorigenic activities of leukocytes in mouse models of cancer development and their translation to the clinic; and ***v.*** development of novel technology platforms for real-time monitoring of leukocyte presence and effector status at near single cell level in patients for evaluating response and resistance to therapy. The long-term goal of our research is to translate basic observations made in the mouse, toward rational design of novel therapeutics whose aim is to block and/or alter rate-limiting events critical for solid tumor growth, maintenance or recurrence in humans, and to leverage these findings for rationale delivery of drugs in the clinic and real time response/resistance monitoring. Currently, we are actively utilizing transgenic mouse models (non-melanoma squamous and

breast cancer, pancreatic adenocarcinoma, and mesothelioma) to reveal functional roles of adaptive and innate leukocytes during tumor development, and to identify new targets for anti-cancer therapy. These experimental studies are conducted in parallel with evaluation of representative human cancer specimens to affirm that mechanisms revealed in the experimental setting represent fundamental parameters of multi-stage cancer development in humans.

**Research Accomplishments:** Dr. Coussens is internationally known for her original and fundamental discoveries on the molecular and cellular mechanisms of chronic inflammation that regulate solid tumor pathogenesis. Her research investigating functional significance of inflammation in cancer resulted in a paradigm shift by revealing that in vivo, activation of chronic inflammatory programs in early neoplasms is required for *promotion* to malignancy. She has elucidated immunologic, molecular and cellular underpinnings of pro-tumor immunity, and discovered previously unappreciated roles for B cells, $CD4^+$ T cells, and discrete myeloid subsets as critical regulators of solid tumor development.

She was first to mechanistically demonstrate in vivo that B cells foster squamous carcinogenesis by activating protumoral activity of myeloid cells infiltrating premalignant tissues (*deVisser et al., 2005; Schioppa et al., 2011*). Using a series of in vivo molecular genetic, biochemical and immunologic approaches, she revealed that humoral immunity and circulating immune complexes potentiate cutaneous carcinogenesis via induction of Th2-type inflammatory pathways in macrophages following activation of FcRγ-mediated signaling that ultimately lead to $CD8^+$ T cell suppression (*Andreau et al., 2010; Affara et al., 2014*). Based on these studies, she examined B cell (CD20)-depleting antibodies in solid tumors and reported that B cell depletion enhanced therapeutic efficacy of chemotherapy by $CD8^+$ T cell-dependent mechanisms (*Affara et al., 2014).* By revealing similar "B cell signatures" in squamous, pancreas and head and neck (HNSCC) cancers, she identified a protumoral role for B cells in human pancreatic cancers (*Gunderson et al., 2016,*). More recently, she extended her preclinical studies to reveal activation of complement cascades, complement protein C5a and its receptor expressed on diverse myeloid subtypes, fosters protumoral effector pathways leading to macrophage-based T cell suppression; inhibition of C5aR signaling blunts these and imparts antigen-specific $CD8^+$ T cell clonal expansion that is synergistic with chemotherapy (*Medler et al, 2018*). That B cells, humoral immunity and FcRγ can enhance solid tumorigenesis remains a novel concept that has challenged existing paradigms in both the cancer biology and tumor immunology fields. Together, these studies identify novel myeloid-based pathways amenable for therapeutic targeting to quell pro-tumoral chronic inflammatory programs that can be leveraged for combinatorial strategies with cytotoxic, targeted and immune therapeutics to drive durable T cells responses to improve outcomes.

These preclinical findings and human correlations provided rationale for investigator-initiated proof-of-principle clinical studies evaluating Bruton's Tyrosine Kinase (BTK) inhibitors in combination with gemcitabine and nab-paclitaxel in patients with locally advanced pancreatic adenocarcinomas (NCT02436668), and in combination with PD-1 immune checkpoint blockade in patients with advanced head & neck squamous carcinomas (NCT02454179); patients receiving BTK inhibitors evidence in situ and peripheral (blood) biomarker changes indicative of systemic immune reprograming consistent with quelling of Th2 protumoral immunity (*Tayler et al 2022; Tempero et al, 2021; Sinha et al, 2023*).

Based on her early studies in squamous cancers, she investigated the hypothesis that protumoral macrophages in mammary carcinomas were similarly regulated by lymphocyte-derived paracrine factors. Using transgenic mouse models, she demonstrated that interleukins (IL)-4 and 13, derived from Th2-$CD4^+$ T cells induce protumor activities of monocytes and macrophages, that in turn potentiate late-stage cancer progression and pulmonary metastasis (*DeNardo et al., 2009*). With the clinical potential of targeting macrophages via CSF1/CSF1R-blockade, she evaluated small molecule CSF1R antagonists and was first to report that clinical compounds targeting this macrophage survival pathway disrupt late-stage tumor progression and enhance chemo-sensitivity (*DeNardo et al., 2011; Strachan et al., 2013*) and radiation therapy sensitivity (*Shiao et al., 2015*) by $CD8^+$ T cell-dependent mechanisms. Together, these studies provided supporting data for an investigator-initiated phase Ib/II clinical trial evaluating a CSF1R inhibitor with chemotherapy in women with metastatic triple negative breast cancer (NCT01596751) funded by a Komen award (Coussens: coPI). Her preclinical studies have subsequently led to identification of a rare population of intratumoral $TIM3^+$ dendritic cells, whose maturation and production of IL-12 is repressed by macrophage-derived IL-10 in mammary tumors; these are critical for cross presentation and cytotoxic activity of intratumoral $CD8^+$ T cells, and importantly provide an immune-based signature for identifying patients likely

to respond to immune therapy (*Ruffell et al., 2014; de Mingo Pulido et al., 2018).* These studies set the stage for her and collaborators to identify a macrophage-based RNA signature that identifies women with breast cancer, and a peripheral (blood-based) monocyte signature identifying women with endometrial cancer and breast cancer *(Casetta et al., 2019*). Her current research in this area is focused on understanding epigenetic regulation of macrophages and T cells in vivo, for identification of novel targets for therapy. Her pioneering research investigating the functional significance of myeloid biology in the pathogenesis of solid tumors has resulted in unleashing of a previously unappreciated area of tumor immunology that is now being embraced for its therapeutic relevance to combat cancer.

Together, a significant impact of her seminal research has been recognition that tissues vary with regards to "types" of immune programs exploited to potentiate and/or control early cancer. Her original findings underscore the tenet that complexity and tissue-specificity of host-tumor programs must be considered for therapy (*Coussens and Werb, 2001*; *deVisser et al., 2006; Tlsty and Coussens 2006; Hanahan and Coussens, 2012*; *Coussens et al., 2013; Ruffell et al., 2015; Medler et al., 2015*; *Palucka and Coussens, 2016*). Examples of this are illustrated by her studies described above, but also in her efforts to understand tissue-specific roles for stromal cell-derived proteases (24 publications). These studies fostered collaborative endeavors to develop in vivo imaging approaches for select proteolytic activities and/or immune cell infiltrates (13 publications), early development of a 13-color polychromatic flow cytometry platform for leukocyte lineage analysis to identify the spectrum of lymphoid and myeloid cells infiltrating solid tumors that was later disseminated as an SOP by the NCI-TMEN Network (*Ruffell et al., 2012; Del Alcazar et al., 2017*), development of an inexpensive multiplex immunohistochemistry (mIHC) platform enabling quantitative and simultaneous evaluation of 12-29 epitopes in one FFPE tissue section, thus preserving regional geography so as to appreciate and monitor cellular heterogeneity in tumors in situ (*Tsujikawa et al., 2017; Banik et al., 2020*). With this platform, she and collaborators recently published an immune Atlas for pancreatic adenocarcinoma utilizing ~130 surgical resection specimens revealing previously unappreciated heterogeneity of immune contexture in this disease (*Liudahl et al., 2021*), and also providing a baseline data set in which to evaluate impact of neoadjuvant immunotherapy (*Byrne et al., 2021*). These powerful platforms enable retrospective or prospective evaluation of tissue/tumor specimens and peripheral blood at near single cell levels for preclinical and clinical patient stratification and therapy response monitoring (*Del Alcazar et al., 2016; Cooper et al., 2016; Gopalakrishnan et al, 2017; Li et al., 2018; Pennock et al., 2018; Means et al., 2019; Reddy et al., 2019; Blair et al., 2019; Hassan et al., 2019; Michaelis et al., 2019; Tsujikawa et al., 2020; Pennycuick et al., 2020; Vayrnen et al., 2021; Link et al., 2021; Byrne et al., 2021; Tempero et al., 2021; Labrie et al., 2021; Yoshimura et al., 2021; Taylor et al., 2022; Johnson et al., 2022; Kitko et al., 2022; Sinha et al., 2023*), as well as providing data sets for analytical tool development for spatial ecology and immune contexture synthesis (*Chang et al., 2017; Tsujikawa et al., 2019; Schapiro et al., 2022a,b; Blise et al., 2022, Mi et al, 2022; Brockman et al., 2023)*

**VI. PUBLICATIONS**

**Peer-Reviewed Manuscripts (Scopus, h-index: 83; Google Scholar, h-index: 95)**


1. Francke U, de Martinville B, **Coussens L**, Ullrich A. (1983) The human gene for the Beta subunit of nerve growth factor is located on the proximal short arm of chromosome 1. *Science* 222:1248-1251. PMID: 6648531
2. Ullrich A, Gray A, Berman C, **Coussens LM,** Dull T. (1983) Sequence homology of human and mouse Beta-nerve growth factor subunit genes. *CSHSQ* 48:435-442. PMID: 6327169
3. Breakefield X, Castiglione C, **Coussens L**, Axelrod F, Ullrich A. (1984) Structural gene for Beta-nerve growth factor is not defective in familial dysautonomia. *Proc. Natl. Acad. Sci. USA* 81:4213-4216. PMID: 6330750
4. Ullrich A, **Coussens L**, Hayflick J, Dull T, Gray A, Tam A, Lee J, Yarden Y, Libermann T, Schlessinger J, Downward J, Bye J, Whittle N, Waterfield M, Seeburg P. (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. *Nature* 309:418-425. PMID: 6328312
5. Ullrich A, Bell J, Chen E, Herrera R, Petruzzelli L, Dull T, Gray A, **Coussens L**, Liao Y-C, Tsubokawa M, Mason A, Seeburg P, Grunfield C, Rosen O, Ramachandran J. (1985) Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. *Nature* 313:756-761. PMID: 2983222
6. Lauffer L, Garcia P, Harkins R, **Coussens L**, Ullrich A, Walter P. (1985) Topology of the signal recognition particle receptor in the endoplasmic reticulum membrane. *Nature* 318:334-338. PMID: 2999608

7. Schechter A, Hung M-C, Vaidanathan L, Weinberg R, Yang-Feng T, Francke U, Ullrich A, **Coussens L.** (1985) The *neu* gene: An *erbB*-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. *Science* 229:976-978. PMID: 2992090
8. **Coussens L**, Yang-Feng T, Liao T-C, Chen E, Gray A, McGrath J, Seeburg P, Libermann T, Schlessinger J, Francke U, Levinson A, Ullrich A. (1985) Tyrosine kinase receptor with extensive homology to the EGF receptor shares chromosomal location with *neu* oncogene. *Science* 230:1132-1139. PMID: 2999974
9. **Coussens L**, Van Beveren C, Smith D, Chen E, Mitchell R, Isacke C, Verma I, Ullrich A. (1986) Structural alteration of viral homologue of receptor proto-oncogene *fms* at carboxyl terminus. *Nature* 320:277-280. PMID: 2421165
10. Ullrich A, Riedel H, Yarden Y, **Coussens LM**, Gray A, Dull T, Schlessinger J, Waterfield MD, Parker PJ. (1986) Protein kinases in cellular signal transduction: Tyrosine kinase growth factor receptors and protein kinase C. *CSHSQ* 51:713-724. PMID: 3472757
11. Chen E, **Coussens LM**, Liao Y-C, Smith D, Yang-Feng T, McGrath J, Van Beveren C, Verma IM, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A. (1986) Structural features of growth factor receptors with oncogenic potential. *Biochem. Soc. Symp*. 52:65-82. PMID: 3579970
12. Parker P, **Coussens L**, Totty N, Rhee L, Young S, Chen E, Stabel S, Waterfield M, Ullrich A. (1986) The complete primary structure of protein kinase C—the major phorbol ester receptor. *Science* 233:853-859. PMID: 3755547
13. **Coussens L**, Parker P, Rhee L, Yang-Feng T, Chen E, Waterfield M, Francke U, Ullrich A. (1986) Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways. *Science* 233:859-866. PMID: 3755548
14. **Coussens L**, Rhee L, Parker P, Ullrich A. (1987) Alternative splicing increases the diversity of the human protein kinase C family. *DNA* 6:389-394. PMID: 3677994
15. Yarden Y, Kuang W-J, Yang-Feng T, **Coussens L**, Munemitsu S, Dull T, Schlessinger J, Francke U, Ullrich A. (1987) Human proto-oncogene *c-kit*: A new cell surface receptor-tyrosine kinase for an unidentified ligand. *EMBO J*. 6:3341-3351. PMID: 2448137
16. MacDonald R, Pfeffer S, **Coussens L**, Tepper M, Brocklebank C, Mole J, Anderson J, Chen E, Czech M, Ullrich A. (1988) A single receptor binds both insulin-like growth factor II and mannose-6-phosphate. *Science* 239:1134-1137. PMID: 2964083
17. Formby B, Ullrich A, **Coussens L**, Walker L, Peterson C. (1988) Growth hormone stimulates insulin gene expression in cultured human fetal pancreatic islets. *J. Clin. Endo. Metab.* 66:1075-1079. PMID: 3283160
18. Mosthaf L, Grako D, Dull T, **Coussens L**, Ullrich A, McClain D. (1990) Functionally distinct insulin receptors generated by tissue-specific alternative splicing. *EMBO J.* 9:2409-2413. PMID: 2369896
19. **Coussens LM**, Yokoyama K, Chiu R. (1994) Transforming Growth Factor $ß_1$-mediated induction of *junB* is selectively inhibited by expression of Ad.12-E1A. *J. Cell. Physio.* 160:435-444. PMID: 8077281
20. **Coussens LM**, Hanahan D, Arbeit J. (1996) Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. *Am. J. Pathol.* 149:1899-1917. PMID:8952526
21. **Coussens LM**, Werb Z. (1996) Matrix metalloproteinases and the development of cancer. *Chemistry and Biology* 3:895-904. PMCID: PMC8939708
22. Bergers G, Hanahan D, **Coussens LM.** (1998) Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. *Int. J. Dev. Biol. 42*:995-1002. PMID: 9853830
23. **Coussens LM,** Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey, GH, Hanahan D. (1999) Inflammatory mast cells upregulate angiogenesis during squamous epithelial carcinogenesis. *Genes & Development* 13:1382-1397. PMID: 10364156

- Featured as journal cover image

24. McKerrow JM, Bhargava V, Hansell E, Kuwahara T, Matley M, **Coussens LM,** Warren R. (2000) A functional proteomics screen of proteases in colorectal carcinomas. *Molecular Medicine* 6:450-460. PMID: 10952024
25. Bergers G, **Coussens LM.** (2000) Extrinsic regulators of epithelial tumor progression: metalloproteinases. *Curr. Opin. Genetics & Development* 10:120-127. PMID: 10679388
26. **Coussens LM,** Tinkle CL, Hanahan DH, Werb Z. (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. *Cell* 103:481-490. PMID: 11081634

27. van Kempen LCL, Rhee JS, Dehne K, Lee J, Edwards DR, **Coussens LM**. (2002) Epithelial carcinogenesis: Dynamic interplay between neoplastic cells and their microenvironment. *Differentiation* 70: 610-623. PMID: 12492502
28. **Coussens LM**, Fingleton B, Matrisian LM. (2002) Matrix metalloproteinases and cancer: Trials and tribulations. *Science* 295:2387-2392. PMID: 11923519
29. **Coussens LM**, Werb Z. (2002) Inflammation and cancer. *Nature* 420: 860-867. PMID: 12490959
30. Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, **Coussens LM,** Hanahan D. (2003) Immune enhancement of skin carcinogenesis by $CD4^+$ T cells. *J Exp. Med*, 197:1017-1028. PMID: 12695493
31. van Kempan LCL, Ruitter DJ, van Muijen GNP, **Coussens LM.** (2003) The tumor microenvironment: a critical determinant of neoplastic evolution. *Euro J Cell Biol,* 82:539-548. PMID: 14703010
32. Rhee JS, Diaz R, Korets L, Hogson G, **Coussens LM**. (2004) TIMP-1 alters susceptibility to carcinogenesis. *Cancer Research* 64:952-961. PMID: 14871825
33. Chantrain CF, Shimada H, Groshen S, Ye W, Shalinsky DR, Werb Z, **Coussens LM**, DeClerck YA. (2004) Stromal matrix metalloproteinase-9 (MMP-9) regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. *Cancer Research* 64:1675-1686. PMID: 14996727
34. Baluk P, Raymond WW, Ator E, **Coussens LM**, McDonald DM, Caughey GH. (2004) Matrix metalloproteinase-2 and -9 expression increases in Mycoplasma-infected airways but is not required for micro vascular remodeling. *Am J Physiol Lung Cell Mol Physiol*, 287:307-317. PMID: 15075248
35. de Visser KE, Korets LV, **Coussens LM**. (2004) Early neoplastic progression is complement-independent. *Neoplasia* 6: 768-776. PMID: 15720803
36. Jodele S, Chantrain CF, Blavier L, Crooks GM, Shimada H, **Coussens LM**, DeClerck YA. (2005) The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9-dependent. *Cancer Research,* 65: 3200-3208. PMID: 15833851
37. Robinson S, **Coussens LM**. (2005) Soluble mediators of inflammation during tumor development. *Adv Cancer Research* 93:159-187. PMID: 15797447
38. Fingleton B, **Coussens LM**. (2005) Host-tumor interactions influencing cancer progression. *Drug Discovery Today: Disease Mechanisms*, 2:199-204
39. de Visser KE, Korets LV, **Coussens LM**. (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. *Cancer Cell* 7:411-423. PMID: 15894262

*Featured in:*

- *Faculty of 1000 – Exceptional (Factor 6.0).* Authoritative evaluation by R. Abraham, Wyeth Research. http://f1000biology.com/guardpages/evaluation/1015124//
- *Nature* 435:752-753 (2005). 'Inflammation by Remote Control'. A. Mantovani
- *Cancer Cell* 7: 403-405 *(*2005). 'The role of the immune system in early carcinogenesis: B-ware the double-edged sword'. A. Houghton, H. Uchi, and J.D. Wolchok.
- *Nature Reviews Immunology* 5:517 (2005). 'B cells lead the way in tumour progression'. K. Minton
- *Nature Reviews Cancer* 5:501 (2005). 'B cells lead the way in tumour progression'. K. Minton

40. de Visser KE, **Coussens LM**. (2005) The interplay between innate and adaptive immunity regulates cancer development. *Cancer Immunology & Immunotherapy*, 54:1143-1152. PMID: 15889249
41. de Visser KE, Eichten A, **Coussens LM**. (2006) Paradoxical roles of the immune system during cancer development. *Nature Reviews Cancer*, 6:24-37. PMID: 16397525
42. Tlsty TD, **Coussens LM.** (2006) Tumor stroma and regulation of cancer development. *Ann Rev Pathol. Mech of Disease*, 1: 119-150. PMID: 18039110
43. van Kempen LCL, de Visser KE, **Coussens LM**. (2006) Inflammation, Proteases and Cancer. *Euro J Cancer,* 42: 728-734. PMID: 16524717
44. Yuan F, Verhelst HL, Blum G, **Coussens LM**, Bogyo M. (2006) A selective activity-based probe for the papain family cysteine protease dipeptidyl peptidase I/Cathepsin C. *J Am Chem Society*, 128: 5616-5617. PMID: 16637611
45. Junankar SR, Eichten A, Kramer A, de Visser KE **Coussens LM**. (2006) Analysis of immune cell infiltrates during squamous carcinoma development. *J Invest Dermatol*, 126:36-4. PMID: 17069009
46. Tan TT, **Coussens LM**. Humoral immunity, inflammation and cancer. (2007) *Curr Opin Immunology* 19(2), 209-216. PMID: 17276050
47. Johansson M, Tan T, de Visser KE, **Coussens LM**. (2007) Immune cells as anti-cancer therapeutic targets and tools. *J Cellular Biochemistry*, 101: 918-926. PMID: 17265430
48. Schwartz DR, Moin K, Yao B, Matrisian LM, **Coussens LM**, Bugge TH, Fingleton B, Acuff KB,

Sinnamon M, Nassar H, Krawetz SA, Linebaug BE, Sloane, BF. (2007) Hu/Mu ProtIn oligonucleotide microarray: dual species array for profiling protease and protease inhibitor gene expression in tumors and their microenvironment. *Mol Cancer Res,* 5:443-454. PMID: 17510311

49. Egeblad M, Shen HCJ, Behonick DJ, Wilmes L, Eichten A, Korets L, Kheradmand F, Werb Z, **Coussens LM.** (2007). Type I collagen is a modifier of matrix metalloproteinase 2 function in murine skeletal development. *Dev Dynamics,* 36:1683-1693. PMID: 17440987

- Featured as journal cover image

50. Eichten AE, Hyun WC, **Coussens LM**. (2007) Distinctive features of angiogenesis and lymphangiogenesis determine their functionality during de novo tumor development. *Cancer Research,* 67:5211-5220*.* PMID: 17545601

- Featured as journal cover image

51. DeNardo D **Coussens LM**. (2007) Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. *Breast Cancer Res,* 9:212-222. PMID: 17705880
52. Kopitz C, Gerg M, Bandapalli O, Ister D, Pennington CJ, Hauser S, Flechsig C, Krell HW, Antolovic D, Brew K, Nagase H, Stangl M, Hann von Weyhern CW, Brucher BLDM, Brand K, **Coussens LM**, Edwards DR, Kruger A. (2007) TIMP-1 promotes liver metastasis by induction of HGF-signaling. *Cancer Research,* 67:8615-8623. PMID: 17875701
53. DeNardo DG, Johansson M, **Coussens LM**. (2008) Immune cells as mediators of solid tumor metastasis. *Cancer Metastasis Rev*. 27:11-18. PMID: 18066650
54. Johansson M, DeNardo DG, **Coussens LM**. (2008) Polarized immune responses differentially regulate cancer development. *Immunol Rev*., 222:145-154. PMCID: PMC2494984
55. Kenny H, Kaur S, **Coussens LM**, Lengyel E. (2008) Adhesion of OvCa cells to peritoneum is mediated by MMP-2 cleavage of fibronectin*, J Clin Invest.* 118(4)1367-1379. PMID18340378
56. Wolf K, Alexander S, Schacht V, **Coussens LM**, vom Andrian U, van Rheenan J, Deryugina E, Friedl P. (2009) Collagen-based cell migration models in vitro and in vivo. *Seminars Cell Dev Biol.,* 20(8): 931-941. PMID: 19682592
57. Yagui-Beltran A, **Coussens LM**, Jablons DM. (2009) Respiratory homeostasis and exploitation of the immune system for lung cancer vaccines. *US Oncology*. 5(1):40-47. PMC: 3285551
58. Watkins GA, Jones EF, Shell MS, VanBrocklin HV, Pan MH, Hanrahan SM, Feng JJ, He J, Sounni NE, Dill KA, Contag CH, **Coussens LM**, Franc BL. (2009) Development of an optimized activatable MMP-14 targeted SPECT imaging probe. *Bioorganic & Medicinal Chemistry*, 17:653-659. PMID: 19109023
59. DeNardo DG, Baretto JB, Andreu P, Vasquez L, Kolhatkar N, **Coussens LM**. (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. *Cancer Cell*, 16:91-102. PMID: 19647220

*Featured in:*

- *Faculty of 1000 – Exceptional (Factor 9.0).* Authoritative evaluation by A. Mantovani, Univ. of Milan. http://f1000biology.com/guardpages/evaluation/1163484//
- *Cancer Cell* 16:81-82 (2009). 'Metastasis-Promoting Immunity: When T cells turn to the dark side' by D. Pardoll
- *Nature Reviews Cancer* 9:609 (2009). *'*Influencing bad behaviour' *by* N. McArthy
- *Nature Biotechnology* 27:828 (2009) . 'Promoting metastasis' by L. DeFrancesco
- *Nature Medicine* 15:1135 (2009). 'Not Immune' by C. Schubert
- *Ranked as a "Top Cancer Papers" between 2008-2011, Nature Medicine, 17:262-265; Nature Medicine 17: 278-279; Nature Medicine, 17:295*

60. Sista AK, Knebel RJ, Tavri SA, Johansson M, DeNardo DG, Boddington SE, Kishore SA, Ansari C, Reinhart V, Coakley FV, **Coussens LM**, Daldrup-Link HE. (2009) Optical Imaging of the peri-tumoral inflammatory response in breast cancer. *J Transl Med*, 7(1): 94-100. PMID: 19906309
61. Andreu P*, Johansson M*, Affara NI*, Tan TT, Junankar S, Korets L, Lam J, Tawfik D, Pucci F, De Palma M, DeNardo D, de Visser KE, **Coussens LM**. (2010) FcRγ activation regulates inflammation-associated squamous carcinogenesis. *Cancer Cell,* 17(2):121-134. PMID: 20138013

*, equal contribution

*Featured in:*

- *Cancer Cell* 17(2) 111-112 (2010). '*La mala educacion of tumor-associated macrophages: Diverse*

*pathways and new players',* by A. Mantovani

- *Nature Reviews Immunology* 10:158 (2010). 'Antibodies lend support to tumors', by, L. Byrd
- *Faculty of 1000 – Exceptional (Factor 6.4).* Authoritative evaluations by X. Ma (Weill Medical College of Cornell) and F. Kiefer (Max-Planck-Institute, Germany). http://f1000biology.com/article/id/2467956
- *Ranked as a "Top Cancer Papers" between 2008-2011, Nature Medicine, 17:262-265; Nature Medicine 17: 278-279;*
- *Nature Medicine* (2011), 17(3) 285-286. 'B Cells and Macrophages in Cancer: Yin and Yang', by A. Mantovani

62. Dennemarker J, Lohmuller T, Mayerie J, Tacke M, Lerch MM, **Coussens LM**, Peters C, Reinheckel. (2010) Deficiency for cysteine protease cathepsin L promotes tumor progression in mouse epidermis mice. *Oncogene,* 29(11):1611-1621. PMID: 20023699
63. Sounni NE, Dehne K, van Kempen LCL, Egeblad M, Affara NI, Cuevas I, Wiesen J, Junankar S, Korets L, Lee J, Shen J, Morrison C, Overall CM, Krane SM, Werb Z, Boudreau N, **Coussens LM**. (2010) Stromal regulation of vessel stability by MMP14 and TGFβ. *Disease Model. Mech.* 3:317-332. PMID: 20223936
64. Okamoto J, Hirata T, Chen Z, Zhou HM, Mikami I, Li H, Beltran A, Johansson M, **Coussens LM**, Clement G, Shi Y, Zhang F, Koizumi K, Shimizu K, Jablons DM, He B. (2010) EMX2 is epigenetically silenced and suppresses growth in human lung cancer. *Oncogene,* 29(44):5969-5975. PMID: 20697358
65. Doedens A, Stockman C, Rubenstein M, Liao D, DeNardo D, **Coussens LM**, Karin M, Goldrath A, Johnson R. (2010) Macrophage expression of HIF1α suppresses T cell function and promotes tumor progression. *Cancer Res,* 70(90): 7465-7475. PMID: 20841473
66. Ursini-Siegel J, Cory S, Zuo D, Hardy WR, Rexhepaj E, Lam S, Schade B, Jirstrom K, Bjur E, Piccirillo CA, DeNardo D, **Coussens LM**, Brennan DJ, Gallagher WM, Park M, Pawson T, Hallett M, Muller WJ (2010) Receptor tyrosine kinase signaling in breast cancer cells inhibits the adaptive immune response to favor a pro-tumorigenic state. *Cancer Res,* 70(20): 7776-7787. PMID: 20924104
67. Ruffell B, DeNardo DG, Affara NI, **Coussens LM**. (2010) Lymphocytes in cancer development: Polarization towards pro-tumor immunity. *Cytokine Growth Factor Reviews, 21:3-10.* PMID: 20005150
68. DeNardo DG, Andreu P, **Coussens LM**. (2010) Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. *Cancer Metastasis Rev, 29(2):309-316*, PMID: 20405169
69. Shiao SE, **Coussens LM.** (2010) The tumor-immune microenvironment and response to radiation therapy. *J Mammary Gland Biol Neoplasia*, 15:411-421. PMID: 21161342
70. Masset A, Maillard C, Sounni NE, Jacobs N, Bruyere F, Delvenne P, Tacke M, Reinheckel T, Foidart JM, **Coussens LM**, Noel A. (2011) Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor. *Int J Cancer*, 128:283-293. PMID: 20232379
71. Erez N, **Coussens LM**. (2011) Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. *Int. J Cancer.* 128:2536-2544. PMID: 21387299
72. **Coussens LM**, Pollard JW. (2011) Leukocytes in mammary development and cancer. Cold Spring Harbor Perspectives in Biology, 3(3) PMID: 21123394
73. DeNardo DG, Brennan DJ, Rexhapaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL, **Coussens LM**. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. *Cancer Discovery,* 1(1): 54-67. PMID: 22039576

*Featured in:*

- *Nature* 472 303-304 (2011). '*Macrophages Limit Chemotherapy"* by, M. De Palma and C.E. Lewis
- Nature Reviews Cancer. 11:3056 (2011). '*Bad company*', by N. McCarthy
- *2011 Most-Cited Article in CANCER DISCOVERY*, http://www.aacrjournals.org/site/SpecialPages/most_cited.xhtml

74. Benavides F, Perez C, Blando J, Contreras O, Shen J, **Coussens LM**, Fischer SM, Kusewitt DF, Digiovanni J, Conti CJ (2011) Protective role of cathepsin L in mouse skin carcinogenesis. *Mol Carcinog*. 52: 352-361 PMID:21538579
75. Barbone D, Ryan J, Kolhatkar N, Chacko A, Jablons DM, Sugarbaker DJ, Bueno R, Latei AG, **Coussens LM**, Fennel DA, Broaddus VC. (2011) The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. *Cell Death & Disease.*; 2:e174. doi: 10.1038/cddis.2011.58. PMID: 21697949

76. Schioppa T, Moore R, Thompson R, Rosser E, Kulbe H, Nedospasov S, Mauri C, **Coussens LM**, Balkwill F. (2011) B regulatory cells and the tumor-promoting actions of TNF-(alpha) during squamous carcinogenesis*, Proc. Natl Acad. Sci*. USA, 108(26):10662-10667. PMID: 21670304
77. Daldrup-Link H, Golovko D, DeNardo DG, Ruffel D, Castenada R, Wendland M, Corot C, **Coussens LM**. (2011) MR imaging of tumor-associated macrophages with clinically-applicable iron oxide nanoparticles. *Clin Can Res*. 17(17): 5695-5704. PMID: 21791632

*Featured in:*

- Featured as journal cover image
- Highlighted in Cancer Research 71: 6089, 2011

78. Shiao S, Ganesan AP, Rugo HS, **Coussens LM**. (2011) Immune microenvironments in solid tumors: New targets for therapy. *Genes and Development, 25(24): 2559-2572*. PMID: 22190457
79. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, **Coussens LM**. (2012) Leukocyte composition of human breast cancer. *Proc. Natl Acad. Sci.,109(8):2796-2801.* PMID: 21825174
80. Ruffell B, Affara NI, **Coussens LM**. (2012) Differential macrophage programming in the tumor microenvironment. *Trends Immunol*. *33*: 119-125. PMID: 22277903
81. Daldrup-Link H. & **Coussens LM**. (2012) MR imaging of tumor-associated macrophages. *OncoImmunology* **1**(4), 507-509. PMID: 22754769
82. Hanahan D, **Coussens LM**. (2012) Accessories to the crime: Functions of cells recruited to the tumor microenvironment, *Cancer Cell*, 21: 309-322. PMID: 22439926

- Reprinted as: 'Cell Press Supplement – Hallmarks of Cancer', April 2013. http://onlinedigeditions.com/publication?i=151915.

83. **Coussens LM,** Zitvogel L, Palucka AK. (2013) Neutralizing tumor-promoting chronic inflammation: A magic bullet? *Science*, 339 (117): 286-291. PMID: 23329041
84. Ganessan AP, Johanson M, Ruffell B, Beltran A, Lau J, Jablons DM, **Coussens LM**. (2013) Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cells responses to lung adenocarcinoma. J Immunology, 191(4):2009-2017. PMID: 23851682
85. Gunderson AG, **Coussens LM** (2013) B cells and their mediators as targets for therapy in solid tumors. *Exp Cell Res.* 319, 1644-1649. PMID: 23499742
86. Palucka K, **Coussens LM**, O'Shaughnessy (2013) Dendritic cells, inflammation and breast cancer. Cancer J. 19(6):511-516. PMID 24270350
87. Ruffell B*, Affara NI*, Cottone L, Junankar, S, Johansson M, DeNardo DG, Korets L, Reinheckel T, Sloane BF, Bogyo M, **Coussens LM**. (2013) Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. *Genes Dev*. 27(19): 2086-2098. PMID: 24065739

*, equal contribution

*Featured in:*

- Featured as journal cover image
- Research Highlight 'In Brief'; *'Tumor Microenvironment: Tissue-Specific* Functions'; Nature Reviews Cancer 13, 757 (2013). By: Sarah Seton-Rogers

88. Strachan DC, Ruffell B, Oei Y, Bissell M, **Coussens LM**, Pryer N, Daniel D. (2013) CSF1R inhibition impedes turnover of tumor-associated macrophages and increases infiltration by antitumor CD8+ T cells in murine mammary and cervical carcinomas. *OncoImmunology, 1;2(12):e26968.* PMID: 24498562
89. Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, **Coussens LM**, Brockstedt DG, Dubensky TW, Hassan R, Armstrong TD, Jaffee EM. (2014) A listeria vaccine and depletion of T-regulatory cells activate immunity against early-stage pancreatic intra-epithelial neoplasms and prolong survival of mice. Gastroenterology, 146(7): 1784-1794. PMID 24607504.
90. Affara NI*, Ruffell B*, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, Kulesz-Martin M, Irving B, **Coussens LM**. (2014) B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. *Cancer Cell,* 25(6): 809-821. PMID: 24909985.

*, equal contribution

*Featured in:*

- *Cancer Discovery* 17(2) 111-112 (2014). '*Protumor B cells are therapeutic targets in squamous cell carcinoma',* DOI: 10.1158/2159-8290.CD-RW2014-132. June 19, 2014

- *Immune Regulation News 6.21*June 13, 2014. http://www.immuneregulationnews.com/issue/volume-6-21-jun-13/

91. Fornetti J, Martinson H, Betts CB, Lyons TR, Jindal S, Guo Q, **Coussens LM**, Borges VF, Schedin P. (2014) Mammary gland involution as an immunotherapeutic target for postpartum breast cancer. *J Mammary Gland Biol Neoplasia* 19(2): 213-228. PMID: 24952477.
92. Medler TR, **Coussens LM**. (2014) Duality of the immune response in cancer: Lessons learned from skin. *J Invest Dermatol.* 134(e1):E23-28. PMID: 25302470.
93. Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CMT, Pryer N, Daniel D, Hwang SE, Rugo HS, **Coussens LM**. (2014) Macrophage IL-10 blocks $CD8^+$ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. *Cancer Cell,* 26:623-637. PMID: 25446896.

*Featured in:*

- Preview*. Cancer Cell 26:591-59 3 (2014). 'CD103*$^+$ *dendritic cells producing interleukin-12 in anticancer immunosurveillance',* by L Zitvogel and G Kroemer.
- *Cancer Discovery* 17(2) 111-112 (2014). '*Suppression of dendritic cells by IL10 limits chemotherapy responses',* DOI: 10.1158/2159-8290.CD-RW2014-223. October 30, 2014.

94. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A[13], Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, **Coussens LM,** Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F[12], Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. (2014) Classification of current anticancer immunotherapies. *OncoTarget,* 5(240):12472-12508. PMID: 25537519.
95. Shiao S, Ruffell B, DeNardo DG, Faddegon BA, Park CC, **Coussens LM**. (2015) TH2-polarized $CD4^+$ T cells and macrophages limit efficacy of radiation therapy. *Can Immuno Res.* 3(5):518-525. PMID: 25716473.
96. Cuevas I, Layman H, **Coussens LM**, Boudreau N. (2015) Sustained endothelial expression of HoxA5 in vivo impairs pathological angiogenesis and tumor progression. *PLoS One*. 10(3):e0121720. PMID: 2582196.
97. Ruffell B, **Coussens LM**. (2015) Macrophages and therapeutic resistance in cancer. *Cancer Cell.* 27(4):462-472. PMID:25828805.

- Reprinted as: 'Cell Press Selections – Immuno-Oncology, The Cancer-Immunity Cycle, 2015. http://digitaleditions.sheridan.com/publication/frame.php?i=278807&p=&pn=&ver=flex&submissionGuid=21b50452-1232-46df-b948-2aa05d3a9f13
- Reprinted as: '**Cancer Cell, Best of 2015'**. August 2016. http://ccell_bestof2015.elsevierdigitaledition.com/

98. Cotechini T, Medler TR, **Coussens LM**. (2015) Myeloid cells as targets for therapy in solid tumors. *Cancer J*. 21(4), 343-350. PMID: 26222088.
99. Medler TR, Cotechini T, **Coussens LM**. (2015) Immune response to cancer therapy: Mounting an effective antitumor response and mechanisms of resistance. *Trends in Cancer.* 1:66-75. PMID: 26457331.
100. Davidson N, Armstrong S, **Coussens LM**, Cruz-Correa M, DeBerardinis R, Doroshow J, Hwu P, Kensler T, Morrow M, Mulligan C, Pao W, Platz E, Smith T, Willman C. AACR Cancer Progress Report 2016. *Clin Cancer Res.* Clin Cancer Res. 22(19 Supplement): S1-S137. PMID:27697776.
101. Ruhland M, **Coussens LM**, Stewart S. (2016) Senescence and cancer: an evolving inflammatory paradox. *Biochimica et Biophysica Acta*. 1865:14-22. PMID: 26453912.
102. Lund AW, Medler TR, Leachman SA, **Coussens LM**. (2016) Lymphatic vessels regulate the regional immune landscape: Implications for malignant and non-malignant cutaneous disease. *Cancer Discovery*, 6(1):22-35. PMID: 26552413
103. Gunderson AJ*, Kaneda M*, Tsujikawa T, Affara NI, Nguyen, Ruffell B, Gorjestani S, Liudahl SM,

Truitt M, Olson P, Kim G, Hanahan D, Tempero M, Sheppard B, Irving B, Varner JA*, **Coussens LM***. (2016) Bruton's tyrosine kinase (BTK)-dependent immune cell crosstalk drives pancreas cancer. *Cancer Discovery*, *6(3): 270-285.* PMID: 26715645;

*, equal 1st author, and senior author contributions

*Featured in:*

- Research Highlight. Nature Reviews Cancer 16 (2), 67 (2016). *''Pancreatic Cancer: Spotlight on B cells".* By: Sarah Seton-Rogers
- Views – In the Spotlight. Cancer Discovery, 6(3):230-232 (2016). "*B cells Promote Pancreatic Tumorigenesis*", By: Ali Roghanian, Christopher Fraser, Maruanna Kleyman, Jianzhu Chen.
- Editor's Choice: *Cancer Immunology*. Sci. Signal. 9(422):ec77 (2016). "*B cells fuel pancreatic cancer".* By: Leslie K. Ferrarelli

104. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, **Coussens LM**, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. (2016) Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. *OncoImmunology, 5(3):e1136044.* PMID: 27141370.
105. Palucka AK, **Coussens LM**. (2016) The basis of oncoimmunology. *Cell,* 164(6):1233-1247. PMID: 26967289.
106. Daldrup-Link HE, Mohanty S, Ansari C, Lenkov O, Shaw A, Ito K, Hong SH, Hoffman M, Pisani L, Boudreau N, Gambhir SS, **Coussens LM**. (2016) Alk5-inhibition increases delivery of macromolecular and protein-bound contrast agents to tumors. *J Clin Invest Insight*. 1(6):e85608. PMID: 27182558.
107. Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, Pajarinen JS, Nejadnik H, Goodman S, Moseley M, **Coussens LM**, Daldrup-Link HE. (2016) Iron oxide nanoparticles inhibit tumor growth. *Nature Nanotechnol,*11(11):986-994. PMID: 27668795.
108. Liu Y, Wang Z, De La Torre R, Barling A, Tsujikawa T, Hornick N, Hanifin J, Simpson E, Wang Y, Swanzey E, Wortham A, Ding H, **Coussens LM**, Kulesz-Martin M. (2016) Trim32 deficiency enhances Th2 immunity and predisposes to features of atopic dermatitis. *J Invest Derm.* 137(2):359-366. PMID:27720760.
109. Wilson RA, Espinoza-Diez C, Kanner N, Chattejee N, Ruhl R, Hipfinger C, Advani S, Li J, Khan O, Franovic A, Weis S, Kumar S, **Coussens LM**, Anderson D, Chen CC, Cheresh D, Anand S. (2016) MicroRNA regulation of endothelial TREX1 reprograms the tumor microenvironment. *Nature Comm*., 7:13597. PMID:27886180.
110. Tsujikawa T, Kumar S, Borkar RN, Azimi V, Thibault G, Chang YH, Balter A, Kawashima R, Choe G, Sauer D, El Rassi E, Clayburgh DR, Kulesz-Martin MF, Lutz ER, Zheng L, Jaffee EM, Leyshock P, Margolin AA, Mori M, Gray JW, Flint PW, **Coussens LM**. (2017) Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis. *Cell Reports,* 19:203-217. PMID:28380359

Featured as:

- OHSU School of Medicine, *Paper of the Month*. May 2017

111. Ghast CE, Shaw AK, Wong MH, **Coussens LM**. (2017) Surgical: procedures and methodology for a preclinical murine model of de novo mammary cancer metastasis. *J. Vis. Exp., (125), e54852. doi:* 10.3791/54852. PMID:28784976
112. Del Alcazar CR, Huh SJ, Ekram M, Trinh A, Liu LL, Becca F, Zi X, Kwak M, Bergholtz, H, Su Y, Ding L, Russnes HG, Richardson AL, Babski K, Kim EMH, McDonnell CH, Wagner J, Rowberry R, Freeman G, Dillon D, Sorlie T, **Coussens LM**, Garber JE, Fan R, Bobolis K, Allred DC, Park SY, Michor F, Polyak K. (2017) Immune escape in breast cancer during in situ to invasive carcinoma transition. *Cancer Discovery,* 7(10):1098-1115. PMID: 28652380
113. Chang YH*, Tsujikawa T*, Margolin A, **Coussens LM**, Gray JW. (2017) Multiplexed immunohistochemistry image analysis using sparse coding. *Conf Proc IEEE Eng Med Biol Soc*. 2017:4046-4049. doi: 10.1109/EMBC.2017.8037744. PMID:29060785
*, equal contribution

114. Gopalakrishnan V, Spencer C, Reuben A, Andrews M, Karpinets T, Prieto P, Vicente D, Nezi L, Hoffman K, Cogdill A, Zhao L, Hudgens C, Hutchinson D, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy S, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall E, Rezvani K, Alousi A, Chemaly R, Shelburne S, Vence L, Okhuysen P, Jensen V, Swennes A, McAllister F, Marcelo E, Sanchez R, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman J, Haydu L, Burton E, Gardner J, Sirmans E, Hu J, Lazar A, Tsujikawa T, Diab A, Tawbi H, Glitza I, Hwu WJ, Patel S, Woodman S, Amaria R, Davies M, Gershenwald J, Hwu P, Lee J, Zhang J, **Coussens LM**, Cooper Z, Tetzlaff M, Futreal A, Daniel-MacDougall C, Ajami N, Petrosino J, Sharma P, Allison J, Jenq R, Wargo J. (2018) Gut microbiota are associated with differential responses to PD-1 blockade in melanoma patients. *Science,* 359(359): 97-103. PMID:29097493
115. de Mingo Pulido A, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, **Coussens LM**, Ruffell B. (2018) TIM-3 regulates CD103$^{+}$ dendritic cell function and response to chemotherapy in breast cancer. *Cancer Cell*, 33(1): 60-74. PMID:29316433
116. Binnewies M, Roberts E, Kersten K, Chan V, Fearon DF, Merad M, **Coussens LM,** Gabrilovich D, Ostrand-Rossenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft K, Woodhouse E, Weinberg R, Krummel M. (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy*. Nature Med.* 24(5):541-550. PMID: 29686425
117. Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin J, Sun YH, Rech AJ, Balli D, Hay CA, Sela Y, Merrell AJ, Liudahl SM, Gordon N, Norgard RJ, Yuan S, Yu S, Chao T, Ye S, Eisinger-Mathason TSK, Faryabi RB, Tobias JW, Lowe S, **Coussens LM**, Wherry EJ, Vonderheide RH, Stanger BZ. (2018) Tumor cell-intrinsic factors underlie immune heterogeneity and therapeutic response. *Immunity*, 49(1): 178-193. PMID: 29958801

*Featured in:*

- Preview: *Immunity* 49 (1):11-13 (2018). *'A tumor cell-intrinsic yin-yang determining immune evasion"*. By: Brendan Horton and Stefani Spranger

118. Gast CE, Silk AD, Zarour L, Riegler L, Burkhart JG, Gustafson K, Parappilly MS, Roh-Johnson M, Goodman JR, Olson B, Schmidt M, Swain JR, Davies PS, Shasthri V, Iizuka S, Flynn P, Watson S, Korkola J, Courtneidge SA, Fischer J, Jaboin J, Billingsley KG, Lopez CD, Burchard J, Gray J, **Coussens LM**, Sheppard BC, Wong MH. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. *Science Adv*., *4(9):eaat7828.* PMID:30214939
119. Pennock ND, Martinson HA, Guo Q, Betts CB, Jindal S, Tsujikawa T, **Coussens LM**, Borges VF, Schedin P. (2018) Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of post-partum breast cancer. *J Immuno Ther Cancer. 6(1):98.* https://doi.org/10.1186/s40425-018-0406-y. PMID:30285905
120. Medler TR, Murugan D, Horton W, Kumar S, Cotechini T, Forsyth AM, Leyshock P, Leitenberger JJ, Kulesz-Martin M, Margolin A, Werb Z, **Coussens LM**. (2018) Complement C5a fosters squamous carcinogenesis and limits T cell response to chemotherapy, *Cancer Cell,* 34:561-578. PMID:30300579

*Featured in:*

- Preview: *Cancer Cell* 34:531-533 (2018). *'Complement C51-mediated TAM-ing of antitumor immunity drives squamous carcinogenesis'*. By: D.C. Mastellos, E.S. Reid, and J.D. Lambris.
- Research Watch: *Cancer Discovery* DOI: 10.1158/2159-8290.CD-RW2018-181. '*Inhibiting C5a enhances chemotherapeutic efficacy'*
- Research Highlight: *Nature Reviews: Drug Discovery* 17(12):216 (2018). DOI:10.1038/nrd.2018.216 '*Complementing tumor macrophage reprograming'* By: M. Teresa Villanueva.
- *Faculty of 1000 – Exceptional.* Authoritative evaluation by MB Yaffe (Massachusetts Institute of Technology). 10.3410/f.734170602.793553517.

121. Saung MT, Muth S, Ding D, Thomas DL, Blair AB, Tsujikawa T, **Coussens LM**, Jaffee EM, Zheng L. (2018) Targeting myeloid-inflamed tumor with anti-CSF1R antibody expands CD137$^{+}$ effector T-cells in the murine model of pancreatic cancer. *J Immunother Cancer* 6(1): 118. doi: 10.1186/s40425-018-0435-6. PMID:30424804
122. Keklikoglou I, Cianciaruso C, Guc E, Squadrito ML, Spring LM, Tazzyman S, Lambein L, Poissonnier A, Ferraro GB, Baer C, Cassara A, Guichard A, Iruela-Arispe ML, Lewis CE, **Coussens LM**, Bardia A, Jain R, Pollard JW, De Palma M. (2018) Chemotherapy elicits pro-metastatic extracellular

vesicles in breast cancer models. *Nature Cell Biology,* 21(2): 190-202. PMID:30598531

123. Casetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong D, Cotechini T, Anur P, Lin E, Fidanza A, Yrigoyen ML, Millar MR, Urman A, Ai Z, Spellman P, Hwang ES, Dixon JM, Wiechmann L, **Coussens LM**, Smith HW, Pollard JW. (2019) Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers and therapeutic targets. *Cancer Cell,* 35(4): 588-602. PMID: 30930117

*Featured in:*

- Preview: *Cancer Cell* 35:538-539 (2019). '*Deciphering macrophage and monocyte code to stratify human breast cancer patients'*. By: Vicenzo Bronte
- Highlights from the Literature: *Cancer Immuno Res* June 2019. '*Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprograming, biomarkers, and therapeutic targets"*
- Featured as journal cover image
- Reprinted as 'Cancer Cell Best of 2019', Reprint compendium of 'Most Widely Read Papers of 2019'

124. Tsujikawa T, Thibault G, Azimi V, Sivagnanam, Banik G, Means C, Kawashima R, Clayburgh DR, Gray JW, **Coussens LM**, Chang YH. (2019) Robust cell detection and segmentation for image cytometry reveal Th17 cell heterogeneity. *Cytometry. 95(4): 389-398*. PMID:30714674
125. Means C, Clayburgh DR, Maloney L, Sauer D, Taylor M, Shindo M, **Coussens LM**, Tsujikawa T. (2019) Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status. *Head & Neck, 1-11.* doi.org/10.1002/hed.25740. PMID: 30896061
126. Reddy S, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens C, Tetzlaff M, Reuben J, Tsujikawa T, **Coussens LM**, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward W, Ueno N, Krishnamurthy S, Wargo J, Mittendorf E. (2019) Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer. *Can Immuno Res.*7(6):1025-1035. PMID: 31043414
127. Blair AB, Kim V, Muth S, Saung MT, Lokker N, Blouw B, Armstrong T, Jaffee E, Tsujikawa T, **Coussens LM**, He J, Burkhart R, Wolfgang C, Zheng L. (2019) Dissecting the stromal signaling and regulation of myeloid cells and memory effector T cells in pancreatic cancer. *Clin Can Res.* 25(17):5351-5363. PMID: 31186314
128. Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstron A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy AL, Jaffee E, **Coussens LM**, Brockstedt DG. (2019) Live-attenuated, *Listeria monocytogenes* expressing mesothelin (CRS-207) with chemotherapy for treatment of malignant pleural mesothelioma. *Clin Can Res.,* 25 (19):5787-5798. PMID: 31263030

Featured in:

- Journal cover image
- *News and Views: Nature Reviews Clinical Oncology* 16:726-728 (2019). 'Immunotherapy trials in mesothelioma – promising results, but don't stop here'. By: AK Nowak, PM Forde.

129. Wesolowski R, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Severson P, Karlin DA, Dowlati A, Le MH, **Coussens LM**, Rugo HS. (2019) Phase 1B study of the combination of pexidartinib (PLX3397), a colony stimulating factor receptor 1 (CSF-1R) inhibitor, and paclitaxel in patients with advanced solid tumors. *Ther Adv Med Onc. 11*:*1758835919854238*. PMID: 31258629
130. Vitale I, Manic G, **Coussens LM**, Kroemer G, Galluzzi L. (2019) Macrophages and metabolism in the tumor microenvironment. *Cell Metabolism,* 30(1):36-50. PMID: 31269428
131. Hundeyin M, Kurz E, Mishra A, Rossi JAK, Liudahl SM, Leis K, Mehrotra H, Kim M, Torres LE, Ogunsankin A, Link J, Sears RC, Sivagnanam S, Goecks J, Islam KMS, Dolgalev I, Savadkar S, Wang W, Aykut B, Leinwand J, Diskin B, Adam S, Israr M, Gelas M, Lish J, Farooq MS, Wadowski B, Wu J, Shah S, Adeegbe D, Pushalkar S, Vasudevaraja V, Saxena D, Wong KK, **Coussens LM**, Miller G. (2019) Innate αβT cells mediate anti-tumor immunity by orchestrating immunogenic macrophage programming. *Can Disc.* 9(9):1288-1305. PMID: 31266770

*Featured in:*

- Spotlight: *Cancer Discovery* 9(9):1164-1166 (2019). 'Unconventional T cells in the pancreatic tumor microenvironment: Thinking outside the box'. By: S Banerjee, V Dudeja, A Saluja

132. Michaelis KA, Norgard MA, Zhu X, Levasseur PR, Sivagnanam S, Liudahl SM, Burfeind KG, Olson BG, Pelz KR, Ramos DMA, Maurer HC, Olive KP, **Coussens LM**, Morgan TK, Marks DL. (2019) The TLR7/8 agonist R848 remodels tumor and host immune responses to promote survival in pancreatic cancer. *Nat. Comm. 10(1):4682.* PMID: 31615993
133. Shirai T, Revenko A, Tibbitts J, Ngo A, Mitrugno A, Healy L, **Coussens LM**, McCarty OJT, Monia B, Gruber A. (2019) Antisense oligonucleotide targeting of thrombopoietin gene expression inhibits spontaneous breast cancer progression in mice. *Blood Advances,* 3(20):3080-3091. PMID: 31648335
134. Galliverti G, Wullschleger S, Tichet M Murugan D, Zangger N, Horton W, Korman A, **Coussens LM**, Swartz MA, Hanahan D. (2020) Myeloid cells orchestrate systemic immunosuppression that impairs the efficacy of therapeutic vaccination and masks the effects of immunotherapy against HPV+ cancers. *Can Immuno Res.* 8(1):131-145. PMID: 31771984.
135. Banik G, Betts CB, Liudahl S, Sigagnanam S, Kawashima R, Cotechini T, Larson W, Pai SI, Clayburgh DR, Goeks J, Tsujikawa T, **Coussens LM**. (2020) High-dimensional multiplexed immunohistochemistry characterization of immune contexture in human cancer. *Methods Enzymol., 635:1-20*. PMID: 32122539
136. Tsujikawa T, Crocenzi T, Durham JN, Sugar E, Wu A, Onners B, Nauroth JN, Anders RA, Fertig EJ, Lahreru DA, Reiss KA, Vonderheide RH, Ko AH, Tempero MA, Fisher GA, Considine M, Danilova L, Brockstedt DG, **Coussens LM**, Jaffee EM, Le DT. (2020) Safety, survival, and immune response with GVAX pancreas prime and *Listeria Monocytogenes*-expressing mesothelin (CRS-207) boost vaccines with and without Nivolumab for metastatic pancreatic. *Clin Can Res.* 26(14):3578-3588. PMID: 32273276.
137. Rozenblatt-Rosen O, Regev A, Oberdoerffer P, Nawy T, Hupalowska A, Rood JE, Ashenberg O, Cerami E, Coffey RJ, Demir E, Ding L, Esplin ED, Ford JM, Goecks J, Ghosh S, Gray JW, Guinney J, Hanlon SE, Hughes SK, Hwang ES, Iacobuzio-Donahue CA, Jané-Valbuena J, Johnson BE, Lau KS, Lively T, Mazzilli SA, Pe'er D, Santagata S, Shalek AK, Schapiro D, Snyder MP, Sorger PK, Spira AE, Srivastava S, Tan K, West RB, Williams EH; **Human Tumor Atlas Network** (2020) The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. *Cell*. 181(2):236-249. PMID: 32302568
138. Pennycuick A, Teixeira VH, AbdulJabbar K, Raza SEA, Lund T, Akarca A, Rosrnthal R, Kalinke L, Chandrasekharan C, Pipinikas CP, Lee-Six H, Hynds RE, Gowers KHC, Henry JY, Millar FR, Hagos YB, Denais C, Falzon M, Moore D, Antoniou S, Durrenberger, PF, Furness A, Carroll B, Marceaux C, Asselin-Labat ML, Larson W, Betts C, **Coussens LM**, Thakrar RM, George J, Swanton C, Thirwell C, Campbell PJ, Marafioti T, Yuan Y, Quesada SA, McGranahan N, Janes S. (2020) Immune surveillance in clinical regression of pre-invasive squamous cell lung cancer. *Cancer Discovery,* 10(10); 1489-1499. PMID: 32690541
139. Maller O, Drain AP, Barrett AS, Borquist S, Ruffell B, Zakharevich I, Pham TT, Gruosso T, Kuasne H, Lakins JN, Acerbi I, Barnes JM, Nemkov T, Chauhan A, Gruenberg J, Nasir A, Bjarnadottir O Werb Z, Kabos P, Chen YY, Hwang ES, Park M, **Coussens LM**, Nelson AC, Hansen KC, Weaver VM. (2021) Tumor-associated macrophages drive stromal cell-dependent collagen cross-linking and stiffening to promote breast cancer aggression. *Nature Materials.* 220(4): 548-559. PMID: 33257795
140. Väyrynen SA, Zhang J, Yuan C, Väyrynen JP, Costa AD, Williams H, Morales-Oyarvide V, Lau MC, Rubinson DA, Dunne RF, Kozak MM, Wang W, Agostini-Vulaj D, Drage MG, Brais L, Reilly E, Rahma O, Clancy T, Wang J, Linehan DC, Aguirre AJ, Fuchs CS, **Coussens LM**, Chang DT, Koong AC, Hezel AF, Ogino S, Nowak JA, Wolpin BM. (2021). Spatial characteristics, and prognostic significance of myeloid cell infiltration in pancreatic cancer. *Clin Can Res, 27(4):1069-1081.* PMID: 33262135
141. Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, Waldschmidt DT, Starling N, Bachet JB, Chang HM, Maurel J, Farcia-Carbonero R, Lonardi S, **Coussens LM**, Fong L, Tsao LC, Cole G, James D, Marcarulla T. (2021). Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: Phase 3 RESOLVE study. *Ann Oncol*. 32(5):600-608. PMID: 33539945
142. Liudahl SM*, Betts CB*, Sivagnanam S*, Morales-Oyarvide V, da Silva A, Yuan C, Smuel Hwang S, Grossblatt-Wait A, Leis KR, Larson W, Lavoie MB, Robinson P, Costa AD, Väyrynen SA, Clancy TE, Rubinson DA, Link J, Keith D, Horton W, Tempero MA, Vonderheide RH, Jaffee EM, Sheppard

B, Goecks J, Sears RS, Park BS, Mori M, Nowak JA*, Wolpin BM*, **Coussens LM***. (2021). Leukocyte heterogeneity in pancreatic ductal adenocarcinoma: phenotypic and spatial features associated with clinical outcome. *Cancer Discovery,* 11(8):2014-2031. PMID: 33727309

*, equal 1st author, and senior author contributions

*Featured in:*

- 3rd OncoAlert, presented by A. Mitra (@CD_AACR Academic Recap Video, 1 and 2)
- Highlights from the Literature: *Cancer Immuno Res* October 2021.

143. Gatti G, Betts CB, Rocha D, Nicola M, Grupe V, Ditada C, Nunez NG, Roselli E, Araya P, Dutto J, Boffelli L, Fernandez E, **Coussens LM**, Maccioni M. (2021) High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer. *Breast Cancer Res,* 23(1):40. PMID: 33766090 and 33888121 (correction)
144. Link JM, Liudahl SM, Betts CB, Sivagnanam S, Leis KR, McDonnel M, Pelz CR, Johnson B, Hamman KJ, Keith D, Sampson JE, Morgan TK, Lopez CD, **Coussens LM**, Sears RC. (2021) Tumor infiltrating leukocyte phenotypes distinguish outcomes in related patients with pancreatic adenocarcinoma. *JCO Precis Oncol.* 2021 Feb 5;5:PO.20.00287. doi: 10.1200/PO.20.00287. eCollection 2021. PMID: 34036232
145. Thomas PL, Groves SM, Zhang YK, Li J, Gonzalez-Ericsson P, Sivagnanam S, Betts CB, Chen HC, Liu Q, Lowe C, Chen H, Boyd KL, Kopparapu P, Yan Y, **Coussens LM**, Quaranta V, Tyson D, Iams W, Lovly CM. (2021) Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer. *J Thoracic Onc.* 16(7):1211-1223. PMID: 33839362
146. Byrne KT*, Betts CB*, Mick R*, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O'Hara MH, Liudahl SM, Newcomb C, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Vayrynen SA, Costa AD, Kaiser JC, Wherry EJ, Cheever MA, Wolpin BM, Furth EF, Jaffee EM, **Coussens LM**, Vonderheide RH. (2021) Neoadjuvant selicrelumab, an agonist CD40 antibody, changes the tumor microenvironment in patients with resectable pancreatic cancer. *Clin. Can Res.* 27: 4574-4586. PMID: 34112709

*, equal 1st author contributions

147. Labrie M, Li A, Creason A, Betts CB, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chan YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, **Coussens LM**, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI. (2021) Multi-omics analysis of serial PARP inhibitor-treated metastatic TNBC inform on rational combination therapies. *npj Precision Oncology,* 5(1):92; doi.org/10.1038/s41698-021000232-w. PMID: 34667258
148. Yoshimura K, Tsujikawa T, Mitsuda J, Ogi H, Saburi S, Ohmura G, Arai A, Shibata S, Thibault G, Chang YH, Clayburgh DR, Yasukawa S, Miyagawa-Hayashino A, Konishi E, Itoh K, **Coussens LM**, Hirano S. (2021) Spatial profiles of intratumoral PD-1$^{+}$ helper T cells predict prognosis in head and neck squamous cell carcinoma. *Frontiers in Immunology.* 28(12):769534. doi: 10.3389/fimmu.2021.769534. eCollection 2021. PMID: 34777389
149. Schapiro D, Sokolov A, Yapp C, Muhlich JL, Hess J, Lin JR, Chen YA, Nariya MK, Baker GJ, Ruokonen J, Maliga Z, Jacobson CA, Farhi SL, Abbondanza D, McKinley ET, Betts C, Regev A, Coffey RJ, **Coussens LM**, Santagata S, Sorger PK. (2022) MCMICRO: A scalable, modular image-processing pipeline for multiplexed tissue imaging. *Nature Methods,* 19(3): 311-315. PMID: 34824477
150. Taylor MH*, Betts CB, Maloney L, Nadler E, Algazi A, Guarino MJ, Nemunaitis J, Jimeno A, Patel A, Munugalavadla V, Tao L, Adkins D, Goldschmidt JH, Cohen EE, **Coussens LM***. (2022) Safety and efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: Phase 2 proof-of-concept study. *Clin Can Res,* 28(5): 903-914. PMID: 34862248

*, equal senior author contributions

*Featured in:*

- Journal cover image

151. Blise KE, Sivagnanam S, Banik GL, **Coussens LM**, Goecks J. (2022) Single-cell spatial proteomics analyses of head and neck squamous cell carcinoma reveal tumor heterogeneity and immune architectures associated with clinical outcome. *npj Precision Oncology,* 6(1):10. PMID: 35217711

152. Johnson BE, Creason AL, Stommel JM, Keck JM, Parmar S, Betts CB, Blucher A, Bonafice C, Bucher E, Burlingame E, Camp T, Chin K, Eng J, Estabrook J, Feiler HS, Heskett MB, Hu Z, Kolodzie A, Kong BL, Labrie M, Lee J, Leyshock P, Mitri S, Patterson J, Riesterer JL, Sivagnanam S, Somers J, Sudar D, Thibault G, Weeder BR, Zheng C, Nan X, Thompson RF, Heiser LM, Spellman PT, Thomas G, Demir E, Chang YH, **Coussens LM**, Guimaraes AR, Corless C, Goecks J, Bergan R, Mitri Z, Mills GB, Gray JW. (2022) An omic and multidoimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer, *Cell Reports Medicine,* 3(2): 100525. PMID: 35243422
153. Schapiro D, Yapp C, Sokolov A, Reynolds SM, Chen YA, SUdar D, Xie Y, Muhlich J, Arias-Camison R, Arena S, Taylor AJ, Nikolov M, Tyler M, Lin JR, Burlingame EA, **Human Tumor Atlas Network**, Chang YH, Farki SL, Thorsson V, Venkatamohan N Drewes JL, Pe'er D, Gutman DA, Hermann MD, Gehlenborg N, Bankhead P, Roland JT, Herrndon JM, Snyder MP, Angelo M, Nolan G, Swedlow JR, Schultz N, Merrick DT, Mazzili SA, Cerami E, Rodig SJ, Santagata S, Sorger PK. (2022) MITI minimum information guidelines for highly multiplexed tissue images. *Nature Methods*, 19(3): 262-267. PMID: 35277708
154. Crosby D, Bhatia S, Brindle K, **Coussens LM**, Dive C, Emberton M, Esener S, Fitzgerald RC, Gambhir SS, Kuhn P, Rebbeck T, Balasurbramanian S. (2022) Early detection of cancer. *Science, 18:375 (6586):eaay9004.* PMID: 35298272.
156. Petroni G, Buque A, **Coussens LM**, Galluzzi L. (2022) Targeting oncogene and non-oncogene addiction to inflame the tumor microenvironment. *Nature Reviews Drug Discovery*, 21(6): 440-462. PMID: 35292771.
157. Daniel CJ, Pelz C, Wang X, Munks MW, Ko A, Murugan D, Byers SA, Juarez E, Taylor KL, Fan G, **Coussens LM**, Link JM, Sears RC. (2022) T-cell dysfunction upon expression of MYC with altered phosphorylation at threonine 58 and serine 62. *Molecular Cancer Research*, 20(7):1151-1165. PMID: 35380701
158. Tatarova Z, Blumberg DC, Korkola JE, Heiser LM, Muschler JL, Schedin P, Ahn SW, Mills GB, **Coussens LM**, Jonas O, Gray JW. (2022) Systemic identification of synergistic combinations of targeted agents and immunotherapies in breast cancer using intratumor multiplex implantable microdevice assay. *Nature Biotechnology,* 40(12):1823-1833. PMID: 35788566
159. Sundaram S, Kim EN, Jones GM, Sivagnanam S, Tripath M, Miremadi A, Di Pietro M, **Coussens LM**, Fitzgerald RC, Chang YH, Zhuang L. Deciphering the immune complexity in esophageal adenocarcinoma and pre-cancerous lesions with sequential multiplex immunohistochemistry and sparce subspace clustering (SSC) approach*. Frontiers in Immunology - Cancer Immunity and Immunotherapy*, 13:874255. *doi: 10.3389/fimmu.2022.874255. eCollection.* PMID: 35663986
160. Sepe JJ*, Gardner RT*, Blake MR, Brooks DM, Staffenson MA, Betts CB, Sivagnanam S, Larson W, Kumar S, Bayles RG, Jin H, Cohen MS, **Coussens LM**, Habecker BA. (2022) Therapeutics that promote sympathetic reinnervation modulate the inflammatory response after myocardial infarction. *JACC: Basic to Translational Science, 7(9): 915-930.* PMID: 36317132
*, equal 1st author contributions
161. Abrego J, Sanford-Crane H, Oon Chet, Xiao X, Betts CB, Sun D, Nagarajan S, Bhattacharyya S, Xia Z, **Coussens LM**, Tontonoz P, Sherman MH. (2022) A cancer cell-intrinsic GOT2-PPARγ axis suppresses antitumor immunity. *Cancer Discovery,* 12(10):2414-2433. PMID: 35894778
162. Mi H, Sivagnanam S, Betts CB, Liudahl SM, Jaffee EM, **Coussens LM**, Popel AS. (2022) Quantitative spartial profiling of immune populations reveals prognostic significance in patients with pancreatic ductal adenocarcinoma. *Cancer Research,* 82(23):4359-4372. PMID: 36112643

*Featured in:*

- Journal cover image

163. Kitko CL, Aroro M, DeFilipp Z, Zaid MA, Di Stasi A, Radojcic V, Betts CB, **Coussens LM**, Meyers ML, Qamoos H, Ordentlich P, Kumar V, Quaranto C, Schmitt A, Gu Y, Blazar BR, Wang TP, Salhotra A, Pusic I, Jagasia M, Lee SJ. (2022) Axatilimab for chronic graft-versus-host disease after failure of at least 2 prior systemic therapies: results of a phase 1/2 study. *J Clin Oncol.* 2022 Dec 2:JCO2200958. doi: 10.1200/JCO.22.00958. Online ahead of print. PMID: 36459673
164. Sinha M*, Betts C*, Zhang L, Chen B, Griffith MJ, Solman I, Liu E, Tamaki W, Stultz J, Cheung A, Sivagnanam S, Pener D, Fahlman A, Taber E, Lerner K, Crocker M, Todd K, Rajagopalan B, Vo J, Dragomanovich H, Sudduth-Klinger J, Vaccaro G, Lopez CD, Tempero M, **Coussens LM***, Fong L*. (2023) Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in

metastatic pancreatic ductal carcinoma patients. *J Immunother Cancer,* Jan;11(1):e005425. doi: 10.1136/jitc-2022-005425. PMID: 36593070
*, co-first and co-senior authors

165. Brockman AA, Khurana R, Bartkowiak T, Thomas PL, Sivagnanam S, Betts CB, **Coussens LM**, Lovly CM, Irish JM, Ihrie RA. Alignment, segmentation, and neighborhood analysis of cyclic immunohistochemistry data using CASSATT. *Cytometry Part B: Clinical Cytometry,* 2023 Feb 7. doi: 10.1002/cyto.b.22114. Online ahead of print. PMID: 36748312
166. Steele MM, Jaiswal A, Delclaux I, Dryg ID, Murugan D. Femel J, Son S, du Bois H, Hill C, Leachman SA, Chang YH, **Coussens LM,** Anandasabapathy N, Lund AW. (2023) T cell egress via lymphatic vessels limits the intratumoral T cell repertoire in melanoma. *Nature Immunology,* 24(4): 664-675 PMID: 36849745; PMID: 36932125 (author correction)
167. Ren T, Chen C, Danilov AV, Guan X, Du S, Wu X, Sherman MH, Spellman PT, **Coussens LM**, Adey AC, Mills GB, Wu LY, Xia Z. (2023) Supervised learning of high confidence phenotypic subpopulations from single cell data. *Nature Machine Intelligence. In press.*
168. Gurun B, Horton W, Murugan D, Zhu B, Leyshock P, Qu P, Kumar S, Byrne KT, Vonderheide RH, Margolin AA, Mori M, Spellman PT, **Coussens LM**, Speed TP. An open source computational pipeline for modeling T cell clonotype repertoires using the TCRβ locus sequence analyses. *BMC Genomics. in press*.
    a. Res Sq. 2023 Feb 16:rs.3.rs-2140339. doi: 10.21203/rs.3.rs-2140339/v1. Preprint. PMID: 36824803
169. Doha ZO, Wang X, Calistri NL, Eng J, Daniel CJ, Ternes L, Kim EN, Pelz C, Munks M, Betts C, Kwon S, Bucher E, Li X, Waugh T, Tatarova Z, Blumberg D, Ko A, Kirchenberger N, Pietenpol JA, Sanders ME, Langer E, Dai M, Mills G, Chin K, Chang YH, **Coussens LM**, Gray JW, Heiser LM, Sears RC. MYC deregulation and PTEN loss model tumor and stromal heterogeneity of aggressive triple-negative breast cancer. *Nature Comm., in press*

***Manuscripts Submitted or In Revision:***

- Lee J*, Labrie M*, Wei S*, Betts CB*, Beasley GM, Schuchter LM, Xu W, Yong G, Ma H, Grout M, Torigian DA, Sivagnanam S, Kuang D, Sugarman E, McGettigan, Zheng C, Al-Rohil R, Selim MA, Datto MB, Lopez GY, Nair SK, Ashley DM, Xu X, Amaravadi RK, Karakousis GC, O'Rourke DM, Brem S, O'Malley BW, Demirkan G, Yu S, Lu Y, Camp T, Patterson JA, Wei Z, Corless C, Gabrilovich DI, Liu L, **Coussens LM***, Herlyn M*, Mills G*, Zhang G*. Spatiotemporal analysis of longitudinal metastatic melanoma reveals mechanisms of resistance to cancer immunotherapies. *Submitted.*
  *, equal 1st author, and senior author contributions
- Ghebremedhin A, Shepard RM, Betts C, Dayao DA, Hu J, Chen H, Sasik R, Fisch KM, Uchiyama S, Seo H, Paradise M, Robinson S, Tzipori S, Piedra-Mora C, Das S, Hasteh F, Russo H, Sin X, Xu L, Kirchenberger NC, Chin SM, Von Schalsha T, Martinot TA, Patel SP, Nizet V, Martinot AJ, **Coussens LM**, Varner JA. PI3Kγ inhibition reduces inflammation and promotes survival in SARS-CoV-2 infection. *Submitted.*
- Creason A, Watson C, Gi Q, Persson D, Sargent L, Chen YA, Lin JR, Sokolov A, Sivagnanam S, Wunnemann F, Chin K, Feiler HS, **Coussens LM**, Schapiro D, Gruning B, Sorger PK, Goecks J. A web-based software resource for interactive analysis of multiplex tissue imaging datasets. *Submitted.*
- Link JM, Pelz C, Worth PJ, Owen S, Keith D, Eng J, Sivagnanam S, Langer EM, Grossblatt-Wait A, Creason AL, Egger J, Holly H, Chin K, Kirchenberger N, Betre K, Bucher E, Kilburn D, Hi Z, English E, MacPherson K, Tsuda M, Goecks J, Demir E, Kardosh A, Lopez CD, Sheppard BC, Guimaraes A, Brinkerhoff B, Morgan TK, Mills G, **Coussens LM**, Brody JR, Sears RC. Ongoing replication stress response and new clonal T cell development discriminate between liver and lung recurrence sites and patient outcomes in pancreatic ductal adenocarcinoma. *Submitted.*
- Kim EN, Chen PZ, Bressan D, Tripathi M, Miremadi A, di Pietro M, Coussens LM, Hannon GJ, Fitzgerald RC, Zhuang L, Chang YH. Dual-modality imaging of immunofluorescence and imaging mass cytometry for whole slide imaging with accurate single-cell segmentation
  - bioRxiv. 2023 Feb 23:2023.02.23.529718. doi: 10.1101/2023.02.23.529718. Preprint. PMID:36865274

**Manuscript previews, Editorials, Commentaries, Symposium Reviews**

1. **Coussens LM,** Werb Z. (2001) Inflammatory cells and cancer: Think Different! *J. Exp. Med.* 193:F23-F26. PMID: 11257144
2. Rhee JS, **Coussens LM**. (2002) RECKing MMP functions: Implications for cancer development. *Trends in Cell Biology*, *12:* 209-211. PMID: 12062160
3. van Kempen LCL, **Coussens LM.** (2002) MMP9 potentiates pulmonary metastasis formation. *Cancer Cell*, 2: 251-252. PMID: 12398887
4. DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian L, Sloane BF, Noel A, Hendrix MJ, **Coussens LM**, Padarathsingh M. (2004) Proteases, Extracellular Matrix and Cancer: A workshop of the PathB study section. *Am J Pathol,* 164:1131-1139. PMID: 15075248
5. Balkwill F, **Coussens LM**. (2004) Inflammation and cancer – the missing link? *Nature* 431:405-406. PMID: 15385993
6. De Clerck YA, Weissman BE, Yu D, Parsons R, Bar-Eli M, Roy-Burman P, Seewaldt VL, Cress AE, Languino LR, Batra SK, Tang CK, Sheng S, Chen WT, Chellappan S, Cheng SY, Ladisch S, McCarthy JB, **Coussens LM**, Cohen MB. (2006) Tumor Progression and Metastasis from Genetic to Microenvironmental Determinants: A Workshop of the Tumor Progression and Metastasis NIH Study Section in Honor of Dr. Martin L. Padarathsingh, May 31, 2006, *Cancer Biol Ther*. 5:1588-1599. PMID: 17224636
7. **Coussens LM.** Inflammation, Proteolysis and Cancer Development. *In:* Cancer Microenvironments. Extended Abstracts for the 37th International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, 2006. (H Esumi, HL Moses, S Hirohashi, K Miyazono, ED). Princess Takamatsu Research Fund. Tokyo Japan, pp. 33-35.
8. Affara NI, **Coussens LM**. (2007) IKKα at the crossroads of inflammation and metastasis. *Cell,* 129: 25-26. PMID: 17418780
9. **Coussens LM**, Jacks T. (2008) Genetic and cellular mechanisms of oncogenesis. Editorial Overview. *Curr Opin Genet Dev*, 18:1-2. PMID: 18440220
10. DeNardo DG, Johansson M, **Coussens LM**. (2008) Inflaming gastrointestinal oncogenic programming. *Cancer Cell*, 14: 7-9. PMID: 18598939
11. Demaria S, Pikarsky E, Karin M, **Coussens LM**, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, Weiner GJ, Fox BA, Coukos G, Wang E, Abraham RT, Carbone M, Lotze MT. (2010) Cancer and inflammation: promise for biologic therapy. *J Immunother*. 33(4):335-351. PMID: 20386472
12. Ruffell B, **Coussens LM** (2011) Histamine restricts cancer: Nothing to sneeze at. *Nat Med* 17, 43-44. PMID:21217680
13. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, **Coussens LM**, DeClerck YA. (2012) Conference Report: Tumor microenvironment complexity: Emerging roles in cancer therapy. *Cancer Research,* 72(10):2473-2480. PMCID: PMC3653596
14. Ruffell B, **Coussens LM** (2013) Some DCs are "B"etter. *Immunity 38(4): 626-628.* PMID: 23601679
15. Chan CJ, **Coussens LM** (2013) Poker face no more: cancer recurrence reveals its hand. *Nature Medicine, 19(12):1569-1570*. PMID: 24309652
16. Anand S, **Coussens LM** (2014) Manipulating micro RNAs to reverse macrophage polarization in glioma. J Natl Can Inst., *106 (8): dju230.* doi: 10.1093/jnci/dju230. PMID: 25136034
17. Zarour LR, Anand S, Billingsley KG, Bisson WH, Cercek A, Clarke MF, **Coussens LM**, Gast CE, Geltzeiler CB, Hansen L, Kelley KA, Lopez CD, Rana SR, Ruhl R, Tsikitis L, Vaccaro GM, Wong MH, Mayo SC. (2017) Colorectal cancer liver metastasis: Evolving paradigms and future directions. Cell Mol Gastroenterol Hepatol, *3(2):163-173.* PMID:28175683
18. Zloza A, Palucka KA, **Coussens LM**, Gotwals PL, Headley M, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA, Wong KK. Bosenberg MW. (2017) Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 Annual Meeting for the Society for Immunotherapy of Cancer. J ImmunoTherapy Cancer, 5(1), 77. PMID:28923102
19. Liudahl SM, **Coussens LM** (2018) B cells as biomarkers: predicting immune checkpoint therapy adverse events. J Clin Invest. 128(2):577-579. PMID: 29309049
20. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, **Coussens LM**, De Carvalho D, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT,

Luke JJ, Minn AJ, Politi K, Shulta L, Simon R, Þórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nistico P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Charen AS, Sweis RF, Valpione S, Butterfield LH, Disis ML, Fox BA, Thurin M, Cesano A, Marincola FM, and on behalf of the Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups. (2019) A comprehensive view on cancer immune responsiveness: A synopsis from the SITC workshop. *J ImmunoTherapy Ca*. 7(1):131-154. PMID: 31113486

21. Datta M, **Coussens LM**, Nishikawa H, Hodi FS, Jain RK. (2019) Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. Am Soc Clin Oncol Educ Book. 39:165-174. PMID: 31099649
22. Egeblad M, **Coussens LM**, Weaver V. (2020) Zena Werb 1945 – 2020. *Nature Cancer*, 1: 753-754.
23. Pucci F, **Coussens LM**. (2021) Redirecting tumor macrophage activity to fight cancer: Make room for the next era of anti-cancer drugs. *Cancer Cell*, *39(10):1300-1302.* PMID: 34637745
24. Anczukow O, Airhart S, Chuang JH, **Coussens LM**, Kuchel GA, Korstanje R, Li S, Lucido AL, McAllister SS, Politi K, Polyak K, Ratliff T, Ren G, Trowbridge JJ, Ucar D, Palucka K. Challenges and opportunities for modelling aging and cancer. *Cancer Cell, 41(4)* 641-645. PMID: 37001528

**Book Chapters**

1. Breakefield XO, Orloff G, Castiglione CM, Axelrod FB, **Coussens LM**, Ullrich A. (1983) Genetic linkage analysis in familial dysautonomia using a DNA probe for Beta-nerve growth factor. In: Biochemical and Clinical Aspects of Neuropeptides: Synthesis Processing and Gene Structure (Koch, G., Richter, D., Eds.) Academic Press, San Francisco, pp. 113-128.
2. Breakfield XO,· Castigliona CM, **Coussens LM**, Axelrod FB, Ullrich A. (1983) Linkage Analysis in Familial Dysautonomia Using Variations in DNA Sequence in the β-Nerve Growth Factor Gene Region: A Beginning. In: Cellular and Molecular Biology of Neuronal Development, pp.309-328. DOI: 10.1007/978-1-4613-2717-2_20
3. Breakefield XO, Castiglione CM, **Coussens LM**, Axelrod FB, Ullrich A. (1984) Linkage analysis in familial dysautonomia using polymorphisms in DNA sequence: A beginning. In: Cellular and Molecular Biology of Neuronal Development (Black, I.B., Ed.) Plenum Press, New York, pp. 309-328.
4. Ullrich A, **Coussens LM**, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J, Downward J, Whittle N, Waterfield MD. Seeburg PH (1985) Structure of human epidermal growth factor receptor and expression of normal and variant mRNAs in epidermoid carcinoma cells. In: Cancer Cells 3: Growth Factors and Transformation, Cold Spring Harbor Laboratory, New York, pp. 1-9.
5. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, **Coussens LM**, Liao Y-C, Tsubokawa M, Grunfield C, Rosen OM, Ramachandran J. (1986) Structure of the human insulin receptor precursor. In: Mechanisms of Insulin Action (Belfrage, P., Donner, J., and Stralfors, P., Eds) Elsevier Science Publishers (Biomedical Division), New York, pp. 1-11.
6. Riedel H, Yarden Y, **Coussens LM**, Lee J, Dull TJ, Gray A, Schlessinger J, Ullrich A. (1986) Structural and functional analysis of cell surface receptors with tyrosine kinase activity. In: Cell Cycle and Oncogenes (Tanner, W., and Gallwitz, D., Eds.) Springer Verlag, Heidelberg, pp. 157-171.
7. Werb Z, Vu TH, Rinkenberger JL, **Coussens LM.** (1999) Matrix-degrading proteases and angiogenesis during development and tumor formation. *In:* Proteases and Protease Inhibitors in Cancer. (L. Matrisian, N. Brunner, and K. Dano, Eds). APMIS 107:11-18. PMID: 10190275
8. Sternlicht MD, **Coussens LM**, Vu T, Werb Z. (2000) Biology and regulation of the matrix metalloproteinases. *In:* Matrix Metalloproteinase Inhibitors in Cancer Therapy. (NJ Clendeninn and K Apperlt, Eds). Humana Press, Totowa NJ, USA, pp. 1-38.
9. **Coussens LM**, Shapiro SD, Soloway PD, Werb Z. (2001) Models for gain-of-function and loss-of-function of MMPs: Transgenic and gene targeted mice. *In:* Methods in Molecular Biology: Matrix Metalloproteinases. (I. Clark, Ed.). Humana Press, Totowa, NJ, USA. pp. 149-179. PMID: 11217297
10. de Visser KE, **Coussens LM.** (2004) Inflammation and matrix metalloproteinases: Implications for cancer development. *In*: Cancer and Inflammation. (Morgan D, Forssman U, and Nakada M, Eds) Birkhauser Publishing, Basel, Switzerland. pp. 71-97.
11. Diaz RJ, Eichten AE, de Visser KE, **Coussens LM**. (2005) Matrix metalloproteinases: Mediators of Tumor-Host Cell Interactions. *In:* Cancer Growth and Progression, Vol. 15. 2nd Edition (Hans E. Kaiser, Series Ed), Integration/Interaction of Oncologic Growth, (Gary Meadows, Ed), Springer, The Netherlands.

pp. 81-126.

12. Eichten A, Shen HCJ, **Coussens LM**. (2005) Three-dimensional visualization of blood and lymphatic vasculature in tissue whole mounts using confocal microscopy. *In:* Current Protocols in Cytometry, Unit 12.5, John Wiley & Sons, Inc., Canada. pp 12.5.1-12.5.11. PMID: 18770816
13. de Visser KE, **Coussens LM**. (2006) The inflammatory tumor microenvironment and its impact on cancer development. *In:* Infection and Inflammation: Impacts on Oncogenesis (T Dittmar, KS Zaenker, A Schmidt, Ed) Karger Pub. Basel Switzerland, vol 13, pp 118-137 PMID: 16627962
14. Eichten AE, de Visser KE, and **Coussens LM**. (2008) Macrophages in tumor development and metastasis. *In:* Cancer Growth and Progression, 2nd Edition (Hans E. Kaiser and Aejaz Nasir, Eds), Selected Aspects of Cancer Progression: Metastasis, Apoptosis and Immune Response. (Ronald H. Goldfarb, Ed), Springer, The Netherlands. *Vol 11, pp115-137.*
15. De Palma M, **Coussens LM.** (2008) Immune cells and inflammatory mediators as regulators of tumor-associated angiogenesis. *In:* Angiogenesis: an Integrative Approach from Science to Medicine (W.D. Figg, J Folkman, Eds.) Springer Science, New York, NY USA, *pp 225-238.*
16. Affara NI, **Coussens LM.** (2008) Proteolytic pathways: Intersecting cascades in cancer development. *In:* The Cancer Degradome-Proteases and Cancer Biology, 1st Edition (Dylan Edwards, Gunilla Hoyer-Hansen, Francesco Blasi, Bonnie F. Sloane, Eds), Springer Science and Business Media, *pp 157-182.*
17. Affara NI, Andreu P, **Coussens LM.** (2009) Delineating protease function during cancer development. *In:* Methods in Molecular Biology, Proteases and Cancer. (Thomas Bugge and Toni Antalis, Eds.) Humana Press, *539:1-32*. PMID: 19377975
18. de Visser KE, **Coussens LM**. (2011) Utilizing mouse models of human cancer for assessing immune modulation of cancer development. *In:* Mouse Models for Cancer Research. (Jeffrey Green and Thomas Ried, Eds.). Springer Science, *Chapter 21, 443-463.*
19. Kumar S, **Coussens LM.** (2014) Cancer Microenvironments as Therapeutic Targets. In. Pathobiology of Human Disease. (Linda M. McManus, Richard N. Mitchell, Eds) Elsevier, San Diego USA; 2014. pp. 412-422.
20. Kumar S, Chan CJ, **Coussens LM**. (2016) Inflammation and Cancer. Inflammation and Cancer. In: Encyclopedia of Immunobiology, Vol. 4, pp.406–415. (Ratcliffe, M.J.H. Editor in Chief), Oxford: Academic Press.
21. Liudahl SM, **Coussens LM** (2018) To help or to harm: Dynamic roles of $CD4^+$ T helper cells in solid tumor micorenvironments. In: Immunology – Immunotoxicology, Immunopathology, and Immunotherapy. Vol 1. (M.A. Hayat, Eds). Elsvier/Academic, United Kingdom; 2018. Chapter 8. pp 98-117.
22. Gray E, Liudahl S, Sivagnanam S, Betts C, Link J, Keith D, Sheppard B, Sears R, Thibault G, Gray JW, **Coussens LM**, Chang YH. (2020) Activation vs. Organization: Prognostic Implications of T and B Cell Features of the PDAC Microenvironment. In: Bebis G., Alekseyev M., Cho H., Gevertz J, Rodriguez Martinez M. (eds) Mathematical and Computational Oncology. ISMCO 2020. Lecture Notes in Computer Science, vol 12508. Springer, Cham. https://doi.org/10.1007/978-3-030-64511-3_5
23. Kumar S, Poissonnier A, Betts CB, Murugan D, Valen Egeland E, Ehlers F, Woods J, Beleen N, **Coussens LM**. (2021) Tumor-infiltrating myeloid cells in cancer progression and therapy response. In: Cancer Immunotherapy Principles and Practice (Lisa H. Butterfield, Howard L. Kaufman, Francesco M. Marincola, Eds), Springer Publishing Company. Second Edition; Chapter 34, pp 444-461.

**Book Editor**

1. Advances in Experimental Medicine and Biology: Tumor Microenvironment, Study Protocols. Eds: Constantinos Koumenis, **Lisa M Coussens**, Amato Giacci, Ester Hammond. Springer International Publishing. ISSN 0065-2598 and 2214-8019 (electronic). ISBN 978-3-319-26664-0.

**Published Abstracts**

1. Laig-Webster M., **Coussens LM,** Caughey GH. (1998) A general method for genotyping mast cell-deficient $KIT^W/KIT^{Wv}$ mice by allele-specific polymerase chain reaction. *FASEB J*, 12:A895
2. McDonald DM, Thurston G, Murphy TJ, **Coussens L**, Baluk P. (1998) Wild-type FVB/N mice are unusually susceptible to *Mycoplasma pulmonis* respiratory tract infection. *FASEB J* 12(5) 4559 Part 2.
3. Baluk P, **Coussens LM**, Werb Z, Raymond WW, Caughey GH, McDonald DM. (1999) Gelatinase B is not essential for microvascular remodeling in airway inflammation. *Am. J. Resp. Crit. Care Med.* 159:A353
4. van Kempen L, Rhee JS, Reuter J, Krane S, **Coussens LM**. (2001) To digest or not digest: Collagen Type I remodeling during squamous carcinogenesis. *Mol. Biol. Cell.* 12:269a.

5. van Kempen L, Rhee JS, Reuter J, Krane S, **Coussens LM**. (2002) To digest or not digest: Collagen Type I remodeling during squamous carcinogenesis. *Proceedings American Association for Cancer Research*, 43:535.
6. Chantrain C, Shimada H, **Coussens L**, Shalinsky D, Brekken J, De Clerck YA. (2002) Role of matrix metalloproteinase-2 and -9 in neuroblastoma angiogenesis and metastasis. *Proceedings American Association for Cancer Research*, 43:539.
7. Machamer JE, van Kempen LCL, **Coussens LM**. (2002) Endothelial cell migration through collagen is independent of collagenolysis. The International Symposium on Laboratory Automation and Robotics 2002, Boston, MA. Published online: http://198.199.168.17:8080/islar/proceedings.nsf/
8. van Kempen LCL, Lee J, Krane S, **Coussens LM**. (2002) Type I collagen remodeling functionally regulates vascular permeability and epithelial carcinogenesis. *Mol. Biol. Cell*. 13: 4a
9. Diaz RJ, van Kempen L, Dehne K, Schmuth M, Krane S, Albertson D, **Coussens LM**. (2004) Type I collagen remodeling regulates keratinocyte malignant potential. *Proceedings American Association for Cancer Research*, 45:792
10. de Visser KE, **Coussens LM**. (2004) The interplay between adaptive and innate immunity promotes cancer development. *Proceedings American Association for Cancer Research*, 45:403.
11. Eichten A, **Coussens LM**. (2004) Microenvironmental regulation of lymphatic metastasis development. *Proceedings American Association for Cancer Research*, 45:335.
12. **Coussens LM**. (2004) ECM architecture regulates tissue homeostasis and disease pathogenesis. *FASEB J*, 18:A21-A21.
13. **Coussens LM**. (2004) Inflammation and cancer. *Toxicologic Pathology, 32:732.*
14. Rugo HS, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Karlin DA, Dowlati A, Le MH, **Coussens LM**, Wesolowski R. (2014) Phase Ib study of PLX3397, a CSF1R inhibitor, and paclitaxel in patients with advanced solid tumors. (Clinical trial information: NCT# NCT01525602). Eur Soc Med Onc 2014. Abstract #8457.
15. Sharma N, Wesolowski R, Reebel L, Rodal MB, Peck A, West B, Karlin DA, Dowlati A, Le MH, **Coussens LM**, Rugo HS. (2014) A phase Ib study to assess the safety of PLX3397, a CSF1 receptor inhibitor, and paclitaxel in patients with advanced solid tumors. (Clinical trial information: NCT# NCT01525602). Abstr TPS3127. 2014 ASCO Annual Meeting Chicago, IL USA. Clin Oncol 32(15):TPS3127.
16. Shiao SL, DeNardo DG, Faddegon BA, Underhill DM, Park CC, **Coussens LM**. (2015) Abstract A28: Impact of macrophage function on the efficacy of radiation therapy. 75 (1 Suppl): Abstract nr A28. doi:10.1158/1538-7445.CHTME14-A28.
17. Hassan R, Antonia SJ, Alley EW, Kindler HL, Jahan T, Grous JJ, Honarmand S, McDougall K, Whiting CC, Nair N, Lemmens E, Tsujikawa T, Kumar S, **Coussens LM**, Murphy AL, Thomas A, Brockstedt DG. (2015) RS-207, a mesothelin-targeted immunotherapy, in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM) (Clinical trial information: NCT# NCT01675765). 18th ECCO - 40th ESMO European Cancer Congress, 25 Sep - 29 Sep 2015, Vienna, Austria.
18. Link JM, Allen-Peterson B, Gunderson A, Jorgens D, Dorrell C, Hooper J Streeter P, Grompe M, **Coussens LM**, Gray J, Hardaker H, Lopez CD, Sears RC, Sheppard BC. (2015) Developing a molecular and cellular atlas of pancreatic disease. AACR Special Conference on Pancreatic Cancer: Innnovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Cancer Res 2015;75(13 Suppl):Abstract nr B118.
19. Tsujikawa T, Borkar RN, Azimi V, Rassi EE, Clayburgh DR, Kumar S, Gunderson AJ, Kulesz-Martin M, Flint PW, **Coussens LM.** (2015) Multiplex immunohistochemistry for immune profiling of HPV-associated head and neck cancer. J ImmunoTherapy of Cancer. 3(2):p419.
20. Tempero M, **Coussens LM**, Fong L, Manges R, Singh P, Li Y, Cole G, James DF, Tabernero J. (2016) A randomized, multicenter, double-blind, placebo-controlled study of the Bruton Tyrosine Kinase inhibitor, ibrutinib, vs. placebo in combination with nab-paclitaxel and gemcitabine in the first line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE). (Clinical trial information: (NCT# NCT02436668). Abstract TPS483. 2016 Gastrointestinal Cancers Symposium (January 21-23, 2016), San Francisco CA USA. J Clin Oncol 34(4):TPS483
21. Tempero MA, **Coussens LM**, Fong L, Manges R, Singh P, Li Y, Cole GW, James DF, Tabernero J. (2016) A randomized, double-blind, placebo-controlled study of ibrutinib, a Bruton Tyrosine Kinase inhibitor, with with nab-paclitaxel and gemcitabine in the first line treatment of patients with metastatic pancreatic

adenocarcinoma (RESOLVE). (Clinical trial information: NCT# NCT02436668). Abstract 164533. 2016 ASCO Annual Meeting (June 3-7, 2016) Chicago, IL USA. J Clin Oncol 34(15):TPS2601.

22. Hassan R, Alley EW, Kindler HL, Antonia SJ, Jahan TM, Honarmand S, McDougall K, Whiting CC, Nair N, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, **Coussens LM**, Murphy AL, Thomas A, Brockstedt DG. (2016) CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM) (Clinical trial information: NCT# NCT01675765). Abstract 170532. 2016 ASCO Annual Meeting (June 3-7, 2016). Chicago, IL USA. J Clin Oncol 34 (15): 8558.
23. Wesolowskia R, Sharma N, West B, **Coussens LM**, Marimuthu A, Pelayo M, Le MH, Hsu H, Karlin DA, Rugo HS. (2016) A phase Ib study of pexidartinib (PLX3397) and weekly paclitaxel in patients with advanced solid tumors including an ovarian cancer subset. (Clinical trial information: NCT# NCT01525602). Poster 293. 47th Annual meeting on Women's Cancer, Society of Gynecologic Oncology. Gynecologic Onc 141:121.
24. Tempero M, Oh D, Macarulla T, Reni M, Van Cutsem E, Hendifar A, Waldschmidt D, Starling N, Bachet J, Chang H, Maurel J, Lonardi S, **Coussens LM**, Fong L, Tsao L, Cole G Jr, James D, Tabernero J. (2019) Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study. Ann Oncol. 2019 Jul;30 Suppl 4:iv126. doi: 10.1093/annonc/mdz154.001. Epub 2019 Dec 4. PMID: 32085015.
25. Sinha M, Griffith M, Betts C, Choe G, Sivagnanam S, Cheung A, Tamaki W, Liu E, Sudduth-Klinger J, Vaccaro G, Lopez C, Fong L, **Coussens L**, Tempero M. (2019) Immune modulatory effects of ibrutinib in pancreatic ductal adenocarcinoma. Ann Oncol. 2019 Jul;30 Suppl 4:iv40. doi: 10.1093/annonc/mdz155.145. Epub 2019 Dec 4. PMID: 32085149.
26. Thomas PL, Betts C, Gonzalez G, Coussens LM, Lovly CM. 2020. Defining immune contexture in small cell lung cancer: Implications for immunotherapy. Can Res. **DOI:** 10.1158/1538-7445.AM2020-3862

**Patents**

1. Coussens LM and Werb Z. *Novel Indications for Transforming Growth Factor-Beta Regulators*. U.S. Patent Publication #2008-0206219-A1. International filing date: August 9, 2004. Application Filing Number: 60/493,643; Docket Number: 23540-09361/PCT; International Publication Number WO 2005/013915 A2; International Application Number: PCT/US2004/025902
2. DeNardo D, Brennan D, **Coussens LM**. *Phenotyping Tumor-Infiltrating Leukocytes*. US patent publication No.: US 2014/0100188 A1, April 10, 2014; EP application: 10802804.4, AU application: 2010276324.
3. Tsujikawa T, Kumar S, **Coussens LM**. *Multiplex Immunohistochemistry Image Cytometry.* US Provisional application 62/257,926. November 20, 2015. US Patent Publication Number: 20170160171 (June, 2017)
4. Chang YH, Tsujikawa T, **Coussens LM,** Gray JW, *Automated Image Analysis Tool for Multiplexed Immunohistochemistry/immunofluorescence* (Application number: 62481842)

## VII. RESEARCH AWARDS AND GRANTS:

**CURRENT**

**No Number** (PI: Coussens) 04/01/22 – 03/31/24
**Source:** National Foundation for Cancer Research $300,000 total directs
**Title**: *Multi-omics analysis of immune therapy responses in mammary carcinoma.*
The goal of this project is to develop analytical tools for multi-omic auditing of breast cancer responses to immune therapies
**Role**: PI

---

**No Number** (PI: Heiser/Mitri) 01/01/22 – 12/31/24
**Source:** Wayne D. Kuni & Joan E. Kuni Foundation $998,733 total directs/indirects
**Title**: *A preclinical approach to targeting cell state in aggressive metastatic breast cancer*
A comprehensive assessment of therapy-associated cancer cell states in metastatic TNBC
**Role**: co-I

---

**SRA-22-063** (PI: Coussens) 02/01/22 – 01/31/25
**Source:** ZelBio, Inc $508,288 total directs/indirects
**Title**: *Immune modulation in response to ZB131 anti-CSP monoclonal antibody treatment for solid tumors*

Clinical study of ZB131-101 before and after treatment with ZB131 for indicators of mechanisms of response and/or resistance to therapy
**Role**: PI

---

**C19767/A27145** (PI: Tlsty) 01/02/21 – 12/31/22
**Source:** Cancer Research UK (CRUK)
**Title:** *STrOmal ReprograMing (STORMing) provides new directions to prevent and revert chronic inflammation-associated cancers*
The goal of the study is to gain mechanistic insight into key events that typify progression of chronic inflammation-associated cancers
**Role:** co-I

---

**No Number** (PI: Coussens) 01/01/22 – 12/31/22
**Source:** Brenden-Colson Center for Pancreatic Health $150,000 total directs
**Title**: *Immune cells in pancreatic disease*
The goal of this project is to identify and define roles for leukocytes in states of pancreatic disease
**Role**: PI

---

**No Number** (PI: Mills) 01/01/21 – 12/31/23
**Source:** Wayne D. Kuni & Joan E. Kuni Foundation $1,500,000 total directs/indirects
**Title**: *Blood Biopsies as a Cost-Effective Approach to Democratize Personalized Therapy for OR & WA Patients*
Development of technologies to measure multiple analytes in patient blood and determine if information can be used in place of tissue biopsies to guide cancer treatments.
**Role**: co-I

---

**5 U2C CA 233280** (PI: Goecks/Mills/Thomas) 09/01/18 – 08/30/23
**Source:** NIH/NCI $8,842,537 total directs/indirects
**Title*:*** *Omic and multidimensional spatial atlas of metastatic breast and prostate cancers*
Apply state of the art analysis tools to prospective samples and identify changes in components and structures of cancers enabling them to escape therapeutic co.
**Role**: co-I

---

**P30 CA069533** (PI: Druker) 07/01/22 – 06/30/27
**Source:** NIH/NCI $23,180,495 total directs/indirects
**Title*:*** *OHSU Knight Comprehensive Cancer Institute*
Support the administration, programs, Clinical Protocol & Data Management, Protocol Review & Monitoring System, and shared resources of the Knight Cancer Institute at OHSU.
**Role**: Associate Director for Basic Science

---

**SAC210100** (PI: Coussens) 08/01/21 – 08/01/24
**Source**: Susan G. Komen Breast Cancer Foundation $600,000 totaldirects/indirects
**Title**: *Immune-mediated protumoral pathways in breast cancer*
Investigate impact of CSF1R-blockade plus chemotherapy on sensitivity to immune checkpoint therapy by relieving tumor-induced T cell dysfunction, and enabling activation of long-term T cell memory to combat ongoing and subsequent tumor growth.
**Role**: PI

---

**R01 CA226909** (PI: Varner/Cohen) 07/01/18 – 06/30/23
**Source**: NIH/NCI $1,911,630 total directs/indrects
(Coussens $315,385)
**Title**: *Therapeutic targeting of macrophage PI3Kgamma in HNSCC*
Identify mechanisms by which PI3Kg inhibitors synergize with anti-PD-1 using mouse models of HPV+ and HPV- carcinogen-induced HNSCC and to determine the effect of the PI3Kg inhibitor IPI-549 on tumor immune responses in patients with resectable HNSCC or recurrent/metastatic HNSCC
**Role**: co-I

---

**U01 CA224012** (mPI: Sears, Coussens, Demir, Brody) 09/12/19 – 08/31/24
**Source**: NIH/NCI $2,138,947 total directs/indirects
**Title**: *Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens*

The goal is to conduct comparative analysis of patient-derived models of pancreatic ductal adenocarcinoma from patient specimens to determine biologic differences and responses to perturbagens.
**Role**: multi-PI

**R01 CA 223150** (PI: Jonas) 07/01/18 – 06/30/23
**Source:** NIH/NCI $175,574 total directs/indirects (Coussens)
**Title:** *In situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices*
Evaluate immune contexture in response to therapies in mammary tumors implanted with microdevices to examine immune responses to combination therapies
**Role**: co-I

**R01 HL093056** (PI: Habecker) 07/01/19 – 06/30/23
**Source**: NIH/NHLBI $2,463,192 total directs/indirects (Coussens $65,228 directs)
**Title**: *Neurotrophins and post-infarct plasticity in cardiac sympathetic neurons*
Elucidate structural and functional changes induced in the heart by sympathetic reinnervation after MI, and the role of noradrenergic neurotransmission in restoring electrical stability.
**Role**: collaborator

**SRA-21-097B** (PI: Kumar) 04/01/22 – 03/21/23
**Source**: HiberCell, Inc. $268,968 Total directs/indirects
**Title:** *Reprogramming tumor microenvironment for cancer therapy by targeting stress signaling pathway*
Establish the molecular link connecting CSF1R activation and PERK activity in macrophages
**Role: co-I**

**CRUK6841219** (PI: Chang/Zhuang) 10/01/20 – 09/31/22
**Source**: Cancer Research UK $288,496 total directs
**Title**: *Deciphering the immune complexity in esophageal adenocarcinoma and pre-cancerous lesions with multiplex immunostaining and Sparse Subspace Clustering (SCC) approach*
Develop approach for multiplex IHC analytics to study immune complexity in esophageal adenocarcinoma.
**Role**: co-I

**R01 CA169175** (PI: Schedin) 04/01/20 – 03/31/25
**Source**: NIH/NCI $7,494 (salary only)
**Title**: *NSAIDs During Postpartum Involution for Breast Cancer Chemoprevention*
Pre-clinical investigation of ibuprofen intervention necessary to advance to a clinical chemoprevention trial.
**Role**: co-I

**No Number** (PI: Heiser, Coussens, Schultz) 07/01/22 – 06/30/23
**Source**: OHSU Center for Women's Health, Circle of Giving $125,000 total directs
**Title:** *A comprehensive approach to examine neutrophil elastase in breast cancer*
Develop and deploy novel FRET reporters designed to assess neutrophil elastase activity in the tumor ecosystem and to assess the role of neutrophil elastase activity in mediating disease progression and response to therapy
**Role:** multiPI

**T32 CA254888** (multiPI: Coussens/Zuckerman) 02/01/21 – 01/31/26
**Source:** NIH/NCI $2,048,233 total directs
**Title:** *Integrated training in quantitative and experimental cancer systems biology*
Training of graduate and postdoctoral fellows in quantitative and experimental systems biology
**Role:** multiPI

**W81XWH-20-1-0007** (PI: Poissonnier) 01/15/20 -01/14/23
**Source:** DOD, BCRP $461,746 (Coussens $0)
**Title:** *Relieving immune suppressive pathways in breast cancer to improve outcomes*
Evaluate therapeutic response in mammary tumorbearing mice with CSF1R blocking mAb combined with PTX, αPD1 and entinostat, to reveal efficacy, mechanisms, and response predictors
**Role**: Mentor

**K00 CA212132** (PI: Berens) 11/16/18 - 06/30/22
**Source:** NIH/NCI $319,846 (Coussens $0)
**Title**: *Impact of cytoskeletal regulators on cancer cell stromal invasion*

Establish how the activated T cell surface marker known as CD69 and other immune surface genes enhance cancer metastasis; and determine if the acquisition of immune surface markers thwarts immune-mediated destruction of cancer cells in vitro
**Role**: Mentor

---

**No Number** (PI: Berens) 12/01/21 – 12/11/22
**Source:** Collins Medical Trust $30,000 total directs
**Title:** *Neoplastic immune surface mimicry as a modulator of the immune response against breast cancer*
Determine whether the acquisition of immune surface receptors by neoplastic breast epithelium confers resistance to cytotoxic activity from the immune system
**Role:** Mentor

---

**PREVIOUS**

**USPHS 5 T32 CA09056** (PI: Fox, F, UCLA) 07/01/89 –06/30/92
**Source:** NIH/UCLA $9,300 directs/yr1
**Title**: *Regulation of junB Gene Expression by TGF-Beta* $25,800 directs/yr 1-3
Competitive Pre-Doctoral award to study transcription factor *junB.*

---

**Univ. of Calif., Dissertation Year Fellowship** (PI: Coussens, LM, UCLA) 10/1/92 – 09/31/93
**Source:** University of California, Office of the President $13,350 directs/yr
**Title**: *Effects of E1A on TGF-Beta-inducible junB Expression*
Competitive Pre-Doctoral award to study transcription factor *junB.*

---

**USPHS 5 T32 CA09043** (PI: Bishop, KM, UCSF) 10/01/93-06/31/96
**Source:** NIH/UCSF $25,000 directs/yr
**Title**: *Molecular Analysis of Tumor Viruses* $75,000 directs/yr 1-3
Post-Doctoral fellowship to study mouse model of epithelial carcinogenesis.

---

**American Social Health Association/Pfizer Post-Doctoral Research Fellowship in Sexually Transmitted Diseases** (PI: Coussens, LM, UCSF) 10/01/96 – 9/30/98
**Source:** Private Foundation $27,500 directs/ yr 1
**Title**: *Metalloproteinases and Malignant Progression of Squamous Epithelium in K14-HPV16 Transgenic Mice* $56,250 directs/yr 1-2
**Role**: Principal Investigator
Competitive Post-Doctoral fellowship to study proteases and tumor development

---

**P01 CA072006** (PI: Shuman M, UCSF) 06/10/97 – 06/30/03
**Source:** NIH/NCI $803,021 directs/yr 1
**Title**: *Proteases in Cancer Biology and Drug Development* $4,280,649 directs/yr 1-5
Project 3 – Proteases in Models of Tumor Initiation/Progression $165,438 directs/yr 1
**Role**: Co-Investigator, Project 3 $940,281 directs/yr 1-5
The major goal of this project was to study the role of proteases in cancer biology. $72,595 directs/yr 1
Core C – Transgenic Animal Models $470,620 directs/yr 1-5
**Role**: Director (year 4 and 5)
The major goal of this Core is to develop and provide protease null and transgenic mice to program projects.

---

**UCSF IRG-97-150-01** (PI: Coussens LM, UCSF) 07/01/99-06/30/00
**Source:** American Cancer Society $20,000 directs/yr
**Title***: Proteases and Genomics in a Mouse Model of Epithelial Cancer* $20,000 directs/yr 1
**Role**: Principal Investigator
Pilot project tested role of proteinases as effectors of genomic instability.

---

**UCSF Cell Cycle and Dysregulation Program** (PI: Coussens LM, UCSF) 02/01/00-01/31/01
**Source:** UCSF Comprehensive Cancer Center, Intramural $14,000 directs/yr 1
**Title***: Epithelial Neoplastic Progression and Degradation of Type I Collagen* $14,000 directs/yr 1
**Role**: Principal Investigator
Pilot project assessed functional significance of type I collagen metabolism during epithelial carcinogenesis.

---

**Research Evaluation & Allocation Committee** (PI: Coussens LM, UCSF) 07/01/00-06/30/01
**Source:** UCSF Academic Senate $30,000 directs/yr 1
**Title**: *Role of Gelatinase B in Maintenance of Genomic Instability* $30,000 directs/yr 1
**Role**: Principal Investigator
Pilot project tested the role of MMP9 as an indirect regulator of genomic instability.

---

**UCSF IRG AC-04-02** (PI: Coussens LM, UCSF) 10/01/00-09/30/01
**Source:** American Cancer Society $20,000 directs/yr 1
**Title**: *Regulation of Intracellular Signaling Pathways by Gelatinase B/MMP-9* $20,000 directs/yr 1
**Role**: Principal Investigator

Pilot project to study signal transduction pathways regulated by MMP-9.

**The V Foundation for Cancer Research** (PI: Coussens LM, UCSF) 06/02/00-05/31/02
**Source:** Private Foundation $50,000 directs/yr 1
**Title***: Gelatinase B and Epithelial Cancer Development* $100,000 directs/yrs 1-2
**Role**: Principal Investigator
Pilot project to study role of MMP9 during epithelial carcinogenesis.

**Gertrude B. Elion Cancer Research Award** (PI: Coussens LM, UCSF) 07/01/01 – 06/30/02
**Source:** American Association of Cancer Research $50,000 directs/yr 1
**Title**: *Functional Role of MMP-2 During Epithelial Carcinogenesis* $50,000 directs/yr 1
**Role**: Principal Investigator
Pilot project to study role of MMP-2 during epithelial carcinogenesis.

**Univ. of Calif., Cancer Research Coordinating Committee** (PI: Coussens LM, UCSF) 07/01/01 – 06/30/02
**Source:** University of California $48,874 directs/yr 1
**Title**: *Gelatinase A/MMP-2 and Epithelial Cancer Development* $48,874 directs/ yr 1
**Role**: Principal Investigator
Pilot project to study role of MMP-2 as a potentiator of tumor development.

**Hellman Family Award for Early Career Faculty** (PI: Coussens LM, UCSF) 11/01/00-09/30/02
**Source:** UCSF Intramural $49,000 directs/ yr 1
**Title**: *Paracrine Regulation of Epithelial Carcinogenesis by MMP-9* $89,000 directs/yr 1-2
**Role**: Principal Investigator
Pilot project to identify matrix molecules regulated by MMP-9.

**Edward Mallinckrodt, Jr. Foundation** (PI: Coussens LM, UCSF) 10/01/00-09/30/03
**Source:** Private Foundation $61,000 directs/yr 1
**Title**: *Regulation of epithelial cancer by gelatinase B/MMP-9* $194,000 directs/yr 1-3
**Role**: Principal Investigator
Pilot project to determine how MMP-9 regulates proliferation, VEGF bioavailability and angiogenesis during epithelial carcinogenesis.

**P50 CA58207** (PI: Gray, J: UCSF) 03/01/03-02/28/05
**Source:** NIH/NCI $50,000 directs/yr 1
Bay Area Breast Cancer Translational Research Program (SPORE) $100,000 directs/yr 1-2
**Title**: *Type I Collagen Remodeling and Mammary Carcinogenesis*
**Role**: Principal Investigator (Developmental Project)
The overall goal of this pilot project was to explore the role of collagen metabolism during mammary carcinogenesis.

**DE-FG02-05ER6401 (**PI: Franc, B**;** UCSF**)** 03/01/05 – 01/16/06
**Source:** DOE Medical Applications Grant $225,100 directs yr 1
**Title**: Therapeutic Radionuclide Tumor-targeting Strategy for Breast Cancer $1,125,500 total directs
**Role**: Co-Investigator
The specific aim of this project were to develop a radionuclide delivery molecule (RDM) that specifically targets cancer cells that express matrix-metalloproteinase-14 (MMP-14) on their surface and demonstrate delivery of radiolabeled RDM to MMP-14 expressing cells *in vitro* and *in vivo.*

**R01 DK067678** (PI: Cher, M: Wayne State University) 07/01/03-06/30/06
**Source:** NIH/NIDDK $14,675 directs/yr 1
**Title**: *Proteases in Prostate Cancer Bone Metastasis* $122,794 directs/yr 1-4
**Role**: Subcontract Principal Investigator
The major goal of this subcontract is to assist with the planned experiments by providing mice (protease deficient) of defined genotype for proposed studies to analyze proteases during prostate metastasis to bone *in vivo*.

**Opportunity Award, Sandler Family** (PI: Coussens, LM; UCSF) 02/15/05 -02/14/07
**Source:** UCSF Intramural $95,000 directs yr 1
**Title**: *B Lymphocytes as Targets for Cancer Prevention* $191,000 total directs
**Role**: Principal Investigator
The major goal of this project was to investigate the efficacy of targeting B cells for chemoprevention

**DAMD17-02-1-0693** (PI: Sloane, B; Wayne State University) 08/01/02-07/31/06
**Source:** Department of Defense $5,746,832 directs/yr 1-4
***Breast Cancer Center of Excellence*** $49,576 directs/yr 1
**Title**: *Validation of Proteases as Therapeutic Targets in Breast Cancer Functional Imaging of Protease Expression, Activity and Inhibition*
**Role**: Subcontract Principal Investigator $198,307 directs/yr 1-4
The goal of this program was to validate proteases as therapeutic targets in breast cancer by functional imaging of protease expression, activity and inhibition.

**R01 CA94168** (PI: Coussens, LM: UCSF) 04/01/02-06/31/07

**Source:** NIH/NCI $222,500 directs/yr 1
**Title**: *Regulation of Epithelial Cancer by MMP-9/gelatinase B* $1,112,500 directs/yr 1
**Role**: Principal Investigator
The goal of this project was to identify molecules that mediate proliferative and cellular pathways activated by MMP9.

**U54 RR020843** (PI: Smith, J; Burnham Institute) 09/30/04-07/31/09
**Source:** NIH/National Center for Research Resources $1,916,878 directs/yr 1-5
**Title**: Center on Proteolytic Pathways
**Role**: Principal Investigator (Driving Biological Problem #1) $67,306 directs/yr
DBP#1 *Proteolytic Pathways in Acute Vascular Response*

**P01 CA72006** (PI: Werb, Z; UCSF) 07/07/03 – 06/30/08
**Source:** NIH/NCI $1,523,691 directs/yr 6
**Title**: *Proteases in Cancer Biology and Drug Development* $6,354,685 directs/yr 6-11
Project 3 - *Proteases in Models of Tumor Initiation/Progression* $229,788 directs/yr 6
**Role**: Co-Investigator, Project 3 $1,172,879 directs/yr 6-11
The major goal of this project was to study the role of proteases in cancer biology.
Core C - *Transgenic Animal Models* $151,612 directs/yr 6
**Role**: Director $765,974 directs/yr 6-11
The major goal of this Core was to develop and provide protease null and transgenic mice to program projects.

**R01 CA98075** (PI: Coussens, LM; UCSF) 07/01/03-06/30/09
**Source:** NIH/NCI $222,500 directs/yr 1
**Title**: *Microenvironmental Regulation of Tumor Progression* $1,112,500 directs/yr 1-5
**Role**: Principal Investigator
The overall goal of this grant was to determine the role of collagen metabolism on epithelial carcinogenesis.

**P50 CA58207 (van 't Veer; UCSF)** 08/01/92–11/30/12
Source: NIH/NCI
Bay Area Breast Cancer SPORE
Career Development Research Award Multi Project PI: Weaver, Hwang, Coussens (5/1/10-04/30/11)
Title: Risk to Malignancy and Immune and Collagen Status
The goals of this project were to 1) Determine whether immune infiltrate and collagen heterogeneity exist between and within multiple regions of breast tissue, 2) Evaluate whether malignant progression is associated with a distinct immune infiltrate and if that is reflected by physical state of collagen, and 3) Determine relationship between immune infiltrate, collagen, radiographic density and clinical measures of cancer risk.
**Role**: Multi P.I.

**P50 CA58207** (van 't Veer; UCSF) 08/01/92–11/30/12
**Source**: NIH/NCI $40,000 (project expenses only)
**Title**: Bay Area Breast Cancer SPORE
Career Development and Developmental Research Award, Multi Project PI: Boudreau N; Coussens LM (**5/1/10-04/30/11)**
Title: Macrophage-Mediated Delivery of the Breast Tumor Suppressor HoxD10 via Autologous Transfer to Breast Tumors. The aims of this project were to 1) establish function and optimize introduction of the engineered HoxD10 protein into macrophages and/or monocytes; 2) visualization of modified monocyte/macrophage accumulation in mammary tumors in vivo and 3) analysis of the impact of monocyte/macrophage delivered HoxD10 on breast tumor growth, progression and metastasis in MMTV-PyMT mouse model of mammary carcinogenesis.
**Role**: Multi P.I.

**BC051640 Era of Hope Scholar Award** (PI: Coussens, LM; UCSF) 06/01/06 – 05/31/11
**Source:** DoD, U.S. Army Medical Research and Materiel Command $443,205 directs yr
**Title**: Microenvironment Regulation of Mammary Carcinogenesis
The goal of this Scholar Award was to identify leukocytes and their proteases that modify breast carcinogenesis and to develop noninvasive imaging reagents targeting leukocytes to image inflammation.
**Role**: P.I.

**W81XWH-08-PRMRP-IIRA** (multiPI: Broaddus, C; Coussens, LM) 07/01/09 –06/30/12
**Source**: DoD, U.S. Army Medical Research and Materiel Command $293,637 directs/yr
**Title**: Role of Macrophage-induced Inflammation in Mesothelioma
The goals of this project were 1) to determine the functional significance of macrophage phenotype in mesothelioma, 2) to determine the functional significance of macrophages as regulators of mesothelioma apoptosis in vitro and 3) to define the functional significance of macrophage depletion or repolarization on mesothelioma survival in vivo.
**Role**: multi P.I.

**1S10OD010348-01** (PI: Coussens, LM) 06/01/2012 – 05/31/2013
**Source**: NIH $403,978 directs/yr
**Title**: Vevo 2100 Ultrasound System

The goal of this shared instrument grant was to purchase a Vevo 2100 Ultrasound System for imaging tumor development in mouse models of cancer for the Mouse Barrier Facility at UCSF.
**Role**: multi P.I.

**RO1 CA132566** (multiPI: Coussens, LM; Jablons DM) 05/01/08-04/30/13
**Source**: NIH/NCI $190,000 directs/yr
**Title**: Inflammation and Lung Carcinogenesis
The goal of this study was to determine how inflammation and Wnt signaling regulate stem cell niche autonomy during lung carcinogenesis
**Role**: multi P.I.

**R01CA140943** (multiPI: Coussens, Boudreau, Daldrup-Link) 07/01/09 –05/31/14
**Source**: NIH/NCI $166,000 directs/yr
**Title**: *Improved Imaging and Drug Delivery Using Novel Approaches to Regulate Tissue Perfusion*
The major goals of this project are to: examine how short-term inhibition of ALK5 in vivo alters hemodynamics and tissue perfusion in mouse models of cancer.
**Role**: multi P.I.

**RO1 CA130980** (PI: Coussens, LM) 07/01/08-05/31/14
**Source**: NIH/NCI $207,500 directs/yr
**Title**: *Regulation of Inflammation-Associated Epithelial Cancer Development*
The major goals of this project are to: determine regulatory programs activating chronic inflammation during squamous carcinogenesis
**Role**: P.I.

**KG110560** (multiPI: Hwang S; Coussens, LM) 07/1/11 – 06/31/14, no cost extension
**Source**: Komen Foundation, IDEA Award $200,000 directs/yr
**Title**: *Immune and Collagen Basis of Breast Cancer Risk*
The major goals of this study are to: establish whether immune and collagen status is correlated with density-associated breast cancer risk.
**Role**: multi P.I.

**1U54CA163123-administrative supplement** (multiPI: Coussens, LM; Nan, X-L) 08/01/14-07/31/15
**Source**: NIH/NCI $100,000 directs/yr
**Title**: *Leukocyte Biomarkers for Predicting Human Breast Cancer Outcomes*
The major goals of this study are to: utilize advanced high-resolution multi-color fluorescence imaging to reveal the in situ location of distinct immune cell subtypes in breast tumors so as to exploit the information revealed about the immune microenvironment of breast cancer to improve therapeutics and survival.
**Role**: multi P.I.

**1U54CA163123-01** (multiPI: Coussens, LM; Krummel, M) 09/23/11 – 07/31/17
**Source**: NIH/NCI $258,900 directs/yr
**Title**: *Leukocyte Biomarkers for Predicting Human Breast Cancer Outcomes*
The major goals of this study are to: identify myeloid- and lymphoid-based biomarkers representing either functional mediators of immune cell phenotype or instead reflecting leukocyte composition, and which of these in turn represent predictive variables for predicting breast cancer response to CTX +/- macrophage-depletion therapy
**Role**: multi P.I.

**R01 CA155331** (PI: Coussens, LM) 05/01/11 – 03/31/18
**Source**: NIH/NCI $207,500 directs/yr
**Title**: *Regulating the Immune Microenvironment in Breast Cancer*
The major goal of this study is to evaluate the efficacy of $T_H2$-blockade as a therapy for reprogramming pro-tumor immune cells in mouse models of mammary carcinogenesis.
**Role**: P.I.

**W81XWH-10-BCRP-EOHS-EXP** (PI: Coussens, LM) 09/30/11 – 01/01/18
**Era of Hope Scholar Expansion Award**
**Source**: DOD/U.S. Army Medical Research & Materiel Command $346,174 directs/yr
**Title**: *Modulating Immune Response to Improve Therapy for Breast Cancer*
The major goals of this study are to: test the hypothesis that the immune microenvironment in breast cancer can be effectively manipulated therapeutically to limit breast cancer recurrence and extend overall survival
**Role**: P.I.

**SU2C-AACR-DT12-14** (PI: Jafee, E; Vonderheide R) 07/01/14-06/31/18
**Source**: AACR-SU2C $506,960 directs/yr
**Title**: *Transforming pancreatic cancer from a death sentence into a treatable disease*
The major goals of this program are to: 1) Develop novel immune strategies that target patient-unique T cell epitopes in pancreatic ductal adenocarcinoma (PDA) identified by tumor exome sequencing; 2) Conduct a series of “shovel ready” combination clinical trials in PDA and establish biomarkers of tumor microenvironment (TME) reprogramming

– each trial focusing on a novel immune suppressive pathway within the TME; and, 3) Conduct pre-clinical studies in mouse models of PDA to establish novel combinatorial approaches and develop biomarkers that will drive the next generation of PDA clinical trials
**Role**: Dream Team Principal

**KG111084** (multiPI: Coussens, LM; Hwang S, Rugo H) 08/08/11 – 08/07/18
**Source**: Komen Foundation, PROMISE Grant $1,137,344 directs/yr
**Title**: *Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-like Breast Cancer by Targeting Macrophages.*
The major goals of this study are to: test the hypothesis that that macrophages in triple negative (TN)/basal-like breast cancer potentiate late-stage disease progression and limit long-term survival, and that by either minimizing tumor associated macrophages (TAM) recruitment or reprogramming TAM bioactivity, outcomes for patients with TN/basal-like breast cancer will significantly improve.
**Role**: multi P.I.

Externally sponsored research (PI: Coussens, LM) 10/03/14 – 10/02/18
**Source**: Janssen Research & Development LLC $182,159 directs/yr
**Title**: c-FMS inhibitor/JNJ-40646527 and checkpoint blockade in mesothelioma
The major goals of this study are to: 1) Characterize immune complexity and checkpoint expression in the 40L malignant mesothelioma model in control or α-CSF1R -/+ CTX treated mice. 2) Determine efficacy with checkpoint blockade (single, combinations, bispecifics) alone or together with CSF1R blockade/CTX treatment in the 40L model.
**Role**: P.I.

Externally sponsored research (PI: Coussens, LM) 12/01/14 – 06/30/19
**Source**: Deciphera Pharmaceuticals $159,372 directs/yr
**Title**: In vivo study of kinase inhibitors in mesothelioma
The major goals of this study are to: evaluate efficacy of kinase inhibitors and chemotherapy treatment in a murine model of mesothelioma.
**Role**: P.I.

Externally sponsored research (PI: Coussens, LM) 08/14/14 – 08/01/19
**Source**: Acerta Pharma, LLC $146,604 directs/yr
**Title**: Therapeutic efficacy in SCC
The major goals of this study are to: Evaluate therapeutic efficacy of a BTK inhibitor plus and minus chemotherapy in a murine model of SCC
**Role**: P.I.

Externally sponsored research (PI: Coussens, LM) 09/01/16 – 09/30/19
**Source**: Acerta Pharma, LLC $149,738 directs/yr
**Title**: Molecular correlates for NCT02454179
The major goals of this study are to: Evaluate biomarkers of therapeutic response from NCT02454179.
**Role**: P.I.

**A124232 BCRF** (PI: Rugo) 10/01/12-09/30/19
**Source:** The Breast Cancer Research Foundation $30,000 directs/yr
**Title**: *Cellular mechanisms of resistance to antiangiogenic and the impact of immune therapy, and molecular characterization of circulating tumor cells (CTCs) in patients with advanced breast cancer*
The major goals of this study are to: 1) evaluate significance of immune cells in primary mammary carcinomas and lung metastases in the context of response and relapse/resistance to anti-antiangiogenic and/or immune modulating therapy, 2) Investigate the impact of inhibiting immune cell infiltration alone or in combination with antiangiogenic agents or chemotherapy on the growth of primary tumors and metastases, and 3) characterize the expression of a specific set of genes and gene copy number in circulating tumor cells (CTCs) in patients with ABC, including markers of response and resistance to specific types of therapy.
**Role**: subcontract P.I.

Externally sponsored research (PI: Coussens, LM) 03/01/16 – 02/28/19
**Source:** Roche Glycart AG $82,482 directs/yr
**Title**: *CD20 as a therapeutic target in pancreas cancer*
The major goals of this study are to evaluate therapeutic efficacy and identify select cell populations regulating efficacy.
**Role**: P.I.

No number (PI: Chang/Coussens) 07/01/18 – 06/30/19
**Source**: Brenden-Colson Center for Pancreatic Health $80,000 directs/yr
**Title**: *TiME matters in pancreatic cancer*
The goal of this project is to interpret multi-nodal aspects of immune complexity and functionality in tumor biopsy material elucidated by multiplex immunohistochemistry (mIHC)2 to aid patient stratification and response for precision immune therapy of pancreatic cancer.

**Role**: mPI

No number (PI: Coussens) 12/01/18 – 11/30/19
**Source**: Parker Institute for Cancer Immunotherapy $250,593 total directs
**Title**: m*IHC Analysis of PICI trial; Phase 1b/II Clinical Trial with CD40 with or without PD1*
The goal of this project is to evaluate paired biopsy samples for immune contexture changes from a pancreas cancer clinical trial evaluating efficacy of αCD40 agonist mAb +/- αPD-1 mAb
**Role**: PI

**2018-Hillcrest-10** (mPI: Coussens; Adey) 01/01/19 – 12/31/19
**Source**: OHSU Knight Cancer Institute $50,000 total directs
**Title**: *Epigenetic TME Reprograming in TNBC*
The goal of this project is to investigate the impact of a novel combination of immune therapies, along with chemotherapy, to differentially regulate gene expression programs in immune cells present in mammary cancers
Role: mPI

**Externally Sponsored Research; SRA-18-049** (PI: Coussens) 10/12/17 – 10/02/20
**Source:** Syndax Pharmaceuticals Inc. $542,851 total directs
**Title:** *mIHC of Entinostat + pembroluzimab Evaluation*
The Coussens team will perform immunohistochemistry of formalin-fixed, paraffin-embedded (FFPE) pre- and post-treatment patient tissues from a clinical trial evaluating Entinostat + pembroluzimab.
**Role**: PI

**No Number** (PI: Coussens) 01/01/20 – 12/31/20
**Source:** Oregon Health & Science University (SMMART) $188,702 total directs
**Title**: *Multiplex IHC Patient Sample Analysis*
The goals of this project are to facilitate automation and high throughput analysis of a multi-plex IHC platform.
**Role**: PI

**No Number** (PI: Coussens) 01/01/20 – 12/31/20
**Source:** Oregon Health & Science University (SMMART) $50,000 total directs
**Title**: *Multiplex IHC Patient Sample Analysis*
Utilize multi-plex IHC to evaluate immune contexture of patient tumor samples
**Role**: PI

**Externally Sponsored Research; SRA-19-152** (PI: Coussens) 12/04/19 – 12/03/21
**Source**: Innate Pharma S.A. $318,471 total directs
**Title:** *Role of C5aR in overcoming chemotherapy resistance in murine orthotopic (OT) models of squamous carcinogenesis*
Consolidate preclinical evidence for targeting the C5aR axis in oncology.
**Role**: PI

**No number** (PI: Coussens) 10/01/19 – 12/31/21
**Source**: Johns Hopkins University $168,211 total directs
**Title:** *A phase II study of HDAC inhibition to sensitize to immunotherapy in advanced pancreatic cancer*
The goal of this project is to determine if treatment with the histone deacetylase inhibitor (HDACi) entinostat and/ or treatment with immune checkpoint inhibitors (ICIs) has an effect on infiltration and function of lymphoid and myeloid cells into tumors of patients with advanced cancers.
**Role**: subcontract PI

**R21 HD099367** (PI: Maloyan) 09/01/19 – 08/31/21
**Source**: NIH/NICHD $411,620 (Coussens $35,335)
**Title**: *Mechanisms of metabolic dysfunction in the offspring of maternal obesity: role of inflammation*
The goal of this project is to identify potential therapeutic targets to alleviate cardiovascular and metabolic diseases in the offspring of pregnancies complicated by maternal obesity.
**Role**: co-I

## VIII. PROFESSIONAL, UNIVERSITY AND PUBLIC SERVICE

### Memberships and Service to Professional Societies

**American Association for Cancer Research (Member, 1999 - present)**

2003 Subsection Co-chair (Tumor Progression, Invasion and Metastasis) Cellular, Molecular and Tumor Biology Subcommittee, AACR Program Committee for *94th Annual Meeting*.

2003 Chair and organizer, Educational Session *(*Proteases: Successes and Failures): *94th Annual Meeting*, Washington D.C., USA

2003 Minisymposium Co-chair (Inflammatory Mediators & Cancer): *94th Annual Meeting*, Washington D.C., USA

2003 – 2005 Associate Editor, ***Cancer Research***

2004 - 2006 Member, Grants Committee

2004 – 2007 Senior Editor, ***Cancer Research (****Cell, Tumor and Stem Cell Biology* Section)

2005 Minisymposium Co-Chair (Inflammation, Microenvironment and Tumor Progression): *96th Annual Meeting*, Anaheim, CA USA

2005 Session Chair (Inflammation*)*: *AACR Special Conference: Cancer, Proteases and the Microenvironment*, Bonita Springs, Florida. USA

2006 Subsection Co-chair (Tumor Progression, Invasion and Metastasis) of the Tumor Biology Subcommittee, AACR Program Committee for *97th* Annual meeting

2006 Minisymposium Co-Chair (Inflammation and Cancer): *97th Annual Meeting*, Washington DC, USA

2006 Co-Chairperson, Program Committee: *6th Annual Frontiers in Cancer Prevention Research Conference*, December 5-8, 2007, Philadelphia, PA USA.

2006 - 2010 Steering Committee Member: AACR Tumor Microenvironment Working Group (TME/AACR).

2007 – 2009 Deputy Editor, ***Cancer Research***

2007 Organizer, Education session (Inflammation and Cancer), *98th Annual Meeting*, Los Angeles, USA

2007 Minisymposium Co-Chair (Tumor Microenvironment): *98th Annual Meeting*, Los Angeles, CA USA

2007 Co-Chairperson, Program Committee: *2008 99th Annual Meeting of the AACR*. April 12-16, 2008, San Diego, CA. USA

2008 Program Committee Member, Tumor Microenvironment Subcommittee for *99th Annual Meeting of the AACR*. April 12-16, 2008, San Diego, CA. USA

2007 - 2010 Member, AACR Special Conferences Committee

2008 Co-Organizer AACR Special Conference: *Inflammation and Cancer*, with Drs. Michael Karin and Larry Marnett. Oahu, Hawaii, USA.

2008 - 2011 Member, Board of Directors (**elected**)

2009 – 2012 Deputy Editor for Breaking Advances, ***Cancer Research***

2009 Member, 2009 Education Committee, 2009 100th AACR Annual Meeting, Denver, CO. USA

2009 Organizer and Chair: *Inflammation and Cancer: Novel Mechanisms Regulating Protumor Immunity* Major Symposium, 2009 100th AACR Annual Meeting, Denver, CO. USA

2009 Organizer and Chair: Education Session, *Aspects of the Tumor Microenvironment that Regulate Solid Tumor Development,* 2009 100th AACR Annual Meeting, Denver, CO. USA

2010 Co-Chairperson, Program Committee: *2010 101st Annual Meeting of the AACR*, April 17-21, 2010, Washington, DC USA

2009 Member, Scientific Review Committee for *Stand Up to Cancer Innovative Research Grants*

2009 - 2010 Member, Selection Committee: *2010 Pezcoller Foundation-AACR International Award for Cancer Research. Dr. Joseph Schlessinger, recipient*

2010 - 2011 Council Member, *Women in Cancer Research* Council (elected)

2010 Co-Chair, Minisymposium '*The Tumor Microenvironment and Therapeutic Strategies" 2010 101st Annual Meeting of the AACR*, April 17-21, 2010, Washington, DC USA

2010 - 2011 Member, Selection Committee: 2010-2011 *AACR Award for Lifetime Achievement in Cancer Research. Dr. Susan Horwitz, recipient.*

2011 Co-Chair, Minisymposium '*Tumor Microenvironments" 2011 102st Annual Meeting of the AACR*, April 3-6, 2010, Orlando, FL USA

2011 Co-Organizer AACR Special *Conference: Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy,* with Drs. Yves DeClerck (USC, Children's Hospital) and Melody Swartz (EPFL); November 2011, Orlando FL USA

2012 Co-Chairperson, Program Committee: *2012 103rd Annual Meeting of the AACR*, April 3-6,

2010, Chicago, IL USA
2012-present Senior Editor, ***Cancer Immunology Research***
2012 Chair, Plenary session: "Tumor Heterogeneity: Challenges and Therapeutic Opportunities" *2012 103rd Annual Meeting of the AACR*, April 3-6, 2010, Chicago, IL USA
2012 Chair, Education session: "Tumor Microenvironment" *2012 103rd Annual Meeting of the AACR*, April 3-6, 2010, Chicago, IL USA
2012 Chair, 2012 Landon Foundation-AACR INNOVATOR Award for International Collaboration in Cancer Research Scientific Review Committee, Dr. Judith Varner, recipient.
2012 Speaker, 2012 AACR Meet the Research Pioneer, *2012 103rd Annual Meeting of the AACR*, April 3-6, 2010, Chicago, IL USA
2012 Organizing Committee for 9th AACR-Japanese Cancer Association International Conference, February 21-25, 2013, Maui, Hawaii.
2012 Cancer Immunology (CIMM) Chairperson-elect Nominating Committee 2013-2014.
2013 - present Senior Editor, *Cancer Immunology Research*
2013 Member, 2014 AACR Princess Takamatsu Memorial Lectureship Award Committee. *Dr. Rakesh Jain, recipient*
2013 - 2015 Pancreatic Cancer Action Network-AACR Innovative Grants Scientific Review Committee
2014 Chair, Education session: *Phenotyping and Function of Solid Tumor Stroma"* 2014 *105th Annual Meeting of the AACR*, April 2014, San Diego, CA USA
2014 Personalized Career Discussions, Associate Member Council, 2014 *105th Annual Meeting of the AACR*, April 2014, San Diego, CA USA
2015 Program Committee, Second AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy, San Diego, CA USA.
2014 Member Selection Committee, 2014-2015 Pezcoller Foundation-AACR International Award for Cancer Research.
2015 Mentor, WICR Career Mentoring Session, Fourth AACR International Conference on Frontiers in Basic Cancer Research, Philadelphia PA USA
2016 Scientific Program Committee Member, AACR Annual Meeting on April 16 - 20, 2016 in New Orleans, Louisiana USA
2016 Education Committee Member, AACR Annual Meeting on April 16 - 20, 2016 in New Orleans, Louisiana USA
2016 Mentor, AMC/MICR/WICR-sponsored 'Personalized Career Discussions' session, AACR Annual Meeting 2016, New Orleans, LA USA
2016 Member, Steering Committee, AACR Cancer Progress Report, 2016. Chair: Nancy Davidson.
2016 - 2018 Member, Nominating Committee (**elected**).
2016 - 2019 Member, AACR Special Conferences Committee
2016 – 2018 Member, AACR NextGen Grants for Transformative Cancer Research Scientific Review Committee
2017 Search committee member; Editor-in-Chief for *Cancer Research*
2017-present Scientific Editor, ***Cancer Discovery***
2018 Co-organizer 8th AACR Special Conference on *Tumor Immunology and Immunotherapy*, with Drs. Pardol, Mellman and Allison (MDACC). Miami, FL, USA
2018 2018 Annual Scientific Program Committee
2019 Co-chair, 2019 Annual Meeting Program Committee
2019 Chair, 2019 Annual Meeting Education Committee
2019 Member, selection committee, NextGenStar applications, 2019 Annual Meeting
2019 Program Committee, AACR Translational Cancer Research for Basic Scientists Workshop
2019 Chair, Education session: "Molecular Regulation of Cancer Inflammation, Progression and Treatment Resistance" *2019 Annual Meeting of the AACR*, April 2019, Atlanta GA. USA
2019 Fellow of the AACR Academy (Lifetime)
2020 Co-Chair organizer EACR-AACR-ASPIC Basic and Translational Research Conference, '*Tumor Microenvironment'*, with Drs. Caldas (EACR) and Costa (ASPIC). Lisbon, PORTUGAL.
2020-present Course Co-Director, AACR Translational Cancer Research for Basic Scientists Workshop, with Drs. Corcoran, Horwitz, and Oxnard. Virtual in 2020 due to COVID-19

2020 Subcommittee Member, *Immunotherapy: Preclinical and Clinical; Immuno-oncology* Section of Immunology Subcommittee of the Program Committee. 2020 Annual Meeting
2020 Chair, AACR NextGen Grants for Transformative Cancer Research Scientific Review Committee.
2021 Member, Education Committee, 2022 Annual meeting
2021 Mentor, Career Breakout Session: Mentoring the Mentor, 2021 AACR Virtual Special Conference: Pancreatic Cancer.
2021-2024 President-elect, President, Past-President (elected)

- Member, Executive Committee (2021-2024)
- Officer, Board of Directors (2021-2024)
- Member, Science Policy and Government Affairs Committee (2021-2024)
- Member, Finance and Audit Committee (2021-2023)
- Trustee, AACR Foundation Board (2021-2024)
- Member (2021-2022) and Chair (2022-2023), AACR International-Canada Board of Directors

2022 Co-organizer AACR Special Conference on '*Carcinoma in situ', with Drs. Polyak, Esserman, and Reis-Filho).*
2022 Chair, Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research selection committee
2022-2024 Member, AACR Trust in Science Task Force; chair, Dr. William S. Dalton

**American Society for Cell Biology (Member, 2001 – 2008)**

2000 American Society for Cell Biology, photo credits in '*Exploring the Cell'* Ed. W. Wells
2001 Table Leader, Career Discussion Lunch, Women in Cell Biology and Education Committee, 40th Annual Meeting, Washington, DC, USA
2001 Co-chair and Co-organizer, Mini-symposium (Microenvironment/Extracellular Matrix in Development and Disease): 40th Annual Meeting, Washington, DC, USA
2003 Table Leader, Career Discussion Lunch, Women in Cell Biology and Education Committee of the ASCB, *42nd Annual Meeting*, San Francisco, CA, USA
2006 Co-Chair Minisymposium (Cancer Mechanisms*)*: *46th Annual Meeting*, San Diego CA, USA

**American Association for Advancement of Science (Member, 2011 – present)**

2014 - 2017 Member, Electorate Nominating Committee (ENC) of the Section on Medical Sciences (**elected**)
2017 – 2020 Member, Electorate Nominating Committee (ENC) of the Section on Medical Sciences (**elected**)
2016 – 2019 Board of Reviewing Editors, *Science*
2018 AAAS Fellow (Lifetime)

**International Proteolysis Society (Member, 2004 – 2009)**

2007 Member, International Scientific Advisory Committee, 5th General Meeting of the International Proteolysis Society, Rion-Patras, GREECE.
2011 Member, Organizing Committee, 9th General Meeting of the International Proteolysis Society, San Diego CA, USA

**Society for Immunotherapy of Cancer; (Member, 2016-present)**

2013 SITC Annual Meeting, Session Co-Organizer and Co-Chair (with Georgio Trinchieri, NCI), SITC *Tumor Microenvironment and Innate Cell Recognition*, Bar Harbor, MA USA
2018 - 2021 SITC Immune Responsiveness Task Force (member)
2022 SITC - Fellow of the Academy of Immuno-Oncology (Lifetime)

**International Society for Preventive Oncology**

2002 Session Chair (Chemoprevention*)*: *6th Annual Meeting*, Pasteur Institute, Paris, France.
2002 Poster Judge (Chemoprevention*)*: *6th Annual Meeting*, Pasteur Institute, Paris, France.

**International Society for Biological Therapy of Cancer (iSBTc)**

2008 Co-Organizer (with Drs. Michael Karin, Steven Dubinett, George Weiner), *2008 Workshop on Inflammation in Cancer Development*, San Diego CA, USA

**Other Professional Society Memberships**

2000 - 2009 American Society for Matrix Biology
2004 - present American Society for Investigative Pathology
2014 – present American Association of Immunology

## Government Service

| | | |
|---|---|---|
| 2003 - 2006 | National Institutes of Health, Center for Scientific Review | Ad hoc reviewer (10/2003; 02/2005; 10/2005; 06/2006), Tumor Progression & Metastasis (TPM) Study Section, Oncological Sciences Review group |
| 2003 | Division of Cancer Biology, National Cancer Institute: *Microenvironment Think Tank* | Participant and *Reporter* |
| 2003 | Division Cancer Etiology, National Cancer Institute: *Validation of A Causal Relationship: Criteria to Establish Etiology Think Tank* | Invited speaker and Participant |
| 2004 | National Institutes of Health, National Cancer Institute | Subcommittee C (05/2004) – Basic & Preclinical NCI Initial Review Group, NCI-C RPRB (T2) Angiogenesis |
| 2005 | National Institutes of Health, National Cancer Institute | Subcommittee D (02/2005) – Clinical Studies NCI Initial Review Group, NCI-D RPRB Tumor Pathology |
| 2005 | National Institutes of Health, Center for Scientific Review-Oncology | Special Emphasis Panel (SEP); ZRG1 ONC (03) M, Developmental Therapeutics |
| 2010 | National Institutes of Health, Center for Scientific Review-Neuroscience | Special Emphasis Panel (SEP)/Scientific Review Group 2010/05 ZNS1 SRB-R (47) |
| 2010 | National Institutes of Health, Center for Scientific Review-Neuroscience | Special Emphasis Panel (SEP)/Scientific Review Group 2011/01 ZRG1 DTCS-A (81) |
| 2010 - 2011 | Department of Defense (DOD), Breast Cancer Research Program (BCRP) | 6th Era of Hope conference Technical Planning Committee (TPC) |
| 2011 | National Institutes of Health, Center for Scientific Review | Ad hoc reviewer (06/2011), Cancer Immunotherapy & Immunology (CII) Study Section, Oncology 2 - Translational Clinical IRG (OTC) Division of Translational and Clinical Sciences |
| 2016 - present | National Institutes of Health, National Cancer Institute, Division of Extramural Activities | Scientific Advisory Board. Frederick National Laboratory Advisory Committee (FNLAC) |
| 2019 - 2020 | National Cancer Institute (NCI), The Frederick National Laboratory Advisory Committee (FNLAC) | FNLAC *ad hoc* Working Group on Cancer Models and Therapeutic Development |

## Other Professional Ad hoc Service

| | | |
|---|---|---|
| 1999 | Arkansas Science & Technology Authority | Ad hoc Grant Review |
| 2000 | McGraw-Hill, '*Biology'* 6th edition, Ed. P.H. Raven and G.B. Johnson | Ad hoc Review, Chapters 17 and 18 |
| 2001 | Department of Veterans Affairs | Ad hoc Grant Review, Oncology Review Board |
| 2001 | Research Grants Council of Hong Kong | Ad hoc Grant Review |
| 2003 | Danish Cancer Society, DENMARK | Ad hoc Grant Review |
| 2004 | Division of Gastroenterology and Digestive Disease Research Center, Vanderbilt University, Nashville TN, USA | PO1 External Advisory Panel |
| 2004 | Cancer Research Ireland, Irish Cancer Society | Ad hoc grant review |
| 2004 | Dutch Cancer Society | Ad hoc grant review |
| 2004 | Vanderbilt University, Nashville TN, USA; SPORE in GI Cancer | Ad hoc reviewer for SPORE Developmental Research Program |
| 2006 | Keystone Symposia Cancer Study Group for 2009 programming | Study group member |
| 2009 | GlaxoSmith Kline | Member, Tykerb Post-ASCO KOL Advisory Board |
| 2009 - 2010 | Cancer Prevention and Research Institute of Texas (CPRIT) | Member, Scientific Review Committee; Basic Cancer Biology Review Committee |
| 2013 | IARC – Italian Association for Cancer Research | Site visit review committee member, Istituto Clinico |

| | | |
|---|---|---|
| | | Humanitas - Centro Congress |
| 2015 | Celgene Advisory Board | Member |
| 2015 | AstraZeneca Pharmaceuticals LP | Consultant |
| 2015 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Ad hoc P30 review committee for Cancer Immunology Program Review |
| 2015-present | Pharmacyclics, LLC. PCYC-1137-CA Study | Steering Committee Member |
| 2015 | AIRC – Italian Association for Cancer Research | "5xmille" Special Program in Molecular Clinical Oncology (MCO), Ad Hoc review, 2-year extension programs |
| 2015-2016 | 3rd Stand Up to Cancer (SU2C) Innovative Research Grants Committee (IRGC) | Member, IRG committee; AACR |
| 2016-2017 | Pancreatic Cancer Action Network (PanCan), Precision Promise Immunotherapy Working Group | Member |
| 2016 | 2016 Nature Awards for Mentoring in Science (North America, West Coast) | Committee Chair |
| 2017 - present | Dana Farber Cancer Center Breast SPORE | EAB for P50 |
| 2017-present | Cancer Research United Kingdom (CRUK) | Member: Early Detection (EDx) Research Committee |
| 2019 - present | Lustgarten Foundation | Member: *Lustgarten Therapeutics Working Group* |
| 2019, 2021 | Susan G Komen Foundation | Member, Selection Committee, 2019 and 2021 Brinker Awards for Scientific Distinction |
| 2021 | National Foundation for Cancer Research | Member, Selection Committee, Szent-Györgyi Prize for Progress in Cancer Research |
| 2021 | Cold Spring Harbor Laboratories | Member, External review committee for 'Animal Facility/Opportunistic Pathogen' |
| 2021 | Susan G Komen Foundation | Member, Selection Committee, Metastatic breast cancer, collaborative grants selection committee |
| 2022 | Susan G Komen Foundation | Chair, Career Catalyst Research Grants: *Beyond T cells: Next generation breast cancer immunotherapy' committee* |

## Ad hoc Peer-Reviewing

1994 Oncogene;
1995 Am J Pathol; Matrix Biology; J Cell Biology
1999 Am J Pathol; Cancer Letters; Nature Med; Nature; PNAS; Cell Motility & the Cytoskeleton; Can Res;
2000 Am J Pathol; Can Res; Genes & Dev; Int. J Cancer
2001 J Cell Biology; Int. J of Cancer; EMBO; Neoplasia; Can Res
2002 Can Res; Am J Pathol; Int. J Cancer; Biol Chem; Cancer Cell; Cancer Letters
2003 PNAS; Can Res; Int. J of Cancer; J Molecular Medicine; Biol Chem; Science; Cancer Cell; Nature Med; J Leukocyte Biology; Neoplasia; Am J Pathol;
2004 Lancet; Cancer Cell; Can Res; Am J Pathol; J Cell Biology; Nature Reviews Immunology; Nature Reviews Cancer; PNAS; J Biol Chem; Nature; J Exp Med; Int J Cancer
2005 Nature Med, Cancer Cell, Can Res; Am J Pathol; Cell; Nature; Nature Reviews Immunology; Nature Reviews Cancer; Carcinogenesis
2006 Nature Reviews Cancer; Nature; Nature Med; Cell; Can Res; Clinical Can Res; J Exp Med; Cancer Cell: Am J Pathol; J Cell Biology
2007 Cell; Nature; PNAS: J Cell Biology; Can Res; J Exp Med; Breast Cancer Research
2008 Cancer Cell; PNAS; J Immunology; Nature; J Exp Med; Trends in Genetics; Current Opinions in Investigational Drugs
2009 Cancer Cell; Cell; Nature; J Exp Med; J Clin Invest, Can Res; Int J Cancer; Oncogene, J Immunology
2010 Nature; J Exp Med; Nature Med; J Invest Dermatology; Cell; Cancer Cell; J Clinical Onc; PNAS; J Clin Invest; Can Res; Dis Mech Models; Cancer Immuno Immunother;
2011 Nature; Nature Med; Canc Res; Cancer Cell; J Clin Invest; Breast Cancer Research; PlosOne, PNAS; Oncogene; J Exp Med; Oncogene;

2012 PNAS; Can Res; Oncogene; Trends in Immunology; Nature; Clin Can Res; J Exp Med; Cancer Discovery; Immunity; J Cell Physio; JoVE; Immunity; J Clin Invest; BBA - Molecular Basis of Disease; Can Res; EMBO; Genes & Dev; Nature Cell Biol.; TREIMM; Blood; Nature Med; Science Transl Med;
2013 Cancer Discovery; Cell; Genes & Dev; Nature; Can Res, J Translational Medicine; J Exp Res, Nat Med; Frontiers in GI Science; Science Transl Med; Nat Comms; Lung Cancer;
2014 Cancer Cell; Cell; Nature Med; PNAS; J Exp Med; Can Res; Immunity; Can Disc; Br Can Res; Science Transl Med; Pancreas; PNAS;
2015 Science; Nat Rev Clin Onco; Trends in Immunol; Cancer Cell, Can Res; J Clin Invest; J Exp Med; J Natl Can Inst; Science Trans Med; Can Immunol Immunotherapy; Nature Med; Head and Neck; Life Science; JOVE; Cell; PNAS; Genes & Dev
2016 Science; Nature; Nature Cell Biol; Nature Med; J Immunol; Immunity; Genes & Dev; E-Life; Cell Reports; J Clin Invest; J Exp Med; Can Res; Can Immuno Res; Nature Rev Can; Sci Trans Med;
2017 Cell; Cell Reports; Can Immuno Res; Nature Immuno; J Clin Invest; B J Cancer; J Exp Med;
2018 Can Res; J Clin Invest; Nature; OncoImm; Nat Comm; Immunity; Nat Immuno; Cancer Discovery; Cancer Cell; Cell;
2019 Cancer Cell; Carcinogenesis; Cell; Frontiers; Nat Comm; Sci Transl Med; Clin Can Res; J Exp Med.; Histopathology; J Clin Invest.; Meth in Enz; Nature Biomaterials; Sci Data;
2020 Cancer Cell; Carcinogenesis; Cell; Life Science; Nat Comm; Lab Invest; J Exp Med; The Oncologist; Cancer Letters; Curr Opin Immuno.; Exp Rev.; Nature Cancer; Nature Genetics; Theranostics; USCAP;
2021 Cell; Nat Comm;
2022 Nat Comm; Nat Cancer; JITC;

## University Service

### Oregon Health & Science University

2012 - present Faculty member, Graduate program in Molecular & Cellular Biosciences
2012 - present Faculty member, OHSU Knight Cancer Institute, Program in Cancer Biology
2012 - 2013 Chair, Search Committee, Depts of Cell & Developmental Biology, Molecular and Microbial Immunology (Successful co-recruitments of **Evan Lind, Ph.D.**, **Jeffrey Nolze, Ph.D.)**
2013 Chair, Search Committee, Depts of Cell & Developmental Biology, Molecular and Microbial Immunology, Biomedical Engineering, Knight Cancer Institute (Successful recruitments of **Amanda Lund, Ph.D.**)
2013 Co-Chair (with Chris Amling), Search Committee, Dept. of Cell and Developmental Biology, Dept of Urology and Knight Cancer Institute (Successful recruitment of **Kunyoo Shin, Ph.D.**)
2013 Chair, Search Committee, Dept. of Cell and Developmental Biology and Knight Cancer Institute (Successful recruitments of **Sudarshan Anand, Ph.D.**, **Pepper Schedin, Ph.D.,** and **Sara Courtneidge, Ph.D.**)
2012 Chair, V Foundation Scholar nomination committee
2013 - 2018 Member, Center for Women's Health, Internal Advisory Committee
2013 - 2019 Member, OHSU Research Council
2013 – present Member, Limited Submissions Grant Review Selection Committee.
2013 - 2018 Member, Oregon Clinical and Translational Research Institute (OCTRI) Research review committee
2013 - 2015 Member, Search Committee for Chair, Dept. of Medicine. (Successful recruitment of **Sharon Anderson, M.D., Ph.D.**)
2014 - 2016 Member, Research Roadmap Task Force 1
2014 Table Discussion Leader, 2nd Annual BIRCWH Northwest Women's Health Research and Leadership Conference, Portland OR
2014 – 2020 Member, Center for Women's Health, *Circle of Giving* grant review committee
2015 Co-Chair (with Melissa Wong) School of Medicine Search Committee, Collaborative Recruitment of **Naoki Oshimori, Ph.D.** Depts. of Cell, Developmental & Cancer Biology, Dept of Dermatology, and Dept of Otolaryngology, Head and Neck Surgery.
2015 Chair, Search Committee, Dept. of Cell, Developmental & Cancer Biology, and Brenden-Colson Center for Pancreatic Care (BCCPC). (Successful recruitment of **Mara Sherman, Ph.D.)**.
2015 University Shared Resource working group. Chair: Peter Barr-Gillespie
2017 Co-Chair, Search Committee (with Tom Beer), Dept. of Cell, Developmental & Cancer Biology, Dept of Medicine and Div. of Hem/Onc, and Knight Cancer Institute (Successful recruitment of **Amy Moran, Ph.D.)**.
2017 - 2018 Member, Search Committee, Chief Science Officer for School of Medicine. Disbanded search.

2018 Member, Search Committee, Chair, Department of Pathology. Successful recruitment of **Donna Hansel, M.D., Ph.D.**

2018 Co-Chair (with Charles Thomas) School of Medicine Search Committee, Collaborative Recruitment of **Joshua Walker, M.D., Ph.D.** Dept. of Radiation Medicine, Dept. of Cell, Developmental & Cancer Biology, and Knight Cancer Institute.

2018 Co-Chair (with Paul Flint) School of Medicine Search Committee, Collaborative Recruitment of **Ferdinando Pucci, Ph.D**. by Departments of Otolaryngology, Head & Neck Surgery and Dept. of Cell, Developmental & Cancer Biology.

2019 - 2020 Member, OHSU 2025 Research Council

2019 - present Melanoma & Skin Cancer Steering Committee, Dept of Dermatology and Knight Cancer Institute

2020 University response to COVID-19 (COVID-19 Testing Lab Set-up Task Force; Return to Research Task Force)

2020 Co-Chair (with Dr. Kenneth Azarow) Collaborative Recruitment of **Robert Eil, M.D., Ph.D.** Dept. of Surgery, Dept. of Cell, Developmental & Cancer Biology, and Knight Cancer Institute.

2020 Chair, Search Committee, Dept. of Cell, Developmental & Cancer Biology, Knight Cancer Institute (Successful recruitment of **Meghan Ruhland, Ph.D.**)

2020 - present Member, Steering Committee, *Immune Monitoring and Cancer Omics Services (IMCO)*

2020 - present OHSU Knight Cancer Institute Site Co-Leader, AstraZeneca *Partner of Choice Network*

2020 – present Member, Search Committee: Physician-Scientist Assistant Professor, joint recruitment in Depts. of Radiation Medicine, Biomedical Engineering, and The Cancer Early Detection Advanced Research Center within the Knight Cancer Institute. *Ongoing*

2020 Member, Search Committee: Associate Dean, Diversity, Equity and Inclusion. School of Medicine.

2020 – present Member, University Transition Task (UTT) force

2021 Member, Selection Council, Silver Family Foundation Faculty Excellence & Innovation Award

2021 – present Chair, KCRB Vivarium Oversight Committee

2021 – present Member, Research Faculty Compensation Task force, subcommittee for Measurement of Research Success Taskforce, Chair, David Ellison, M.D.

2021 – present Member, Faculty Recognition and Awards Committee

2021 Chair, Search Committee, Dept. of Cell, Developmental & Cancer Biology, and Brenden-Colson Center for Pancreatic Care (BCCPC). (Successful recruitment of **Katelyn Byrne, Ph.D.**).

2022 Co-Chair, Search Committee (with Dr. Shivaani Kummar), Dept. of Cell, Developmental & Cancer Biology, and Division of Hematology Oncology. (Successful recruitment of **Megan Burgers, Ph.D.**).

2022 – present Member, The Healthy Oregon Project (HOP) advisory board.

## University of California; SYSTEM WIDE

1992 - 1993 Graduate Student Representative, Dept. of Biological Chemistry Faculty Council, UCLA

2004 *ad hoc* Member External Advisory Panel; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles CA, USA

2009 Member, Site Visit Programmatic Review Group, Department of Pathology & Laboratory Medicine, UCLA School of Medicine. Graduate Council of the UCLA Academic Senate.

## University of California, San Francisco; CAMPUS-WIDE

1997 Presentation, Donor Seminar, UCSF Development Office

1998 Presentation, Donor Seminar, UCSF Development Office

1999 - 2012 Member, Graduate Program in BioMedical Sciences (BMS)

2000 - 2012 Member, Graduate Program in Biological Sciences (PIBS)

2000 - 2004 Member, Steering Committee, Ovarian Cancer Program Project Grant

2000 - 2005 Member, Scholarships and Awards Committee, Academic Senate, School of Medicine

2001 - 2012 Member, BioMedical Sciences Graduate Program (BMS) Executive Committee

2002 - 2004 Member, Medical Scientist Training Program Executive Committee

2004 - 2006 Member, Search Committee, Director of Molecular Imaging, Dept. of Radiology, Committee Chair: Ron Arenson, M.D. no successful recruitment

2004 - 2006 Member, BioMedical Sciences Graduate Program (BMS); Admissions Committee

2004 Organizer, BioMedical Sciences Graduate Program Retreat, Granlibakken, N. Lake Tahoe, CA USA

2004 - 2012 Member, Graduate program in Immunology

2005 - 2006 Member, Tissue Engineering Ladder-rank Faculty Search Committee, Dept. of Surgery. Committee Chair: Nancy Boudreau, Ph.D. Successful recruitment of Valerie Weaver, Ph.D.

2005 - 2009 Member, Ethel and Jane Sokolow Memorial Cancer Endowment Lectureship Committee.

2006 Member, Cancer Faculty Search Committee, Anatomy Dept., Committee Chair: Zena Werb, Ph.D. Successful recruitment of Jeroen Roose, Ph.D.

2006 Member, Faculty Advisory Committee for 2007 Journalist Seminar on *Inflammation and Disease*.

Sponsored by Associate Vice Chancellor Barbara J. French
2007 Member, committee to select recipient of Dean's Postdoctoral Prize Lecture.
2007 Member, Faculty Search Committee for Restorative Neurosurgery and Stem Cell Neurobiology, VA Medical Center/UCSF NeuroSurgery. Committee Chair: Linda Noble, Ph.D.; Status: not filled.
2009 Member, Committee to choose 1st Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology, School of Medicine, UCSF. Recipient: Thierry Jahon, M.D.
2010 Member, 2010 Selection Committee for the Hellman Family Early-Career Faculty Awards.

### University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center

1999 - 2012 Member, Helen Diller Family Comprehensive Cancer Center
1999 Member, Cancer Center Research Building Space Review Policy Committee
1999 - 2002 Member, Mt Zion Animal Barrier Facility Committee
1999 - 2005 Member, Cancer Center Friday Seminar Series Committee
2000 Organizer and Chair, MZ Cancer Center Research Building Annual Retreat
2001 - 2012 Co-Director, Mouse Pathology Core
2001 Member, 'Star Performance Award' selection committee
2001 Presentation, Evelyn Herman Reception, UCSF Development Office
2001 - 2002 Member, Cancer Center Research Building, 'Cancer Center Faculty Working Group'
2001 - 2006 Member, Mouse Models of Human Cancer Working Group
2002 - 2003 Member, UCSF Mt Zion campus, Animal Protocol Review Committee
2002 Member, ACS IRG grant review committee
2002 - 2006 Steering Committee Member, Mouse Models of Human Cancer
2003 Member, Review Committee, UCSF Comprehensive Cancer Center Stewart Trust Award
2003 - 2009 Chair, UCSF Mt Zion Campus Animal Protocol Review Committee
2003 Member, Search Committee: Associate Director for Administration, UCSF Comprehensive Cancer Center (Erica Weber, recruited)
2004 Member, Review Committee, UCSF Comprehensive Cancer Center Stewart Trust Award
2006 Co-Organizer, UCSF CCC Annual Symposium, *'Inflammation & Cancer: Bench to Bedside'.*
2008 Chair, Committee to nominate Postdoctoral scholar for AACR 2008 Annual Meeting, Inaugural "Future Leaders, New Directions" Special Symposium. Nominee: Laura Soucek, Ph.D. (awarded)
2009 - 2012 Co-Leader, Program in *Cancer Immunity and Microenvironment*

### University of California, San Francisco, Cancer Research Institute

2001 - 2002 Member, Cancer Research Institute Membership Subcommittee

### University of California, San Francisco, Department of Pathology

2003 Member, Committee to recommend faculty for the *Robert E. Smith Endowed Chair in Experimental Pathology*
2004 Member, Search Committee, Ladder rank faculty, Physician-Scientist, Anatomic Pathology. Successful recruitment of Jay Debnath, M.D., Ph.D.
2007 Member, Search Committee, Ladder-rank faculty, Physician-Scientist, Pathology and Neuropathology. Committee Chair: Michael D Prados, M.D.; Status: open.
2008 Member, Search Committee, Ladder-rank faculty, Physician-Scientist, Experimental Pathology. Committee Chair: Benedict Yen, M.D.; Status: open
2009 - 2011 Member, Academic Merit and Promotions Committee; Pathology Dept.

## Public Service:

1990 Lecturer, Science Academy of Whittier, Summer Institute. Whittier College, Whittier, CA
1991 Organizer and Lecturer, Science Academy of Whittier, Summer Institute. Whittier College, Whittier, CA.
1993 Lecturer, Joslyn Community Center. Claremont, CA.
1994 Provided elementary educators with science-related supplies (photos, slides, fixed tissue samples).
1995 Co-Coordinator Hormone Research Institute, 'Take Our Daughters To Work Day', Univ. of Calif., San Francisco
1999 Discussant, American Cancer Society *14th Annual Excalibur Round Table*, San Francisco, CA, USA
2000 Speaker, American Cancer Society *San Mateo County Annual Volunteer Meeting*, San Mateo, CA, USA
2002 Photo credits and interviewed for '*Misdiagnosis: Failure of Promising Cancer Treatment Starts Soul Searching by Researchers & Drug Companies',* in: *San Francisco Chronicle,* May 12, 2002.
2003 Interviewed for article '*Body's First Defense May Be Root of Diseases',* in: *The Washington Post,* February 20, 2003
2003 Interviewed for article '*The Body on Fire*', in: U.S. News & World Report, October 20, 2003
2004 Interviewed for comments in: *Science News*, '*Early Warming: Inflammatory protein tied to colon cancer risk*" February 7, 2004, Vol 165.
2004 Interviewed for article '*The Fires Within'*, in: *TIME* Magazine, February 23, 2004

2004 Interviewed for comments on AACR Annual Meeting in: *Oncology Times*, '*Exercise Reduces Inflammatory Response, May also Reduce Cancer Risk*', Robert H Carlson, 26(11):33-34, June10, 2004
2004 Interviewed for article *'Inflammation and Cancer: The Link Grows Stronger',* in: *Science*, 306, 966-968 (2004)
2005 Interviewed for article *'Quieting a Body's Defenses',* in: *Newsweek*, Special Edition, Summer 2005
2006 Interviewed for "Expert Commentary" by *BreastLink.org,* on article "Association Between Circulating White Blood Cell Count and Cancer Mortality." *Archives of Internal Medicine*, January 23, 2006; 166:188-194. http://www.breastlink.org/index.php?module=announce&ANN_user_op=view&ANN_id=208
2007 UCSF Research Perspectives 2007 – Inflammation as Cause and Consequences of Disease, Media Event for Journalists, September 27, 2007, UCSF Mission Bay Campus
2007 On-Air radio interview by Dave Iversen, KQED *FORUM*, September 28, 2007 San Francisco CA USA
2012 Delta Kappa Gamma Society International, Winter Keynote Lecture; January 23, 2012, Fairfield, CA USA
2012 Continuing Education Webinar, Project LEAD, Center for NBCC Advocacy Training, National Breast Cancer Coalition
2013 Interview by eCancer: The immune microenvironment as an anti-cancer therapeutic strategy. https://www.youtube.com/watch?v=2DRkjERKjrE
2013 Interview by Professor Nicholas Lemoine, on, *Inflammation and Cancer. https://www.youtube.com/watch?v=TMl8ZbznYLM*
2015 Panel discussant for The American Cancer Society, *The Future of Cancer Research*, Portland OR, USA
2015 Panel speaker. American Cancer Society, *Making Strides Initiative* Breakfast, Portland OR, USA
2016 Expert testimony, Department of Defense, Walter Reed Task Force on Metastatic Research. Bethesda MS. USA
2018 Interview, FoxNews.com, by Lindsay Carlton (Senior Producer), on 'Status of Immune Therapy'
2019 Susan G. Komen Oregon and SW Washington, **KEYNOTE SPEAKER**, Dinner event, Portland OR, USA

## IX. TEACHING AND MENTORING

### Formal Scheduled Classes for OHSU Students:

| Qtr | Academic Yr | Course No. & Title | Teaching Contribution | Units | Class Size |
|---|---|---|---|---|---|
| S | 2011/2012 | CELL616; *Advanced Topics in Cancer Biology* | Lecture: *Tumor Microenvironment* | 3 | 20 |
| S | 2012/2013 | CELL616; *Advanced Topics in Cancer Biology* | Lecture: *Tumor Microenvironment* | 3 | 20 |
| S | 2012/2013 | CONJ665; *Development, Differentiation and Cancer* | Course Co-Director, Lecturer | 3 | 10 |
| S | 2013/2014 | HIP505; Human Investigations Program | Lecture: *Team Science: Secrets to success in interdisciplinary research across the lifespan* | 2 | 13 |
| S | 2013/2014 | CELL616; *Advanced Topics in Cancer Biology* | Lecture: *Tumor Microenvironment* | 3 | 12 |
| S | 2013/2014 | CONJ665; *Development, Differentiation and Cancer* | Course Co-Director, Lecturer | 3 | 12 |
| F | 2013/2014 | CONJ650; The Practice and Ethics of Science | Discussion Leader | 1 | 14 |
| S | 2014/2015 | CELL616; *Advanced Topics in Cancer Biology* | Lecture: *Tumor Microenvironment* | 3 | 12 |
| S | 2014/2015 | CONJ665; *Development, Differentiation and Cancer* | Lecturer: Cancer Histopathology, immune biology | 3 | 7 |
| F | 2018/2019 | CONJ650; The Practice and Ethics of Science | Discussion Leader | 1 | 15 |

### Formal Scheduled Classes for UCSF Students:

| Qtr | Academic Yr | Course No. & Title | Teaching Contribution | Units | Class Size |
|---|---|---|---|---|---|
| W | 1997/98 | IDS 100; Histology Laboratory | *Neoplastic Skin Histopathology*; Laboratory lecture & instruction | 10 | 150 |
| W | 1998/99 | IDS 100; Histology Laboratory | *Neoplastic Skin Histopathology;* Laboratory lecture & instruction | 10 | 150 |
| W | 1999/00 | IDS 100; Histology Laboratory | *Neoplastic Skin Histopathology*; Laboratory lecture & instruction | 10 | 150 |
| S | 1999/00 | BMS 297A; Molecular Biology & Pathology of Neoplasia | *Animal Models of Cancer Laboratory*; Laboratory lecture & instruction | 3 | 15 |

| | | | | | |
|---|---|---|---|---|---|
| S | 2000/01 | BMS 297A; Molecular Biology & Pathology of Neoplasia | *Animal Models of Cancer Laboratory*; Laboratory lecture & instruction | 3 | 15 |
| W | 2000/01 | BMS 225; Tissue and Organ Biology | Lecture and laboratory instruction | 3 | 15 |
| S | 2000/01 | BMS 260; Cell Biology | Discussion group leader | 1 | 6 |
| F/W | 2001/02 | IDS 101; Prologue | Laboratory Instructor | 9 | 30 |
| W | 2001/02 | BMS 225; Tissue and Organ Biology | Lecture and laboratory instruction | 3 | 15 |
| W | 2001/02 | IDS 103; Cancer Block | *Invasion & Metastasis*; Lecturer | 7 | 150 |
| S | 2001/02 | BMS 260; Cell Biology | Discussion group leader | 1 | 7 |
| F | 2002/03 | BMS 260; Cell Biology | Discussion group leader | 1 | 6 |
| W | 2002/03 | IDS 103; Cancer Block | *Invasion & Metastasis*; Lecturer | 7 | 150 |
| F/W | 2002/03 | IDS 101; Prologue | Laboratory Instructor | 9 | 30 |
| F | 2003/04 | BMS 260; Cell Biology | Discussion group leader | 1 | 6 |
| S | 2003/04 | BMS 225B, Tissue and Organ Biology | Lecturer and Laboratory Instructor | 1.5 - 5 | tbd |
| W | 2003/04 | Biochem 297; Molecular Biology & Pathology of Neoplasia | *Angiogenesis:* Lecturer | 3 | 30 |
| W | 2003/04 | BMS 297A Molecular Biology & Pathology of Neoplasia Laboratory | Lecturer and Laboratory Instructor, *Animal Models of Neoplasia* | 1 | 10 |
| S | 2003/04 | BMS 225B; Tissue & Organ Biology | Lecturer: Cancer I & Cancer II | 1.5 - 5 | 16 |
| F | 2004/05 | BMS 260; Cell Biology | Discussion group leader | 1 | 6 |
| F | 2005/06 | BMS 260; Cell Biology | Discussion group leader | 1 | 7 |
| W | 2006/07 | Biochem 297; Molecular Biology & Pathology of Neoplasia | *Inflammation and Cancer*: Lecturer | 3 | 30 |
| W | 2008/09 | BMS230; Cellular & Molecular Biology of Cancer | Course Co-Director | 3.5 | 22 |
| W | 2008/09 | BMS230; Cellular & Molecular Biology of Cancer | Lecturer: *Cancer Microenvironments; Inflammation and Cancer* | 3.5 | 22 |
| W | 2010/11 | BMS230; Cellular & Molecular Biology of Cancer | Course Co-Director | 3.5 | 22 |
| W | 2010/11 | BMS230; Cellular & Molecular Biology of Cancer | Lecturer: *Tumor cell heterogeneity*; *Cancer Microenvironments; Inflammation and Cancer* | 3.5 | 22 |

**Postgraduate and Other Courses:**

| | | |
|---|---|---|
| 1989 | M204, *Biochemistry Lab*<br>Univ. of Calif., Los Angeles | Student Teaching Assistant for quarter long course (100 medical students) |
| 1989 | Biology 250, *Human Heredity*; Dept. of Biology<br>Whittier College, Whittier CA | Organized and taught entire lecture-based course (30 undergraduate students) |
| 1990 | Biology 350 & 350L, *Molecular Genetics*; Dept. of Biology, Whittier College, Whittier CA | Organized and taught entire lecture and laboratory course (16 undergraduate students) |
| 1990 | M204, *Biochemistry Lab*<br>Univ. of Calif., Los Angeles | Student Teaching Assistant for quarter long course (100 medical students) |
| 1990 | Biology 250, *Human Heredity*; Dept. of Biology<br>Whittier College, Whittier CA | Organized and taught entire lecture-based course (30 undergraduate students) |
| 1992 | Biology 350 & 350L, *Molecular Genetics*; Dept. of Biology, Whittier College, Whittier CA | Organized and taught entire lecture and laboratory course (16 undergraduate students) |

| | | |
|---|---|---|
| 2002 | Graduate *Oncology*, University of Missouri, Columbia, MS, USA | Invited Guest Lecturer: Lecture syllabus & delivered 2-hr lecture for course (15 students, graduate, medical & postgraduate fellows |
| 2003 | Graduate Program in Cancer Biology, Stanford Univ., Stanford, CA USA | Invited Guest Lecturer: Delivered 1-hr lecture to graduate students in Cancer Biology Graduate program |
| 2004 | Graduate Program in Immunology, Stanford Univ., Stanford, CA USA | Invited Guest Lecturer: Delivered 1-hr lecture to graduate students in Immunology Graduate program |
| 2005 | UCSF Dermatology residents' Basic Science Seminar Series | Invited Guest Lecturer: Delivered 1-hr lecture to UCSF Dermatology Residents (11 M.D. and M.D., Ph.D. Residents) |
| 2008 | ISREC, Lausanne Univ. and Lausanne Ludwig Institute | Guest Instructor: *Exploring the Tumor microenvironment*, postgraduate course. (20 PhD students, 3 hours of instruction) |
| 2009 | OOA Course: Tumor Microenvironment; The Netherlands Cancer Institute | Guest Faculty: (4.5 hours of instruction, 25 PhD students) |
| 2010 | 25th Annual Harvard Tumor Course: Critical Issues In Tumor Microenvironment, Angiogenesis & Metastasis: *From Bench to Bedside & Back* | Faculty member: (2 hours of instruction. 100 students) |
| 2010 | Eppley Institute for Research in Cancer, Univ. of Nebraska Medical Center. Short Course in Cancer Biology: Metastasis and the Tumor Microenvironment | Faculty member: (3 hours of instruction, 166 students) |
| 2010 | San Francisco State University, Dept of Biology Seminar Series | Guest Faculty: (1 1/2 hour of instruction, 75 students) |
| 2011 - present | 26th, 27th, 28th, 30th, 31st, 32nd, 33rd, 34th, 35th Annual Harvard Tumor Course: Critical Issues in Tumor Microenvironment, Angiogenesis & Metastasis: | Faculty member: (2 hours of instruction. 50-100 students; for 35th course in 2020, 123 students virtual due to covid-19) |
| 2017, 2019-present | Jackson Laboratory Short Course on Experimental Models of Human Cancer, Bar Harbor, MN | Faculty member (2 hours of instruction. 50 students in 2017 and 2019; 2020-2021 was virtual with ~650 participants); 2022 was hybrid with 350 registrants |
| 2021 | Biology of Cancer, Sidney Kimmel Comp. Cancer Center at Johns Hopkins University | Lecturer (2 hours of instruction). 35 students; Virtual. |

**High School and Undergraduate Students Supervised or Mentored:**

| Dates | Name | Program or School | Faculty Role | Current position |
|---|---|---|---|---|
| 1998 | Christopher Tinkle | Undergraduate, Univ. of Texas, Austin, TX, USA | Summer Intern Supervisor | Ph.D. awarded 2008; M.D. awarded 2010; Rad/Onc Residency, UCSF Asst Prof, St Judes Childrens Hospital, TENN |
| 2000 | Adam Zucker | Undergraduate, Oberlin College, Ohio USA | Summer Intern Supervisor | unknown |
| 2000 | Ashkan Hirari | Undergraduate, Univ. of Calif., Berkeley, Berkeley CA, USA | Summer Intern Supervisor | unknown |
| 2001 | Jason Reuter | Undergraduate, Univ. of Calif., Berkeley, Berkeley CA USA | Summer Intern Supervisor | unknown |
| 2002 | Destinee Cooper | Undergraduate, Univ. of Calif., Davis USA | Summer Intern Supervisor | unknown |
| 2006 | Sunum Mobin | UCSF Science & Health Education Partnership: High School Intern | Summer Intern Supervisor | unknown |

| | | | | |
|---|---|---|---|---|
| | | Program | | |
| 2008-2009 | Julia Lam | Undergraduate, Univ. of Calif., Berkeley, Berkeley CA USA | Independent study (199), Mentor | B.S. awarded 2009 |
| 2010 | Scott Keil | Undergraduate, The University of Glasgow, Scotland | Summer Intern Supervisor | B.S. awarded 2012 |
| 2010-2011 | Heather Chen | Undergraduate, Univ. of Calif., Berkeley, Berkeley CA USA | Summer Intern Supervisor | unknown |
| 2010 | Amy Desalazar | Cupertino High School Cupertino, CA USA | Summer Intern Supervisor | unknown |
| 2010-2011 | Nikhil Wadhwani | Undergraduate, Sarah Lawrence College, Bronxville, NY USA | Summer Intern Supervisor | B.S. awarded 2012 |
| 2010 | Sharfa Junaid | Undergraduate, Univ. of Calif., San Diego, San Diego CA USA | Summer Intern Supervisor | unknown |
| 2010-2011 | Jon Lau | University of Nevada, Reno, Reno, Nevada | Summer Intern Supervisor | unknown |
| 2011 | Kara Wang | Undergraduate, Pomona College, Claremont, CA USA | Summer Intern Supervisor | unknown |
| 2011 | Graham Litchman | Undergraduate, San Francisco State Univ, San Francisco CA | Summer Intern Supervisor | unknown |
| 2011 | Jessica Wignall | Smith College, Northampton, MA USA | Summer Intern Supervisor | unknown |
| 2013 | Alexander Rosenbusch | University of Erlangen-Nuremberg, Germany | Mentor | Master's Student, University of Erlangen-Nuremberg, Germany |
| 2013 | Alexandra Forsythe | Scripps College, Claremont CA USA | CDCB Summer Intern Program | unknown |
| 2014 | Christine Ho | Univ of Calif., Berkeley | CDCB Summer Intern Program | Undergraduate, UC Berkeley |
| 2014 | Reid M Goodman | Pomona College, Claremont CA | CDCB Summer Intern Program | Medical School |
| 2015 | Chase Smith | Univ of Calif., Berkeley | CDCB Summer Intern Program | Medical School |
| 2015 | Amy LI | Portland State University | CDCB Summer Intern Program | unknown |
| 2015 | Miriam Marx | State University of New York | CDCB Summer Intern Program | unknown |
| 2015 | Ava Young | International School of Beaverton, OR USA | Ted R. Lilley Cancer CURE Program; mentor | unknown |
| 2015-2016 | Lia Kim | Asia Pacific International School, Hauula, HI USA | Emperor Science Award Program and CDCB Summer Intern Program | unknown |
| 2016 | Lea Garzotto | St. Mary's Academy Portland OR | CDCB Summer Intern Program | unknown |
| 2016 | Shiv Shah | Arizona State University | CDCB Summer Intern Program | unknown |
| 2016 | Julia Yu | Emory University | CDCB Summer Intern Program | unknown |
| 2016 | Catherine Sher | Univ. of New Mexico | CDCB Summer Intern Program; Supervisor | unknown |
| 2016 | Kenna Leis | University of Oregon | CDCB Summer | unknown |

| | | | | |
|---|---|---|---|---|
| | | | Intern Program | |
| 2017 | Rowan Talbot-Guerette | University of Rhode Island | CDCB Summer Intern Program | unknown |
| 2017 | Daniel Tolstrup | Seattle Pacific University | CDCB Summer Intern Program | unknown |
| 2017 | Hannah Zhao | University of Southern California | CDCB Summer Intern Program | unknown |
| 2017 | Jane Compton | Northeastern University | CDCB Summer Intern Program | unknown |
| 2017 | Jessica Jue | Carnegie Melon University | CDCB Summer Intern Program | unknown |
| 2018 | Ward Kirschbaum | Cal Poly San Luis Obispo | CDCB Summer Intern Program | unknown |
| 2018 | Ruben Sanchez Flores Jr | University of Oregon | Ted R. Lilley Cancer CURE Program; mentor | unknown |
| 2022 | Emma Jenkins | Pacific University, OR | CDCB Summer Intern Program | Undergraduate, Pacific University, OR |
| 2022 | Briana Johnson | Middlebury College, VT | Murdock Scholar | Undergraduate, Middlebury College, VT |
| 2022 | Bristol Ozturgut | Portland Community College, Portland OR | CDCB Summer Intern Program | Undergraduate, Portland Community College, Portland OR |
| 2022 | Nolan Gregg | Indiana University, Bloomington, IN | CDCB Summer Intern Program | Undergraduate, Indiana Univ., Bloomington, IN |

**Predoctoral Students Supervised or Mentored:**

| Dates | Name | Program or School | Faculty Role | Current position |
|---|---|---|---|---|
| 2000 - 2003 | Jin-Sae Rhee | UCSF M.D., Ph.D., | Ph.D. supervisor | M.D., Ph.D. awarded 2005; Pediatrician (Private Practice) San Jose, CA |
| 2000 | Maria Christophorou | UCSF BMS, graduate student | Faculty coach, BMS 297 | Ph.D. awarded 2006 |
| 2001 | Leslie Chu | UCSF BMS, graduate student | Rotation Supervisor | Ph.D. awarded 2005 |
| 2001 | Rayna Takaki | UCSF BMS, graduate student | Rotation Supervisor | Ph.D. awarded 2006 |
| 2001 – 2002 | Sophia Bruggerman | University of Nijmegan, The Netherlands | Masters Thesis Supervisor | Ph.D. awarded 2007 |
| 2002 | Lucy Lebedeva | UCSF PIBS, graduate student | Faculty coach, BMS 297 | Ph.D. awarded 2005 |
| 2002 | Leslie Chu | UCSF BMS, graduate student | Ph.D. Orals committee | Ph.D. awarded 2005 |
| 2002 | Andre Whitkin | MSTP student, Cornell University USA | Supervised Summer work | unknown |
| 2002 | Karin de Visser | The Netherlands Cancer Institute, The Netherlands | Ph.D. Thesis Reading Committee | Ph.D. awarded 2002 |
| 2003 | Cathy Collins | UCSF MSTP student | MSTP Advisor | PhD awarded 2009 M.D. awarded 2011 |
| 2004 | Eric Tamm | University of British Columbia, Canada | Doctoral Dissertation External Examiner | Ph.D. awarded 2004 |
| 2004 | Annie Hsieh | University of Södertörn, Sweden | Masters Thesis Supervisor | Unknown |
| 2005 | Geoff Benton | UCSF TETRAD/PIBS, graduate student | Ph.D. Orals committee | Ph.D. awarded 2011 |
| 2006 | Morgan Truitt | UCSF BMS, graduate student | Rotation Supervisor | PhD awarded 2016 |

| | | | | |
|---|---|---|---|---|
| 2006 | Danielle Shin | UCSF MSTP student | Rotation Supervisor | Ph.D. awarded 2011 |
| 2006-2008 | Celeste Rivera | SFSU/UCSF NIH Post-baccalaureate Research Experience Program (PREP) student | Masters Thesis Supervisor | M.S. awarded 2010; |
| 2007-2009 | Leslie Vasquez | SFSU/UCSF NIH Post-baccalaureate Research Experience Program (PREP) student | Masters Thesis Supervisor | M.S. awarded 2009 |
| 2008 | Ashley Martin | UCSF BMS, graduate student | Rotation Supervisor | Ph.D. awarded 2012 |
| 2009 | Kay Wiebrands | Master's Student Utrecht University, the Netherlands | Masters Thesis Supervisor | M.S. awarded 2009 |
| 2009-2010 | David Tawfik | Medical Student III, UCSF | MSIII break year. Dean's Quarterly Research Fellowship; PACCTR Fall Quarter Fellowship; | M.D., awarded 2011; |
| 2009-2012 | Renee Vanderlaan | UCSF BMS, graduate student | Chair: Thesis Committee | Ph.D. awarded 2012 |
| 2009-2011 | A. Preethi Ganessan, M.D., Ph.D. | Ph.D. Graduate Student Univ of Southampton | Ph.D. supervisor | Ph.D. awarded 2012 Associate Professor, Rady Children's Hospital of San Diego, UC San Diego, CA |
| 2009-2014 | Jasmine Lau | UCSF BMS, graduate student | Ph.D. Thesis Committee | Ph.D. awarded 2014 |
| 2010 - 2011 | Lucia Cottone | Ph.D. graduate student (San Rafaelle Institute, Milan Italy) | Ph.D. supervisor and 2nd supervisor del candidato | Ph.D. awarded 2012; Postdoctoral fellow, University College London, GB |
| 2011 | Conny Hainer | Master's student, Technical University of Berlin, Berlin, Germany | Masters Thesis Supervisor | M.S. awarded 2012 |
| 2011-2012 | Melissa Wheeler | PharmD student, UCSF | PharmD research mentor | PharmD awarded 2013 |
| 2011-2012 | Paul Huynh | PharmD student, UCSF | PharmD research mentor | PharmD awarded 2013 |
| 2012 | Derek Zachman | OHSU, MD/PhD and PMCB student | Qualifying exam committee | Ph.D. awarded 2018 |
| 2012-present | Tim Butler | OHSU, Cancer Biology graduate student, Spellman lab | Thesis committee | Ph.D. awarded 2016 |
| 2012 | Katelyn Atkins | OHSU, CDB graduate student | Thesis Examiner | Ph.D. awarded 2012 |
| 2013, 2014 | Xiaoming Ouyang | OHSU PMCB/CanBio graduate student. Kulesz-Martin lab | Rotation supervisor; Qualifying Exam Committee | Ph.D. awarded 2018 |
| 2013-2019 | Shannon Liudahl | OHSU Can Bio graduate student Coussens lab | Rotation and Thesis supervisor | Ph.D. awarded 2019, Postdoctoral Fellow, Fred Hutchinson Cancer Center, Seattle WA |
| 2013-2016 | Charles Ghast | OHSU Can Bio/MSTP graduate student Coussens and Wong | Rotation and Thesis supervisor | M.D., PhD. awarded 2018 Private Practise |

| | | | | |
|---|---|---|---|---|
| | | lab. Funding: T32 GM071388-10 (2014-15) | | |
| 2013 | Tyler Risom | OHSU Can Bio Graduate Program | Qualifying Exam committee | PhD awarded 2018 Staff Scientist, Genentech, Ic |
| 2014 | David Messenheimer | OHSU CanBio Graduate program, Fox lab | Thesis committee | PhD awarded 2017 |
| 2014-2017 | Spencer Watson | OHSU Can Bio Graduate Program; Gray lab | Thesis committee | PhD awarded, 2017 Postdoctoral Fellow, EPFL Switzerland |
| 2014 - 2017 | Courtney Betts | OHSU CDB Graduate program, Schedin lab | Thesis committee | PhD awarded 2017 Senior Scientist, Akoyo Inc. |
| 2014 | Zipei Feng | OHSU MSTP/CanBio Graduate program, Fox lab | Qualifying Exam committee | M.D., Ph.D. awarded 2018 |
| 2014 - 2017 | Erica Goddard | OHSU CDB Graduate program, Schedin lab | Thesis committee | PhD awarded, 2017. |
| 2016 | Ryan Lane | OHSU CDB Graduate program, Lund lab | Qualifying Exam committee | PhD awarded, 2019 |
| 2016 - 2019 | Kimberline Yang | Johns Hopkins Univ., CMM Graduate Program, Jaffee lab | External member, Thesis committee | PhD awarded, 2019 |
| 2018 - 2021 | Elliot Gray | OHSU BioMedical Engineering (BME) graduate program | Thesis committee | BME graduate student |
| 2019-2020 | Femke Ehlers | PhD Graduate program, Univ. of Mastricht, The Netherlands | Research supervisor; 6-mo residency | Coussens lab |
| 2020 - present | Katie Blise | OHSU BioMedical Engineering (BME) graduate program | Research Co-mentor | BME graduate student |
| 2020-2021 | Nicky Beleen | PhD Graduate program, Univ. of Mastricht, The Netherlands | Research supervisor; 12-mo residency | Coussens lab |

**Postdoctoral Fellows and Residents Directly Supervised or Mentored**

| Dates | Name | Position & Funding | Faculty Role | Current Position |
|---|---|---|---|---|
| 2000 - 2001 | Ernst Lengyel, M.D., Ph.D. | Post-Doc Researcher, Senior Clinical Fellow | Research Supervisor | Professor and Chair, Dept. Gyn. & Oncology, Univ. of Chicago |
| 2000 -2002 | Leon Van Kempen, Ph.D. | Post-Doc Researcher, Dutch Cancer Society Postdoctoral Fellowship | Research Supervisor | COO and Scientific Director Molecular Pathology Center at Jewish General Hospital, Dept. of Pathology, McGill University, Canada |
| 2002 – 2005 | Robert Diaz, Ph.D. | Post-Doc Researcher; Coussens R01 | Research Supervisor | Senior Scientist, Applied StemCell, Menlo Park, CA |
| 2002 – 2005 | Karin de Visser, Ph.D. | Post-Doc Researcher, Dutch Cancer Society Postdoctoral Fellowship | Research Supervisor | Group Leader, The Netherlands Cancer Inst, Amsterdam, The Netherlands |
| 2003 – 2007 | Alexandra Eichten, Ph.D. | Post-Doc Researcher, Serono Fndt for the Advancement of Medical Science (2003-2005); | Research Supervisor | Staff Scientist, Regeneron Corp., New York USA |
| 2003 - 2005 | Stephen Robinson, | Post-Doc Researcher; | Research | unknown |

| | | | | |
|---|---|---|---|---|
| | Ph.D. | Coussens R01 | Supervisor | |
| 2003 - 2004 | H. Jennifer Shen, Ph.D. | Post-Doc Researcher; Coussens R01 | Research Supervisor | NCI-FDA Oncology Product Research/Review Fellowship |
| 2005 -2010 | David DeNardo, Ph.D. | Post-Doc Researcher; 1) NGA: 5T32CA09043 PI: BISHOP; *Molec. Analysis of Tumor Viruses;* 2) Am Cancer Society Fellowship 2007-2010 | Research Supervisor | Professor, Molecular Oncology and Immunology, Washington University, St Louis, St Louis MS USA |
| 2005 –2007 | Nor Eddine Sounni, Ph.D. | Post-Doc Researcher; Coussens R01 | Research Supervisor | Principle Investigator, Univ. of Liege, Belgium |
| 2006 –2007 | Tingting Tan, M.D., Ph.D. | Post-Doc Researcher; Coussens R01 | Research Supervisor | Internal medicine, Private practice, San Francisco, CA |
| 2006 -2010 | Magnus Johansson, Ph.D., M.B.A. | Post-Doc Researcher; Swedish Cancer Society Fellowship 2006-08 | Research Supervisor | Director, Global Product Pipeline Strategy, Medtronic Diabetes, Los Angeles CA |
| 2006- 2012 | Nesrine Affara, Ph.D. | Post-Doc Researcher; AACR-Astellas USA Fndt in Basic Cancer Research 2009-2010: T32 Cancer Biology 2010-2011 | Research Supervisor | Faculty, Carnegie Mellon University, Doha, Qatar |
| 2007 -2010 | Pauline Andreu, Ph.D. | Post-Doc Researcher; Cancer Research Institute (CRI) Irvington Fellowship 2008-2011 | Research Supervisor | Director, du Pôle Recherche – Faculty of Science, University of Paris**. France** |
| 2008- 2015 | Brian Ruffell, Ph.D. | Post-Doc Researcher; Dept of Defense Postdoctoral fellowship 2009-2012; K99 CA185325 Pathway to independence | Research Supervisor | Associate Professor, Moffitt Cancer Canter, Tampa, FL USA |
| 2009-2011 | Stephen Shiao, M.D., Ph.D. | UCSF Radiation Oncology Hollman Fellow | Research Supervisor | Associate Professor, Cedars Sinai Med. Ctr, Los Angeles CA |
| 2010-2012 | Collin Blakeley, M.D., Ph.D. | UCSF Hematology-Oncology Fellow; T32 Hem/Onc Training Grant 2011-2013 | Research Supervisor | Associate Professor, Div. Hematology & Oncology, UCSF |
| 2010-2013 | Anna Wasiuk, Ph.D | Post-Doc Researcher; Coussens grant | Research Supervisor | Senior Scientist, Celldex Therapeutics, NJ |
| 2012 - 2015 | Andrew Gunderson, Ph.D. | Post-Doc Researcher; T32, Immunology Training grant 2012-2014 | Research Supervisor | Immunology Scientist, Dept. of Surgery, The Ohio State Univ., OH |
| 2012 - 2013 | Tina Bose, Ph.D. | Post-Doc Researcher; Coussens grant | Research Supervisor | unknown |
| 2012 - 2017 | Terry Meddler, Ph.D. | Post-Doc Researcher; T32 Dermatology training grant, 2012-2014; Am. Cancer Society Postdoctoral Fellowship; NCI K22 | Research Supervisor | Assistant Member, Earle A Chiles Research Institute, Portland OR |
| 2012 - 2013 | Aubie Shaw, Ph.D. | Post-Doc Researcher; Coussens grant | Research Supervisor | Assistant Professor, Medical School, Duluth, Univ. of Minnesota, MN |
| 2012 - present | Sushil Kumar, Ph.D. | Post-Doc Researcher; Coussens grant; Collins Medical Trust | Research Supervisor | Research Asst. Prof, Coussens Lab, OHSU |
| 2013 – 2014 | Christopher Chan, Ph.D. | Post-Doc Researcher; Coussens grant | Research Supervisor | Chief Scientific Officer, Pio Therapeutics Oty |

| | | | | |
|---|---|---|---|---|
| | | | | Ltd, Australia |
| 2014 - 2019 | Dhaarini Murugan, Ph.D. | Post-Doc Researcher; Coussens grant | Research Supervisor | Scientist, Notch Therapeutics, Seattle WA |
| 2014 - 2017 | Takahiro Tsujikawa M.D., Ph.D. | Post-Doc Researcher; OCTRI-Translational Catalyst Grant | Research Supervisor | Assistant Professor, Kyoto Prefectural Univ of Medicine. JAPAN |
| 2015-2017 | Tiziana Cotechini, Ph.D. | Post-Doc Researcher; Canadian Institutes of Health Research (CIHR) Fellowship | Research Supervisor | Assistant Professor, Queen's University, Canada |
| 2015-2016 | Mahsa Huanhuan He, Ph.D. | Post-Doc Researcher; Coussens grant | Research Supervisor | Professor, Sun Yat-Sen University (SYSU) in Zhuhai, China |
| 2016 - 2017 | Rie Kawashima, DDS, PhD. | Post-Doc Researcher; Coussens grant | Research Supervisor | Private Practice Tokyo, Japan |
| 2016-2017 | Casey Means, M.D. | Resident Physician, 6-mo research rotation AHNS Endocrine Surgery Section Eisai Research Award | Research Supervisor | Private Practice |
| 2017 - 2018 | Grace Banik, M.D. | Resident Physician, 6-mo research rotation AHNS Endocrine Surgery Section Eisai Research Award | Research Supervisor | Assistant Professor, Oto. Head & Neck Surgery, Univ. of Calif, San Francisco |
| 2017 - present | Amanda Poissonier, Ph.D. | Post-Doc Researcher; CRI Irvington Fellowship, 2019 (declined); BCRP DoD Breast Cancer Postdoctoral Fellowship 2019-2022 | Research Supervisor | Post-Doctoral fellow, Coussens Lab, OHSU |
| 2018 - 2019 | Cecil Gomes, Ph.D. | Post-Doc Researcher; T32 Dermatology training grant | Research Supervisor | Scientist, Caris Life Sciences, AZ |
| 2018 - present | Elvind Valen Egeland, Ph.D. | Post-Doc Researcher; FPIPRO Mobility Grant, Norway | Research Supervisor | Post-Doctoral fellow, Coussens Lab, OHSU |
| 2019 - 2020 | Jennifer Wherley, M.D., M.S., | Resident Physician, 6-mo research rotation AHNS Endocrine Surgery Section Stryker Research Award | Research Supervisor | Resident, Dept. Otolaryngology, Head & Neck Surgery, OHSU |
| 2020 - 2022 | Christian Huisman, Ph.D. | Post-Doc Researcher; Coussens funding | Research Supervisor | Post-Doctoral fellow, Coussens Lab, OHSU |
| 2020 - present | Eric Berens, Ph.D. | Post-Doc Researcher NCI K99/R00 | Research Supervisor | Post-Doctoral fellow, Coussens Lab, OHSU |
| 2021-2022 | Kristen Kramer, M.D., | Resident Physician, 6-mo research rotation | Research Supervisor | Resident, Dept. Otolaryngology, Head & Neck Surgery, OHSU |

## FORMAL INTERNAL FACULTY MENTORING

| Dates | Name | Position while Mentored | Mentoring Role | Current Position |
|---|---|---|---|---|
| 2001 – 2004 | Ernst Lengyel, M.D., Ph.D. | Asst. Adjunct Professor, Dept of Hem/Onc, UCSF | Research Mentor | Prof., and Chair, Dept. Gyn. & Oncology, Univ. of Chicago, Chicago, IL |
| 2002 – 2007 | Darya Soto, M.D. | Asst. Adjunct Professor, Dept of Medicine, UCSF | K08 Research Mentor | Private Practice, Burlingame, CA |
| 2005 – 2007 | Runi Chattopadhyay, M.D. | Clinical Instructor and Clinical Fellow, ept of Medicine, UCSF | Basic Science Mentor, K12 | Private Practice, San Francisco, CA |

| | | | | |
|---|---|---|---|---|
| 2006 – 2011 | Limin Liu, Ph.D. | Assistant Professor, Dept of Immunology, UCSF | Member, Mentoring Committee | Dept. of Microbiology & Immunology, Sandler Center for Basic Research in Asthma, UCSF |
| 2010 - 2011 | Jaynata Debnath, M.D., Ph.D., | Assistant Professor, Dept of Pathology, UCSF | Faculty Mentor | Professor, Dept. of Pathology, UCSF |
| 2014-2020 | Amanda Lund, PhD. | Associate Professor, Dept of Cell, Development & Cancer Biology, OHSU | Member, Mentoring Committee | Associate Professor, NYU Langonne Medical Center |
| 2014-present | Sud Anand, PhD. | Associate Professor, Dept of Cell, Develop, & Cancer Biol, OHSU | Member, Mentoring Committee | same |
| 2014-2016 | Kunyoo Shin, PhD. | Assistant Professor, Dept of Cell, Development & Cancer Biology, OHSU | Member, Mentoring Committee | S. Korea, unknown |
| 2014 - 2018 | Xiaolin Nan, PhD | Assistant Professor, Dept. of Biomedical Engineering, OHSU | Member, Mentoring Committee | Associate Professor, CEDAR, OHSU |
| 2015 – 2019 | Anupriya Aggarwal, Ph.D. | Associate Professor, Dept. of Medicine, OHSU | Member, Mentoring Committee | same |
| 2016 – present | Laura Heiser, Ph.D. | Associate Professor, Dept. of Biomedical Engineering (BME), OHSU | Member, Mentoring Committee | Vice Chair, BME, OHSU |
| 2016 – 2017 | Gulu Gorgun, Ph.D. | Assistant Professor, Dept. of Medicine, Hem/Onc Division, OHSU | Member, Mentoring Committee | unknown |
| 2016-present | Naoki Oshimori, PhD. | Assistant Professor, Dept of Cell, Development & Cancer Biology, OHSU | Member, Mentoring Committee | same |
| 2016 - present | Mara Sherman, Ph.D. | Assistant Professor, Dept of Cell, Development & Cancer Biology, OHSU | Member, Mentoring Committee | same |
| 2018 - present | Julia Maxon, PhD | Assistant Professor, Dept. of Medicine, Hem/Onc Division, and Dept of Cell, Development & Cancer Biology OHSU | Member, Mentoring Committee | same |
| 2017 - present | Amy Moran, Ph.D. | Assistant Professor, Dept of Cell, Development & Cancer Biology, OHSU | Member, Mentoring Committee | same |
| 2017 - present | Joshua Walker, M.D, Ph.D. | Assistant Professor, Dept of Radiation Medicine, and Cell, Development & Cancer Biology, OHSU | Member, Mentoring Committee | same |
| 2019 - present | Ferdinando Pucci, Ph.D. | Assistant Professor, Otolaryngology, Head & Neck Surgery, and Cell, | Member, Mentoring Committee | same |

| | | | | |
|---|---|---|---|---|
| | | Development & Cancer Biology, OHSU | | |
| 2020 – present | Robert Eil., M.D., Ph.D. | Assistant Professor, Surgery, and Cell, Development & Cancer Biology, OHSU | Member, Mentoring Committee | same |
| 2020 – present | Megan Ruhland, Ph.D. | Assistant Professor, Cell, Development & Cancer Biology, and Dermatology, OHSU | Member, Mentoring Committee | same |

**FORMAL EXTERNAL FACULTY MENTORING**

| Dates | Name | Position while Mentored | Mentoring Role | Current Position |
|---|---|---|---|---|
| 2001 - present | Mikala Egeblad, Ph.D. | Post doctoral Fellow (Werb Lab), UCSF, CA USA; Assistant/Associate/Full Professor, Cold Spring Harbor Laboratory, NY USA | External post-doctoral and faculty mentor | Full Professor, Cold Spring Harbor Laboratory, NY USA |
| 2003-2011 | Sheila Stewart, Ph.D. | Assistant Professor of Cell Biology & Physiology, Washington Univ., St Louis, MO, USA | External faculty mentor | Professor of Cell Biology & Physiology, and Medicine, Washington Univ., St Louis, MO, USA |
| 2005-2015 | Neta Erez, Ph.D. | Post doc. Fellow, Hanahan Lab, UCSF CA USA Assistant Professor, | External post doctoral (2005-2010)/faculty (2010-2015) mentor | Professor and Vice Dean, Faculty of Medicine, Tel Aviv Univ. Tel Aviv, Israel |
| 2005-2021 | Sandra McAllister, Ph.D. | Post doctoral fellow Weinberg lab (2005-2009); Assistant Professor of Medicine, Harvard Medical School (2010-2021) | External faculty mentor | Associate Professor of Medicine, Harvard Medical School; Associate Scientist, Brigham & Women's Hospital, Boston MA USA |
| 2012-2017 | Jennifer Guerriero, Ph.D. | Post doctoral fellow (Letai lab), Dana Farber Cancer Inst; A | External post doctoral mentor | Assistant Professor, Brigham and Women's Hospital, Boston MA USA |
| 2012 - present | Michele De Palma, Ph.D. | Assistant Professor, School of Life Sciences Swiss Federal Inst of Technology (EPFL) Lausanne, Switzerland | External faculty mentor | Associate Professor, School of Life Sciences Swiss Federal Inst of Technology (EPFL); Co-director, ISREC, Lausanne, Switzerland |
| 2021 - present | Evanthia RoussoesTorres, M.D., Ph.D. | Assistant Professor of Medicine, Oncology Univ. of Southern Calif. Los Angeles, CA USA | External faculty mentor/Scientific Advisor | Assistant Professor of Medicine, Oncology Univ. of Southern Calif. Los Angeles, CA USA |

Sabbatical Visitors:

1999 - 2000 Yves DeClerck, M.D. Professor, Univ. of Southern Calif. & Children's Hospital Los Angeles

**SUMMARY OF TEACHING HOURS**

| Academic Year | Teaching/Mentoring Summary | Hours |
|---|---|---|
| 1997/98 | Total hours of teaching /mentoring:<br>Formal class or course teaching hours: | 27<br>2 |

| | | |
|---|---|---|
| | Informal teaching hours including prep time: | 1 |
| | Mentoring hours: | 24 |
| 1998/99 | Total hours of teaching /mentoring: | 71 |
| | Formal class or course teaching hours: | 2 |
| | Informal teaching hours including prep time: | 1 |
| | Mentoring hours: | 68 |
| 1999/00 | Total hours of teaching /mentoring: | 108 |
| | Formal class or course teaching hours: | 4 |
| | Informal teaching hours including prep time: | 2 |
| | Mentoring hours: | 102 |
| 2000/01 | Total hours of teaching /mentoring: | 130 |
| | Formal class or course teaching hours: | 16 |
| | Informal teaching hours including prep time: | 9 |
| | Mentoring hours: | 105 |
| 2001/02 | Total hours of teaching /mentoring: | 201 |
| | Formal class or course teaching hours: | 18 |
| | Informal teaching hours including prep time: | 19 |
| | Mentoring hours: | 164 |
| 2002/03 | Total hours of teaching /mentoring: | 314.5 |
| | Formal class or course teaching hours: | 15.5 |
| | Informal teaching hours including prep time: | 17 |
| | Mentoring hours: | 282 |
| 2003/04 | Total hours of teaching /mentoring: | 402 |
| | Formal class or course teaching hours: | 20 |
| | Informal teaching hours including prep time: | 28 |
| | Mentoring hours: | 354 |
| 2004/05 | Total hours of teaching /mentoring: | 395 |
| | Formal class or course teaching hours: | 17 |
| | Informal teaching hours including prep time: | 28 |
| | Mentoring hours: | 350 |
| 2005/06 | Total hours of teaching /mentoring: | 395 |
| | Formal class or course teaching hours: | 17 |
| | Informal teaching hours including prep time: | 28 |
| | Mentoring hours: | 350 |
| 2006/2007 | Total hours of teaching /mentoring: | 473 |
| | Formal class or course teaching hours: | 45 |
| | Informal teaching hours including prep time: | 28 |
| | Mentoring hours | 400 |
| 2008/2009 | Total hours of teaching /mentoring: | 499 |
| | Formal class or course teaching hours: | 51 |
| | Informal teaching hours including prep time: | 48 |
| | Mentoring hours | 400 |
| 2009/2010 | Total hours of teaching /mentoring: | 499 |
| | Formal class or course teaching hours: | 51 |
| | Informal teaching hours including prep time: | 48 |
| | Mentoring hours | 400 |
| 2010/2011 | Total hours of teaching /mentoring: | 499 |
| | Formal class or course teaching hours: | 51 |
| | Informal teaching hours including prep time: | 48 |
| | Mentoring hours | 400 |
| 2011/2012 | Total hours of teaching /mentoring: | 460 |
| | Formal class or course teaching hours: | 20 |
| | Informal teaching hours including prep time: | 40 |
| | Mentoring hours | 400 |
| 2012/2013 | Total hours of teaching /mentoring: | 500 |
| | Formal class or course teaching hours: | 60 |
| | Informal teaching hours including prep time: | 40 |
| | Mentoring hours | 400 |
| 2013/2014 | Total hours of teaching /mentoring: | 500 |
| | Formal class or course teaching hours: | 60 |

| | | |
|---|---|---|
| | Informal teaching hours including prep time:<br>Mentoring hours | 40<br>400 |
| 2014/2015 | Total hours of teaching /mentoring:<br>Formal class or course teaching hours:<br>Informal teaching hours including prep time:<br>Mentoring hours | 500<br>60<br>40<br>400 |
| 2015/2016 | Total hours of teaching /mentoring:<br>Formal class or course teaching hours:<br>Informal teaching hours including prep time:<br>Mentoring hours | 500<br>10<br>40<br>400 |
| 2016-2022 | Total hours of teaching /mentoring:<br>Formal class or course teaching hours:<br>Informal teaching hours including prep time:<br>Mentoring hours | 515<br>5<br>10<br>500 |

## X. INVITED LECTURES AND SEMINARS

### National and International Symposia and Workshops

**1994**

- *Current Transgenic Technology*, B & K Universal, San Mateo, CA, USA

**1996**

- *Human Tumor Heterogeneity II*: Cytometric Measurement of Growth Regulation and Genetic Alterations: International Society of Analytical Cytometry. Kananaskas, Alberta, Canada.

**1997**

- *GeneMedicine-Boehringer Mannheim Cancer Alliance: Technology Workshop*. Cancún Mexico.
- *Biology of Proteolysis*, Cold Spring Harbor Laboratory, NY, USA
- *Molecular Biology & Pathology of Neoplasia*, AACR, Keystone, CO, USA
- *Matrix Metalloproteinases*, Gordon Research Conference, Proctor Academy, New London, NH, USA

**1998**

- *Proteolysis*, Gordon Research Conference, Colby-Sawyer College, New London, NH, USA
- *Cellular Targets of Viral Carcinogenesis*, AACR Special Conference. Dana Point, CA, USA
- *Mechanisms of Tumor Growth & Invasion Mediated by Proteolysis*, UCSF-Molecular Design Institute. San Francisco, CA, USA
- *Tumor Microenvironment*, Education Session, AACR Annual Meeting. Philadelphia, PA, USA

**1999**

- *Matrix Metalloproteinases*, Gordon Research Conference, Colby-Sawyer New London, NH, USA.

**2000**

- *Epithelial-Stromal Interactions & Tumor Progression Workshop*, National Cancer Inst., Bethesda, MD, USA
- 10th National Conference of the Inflammation Research Association, Hot Springs, VA, USA

**2001**

- *'Meet-the-Expert' Sunrise Session,* AACR Annual Meeting, New Orleans, LA, USA
- *2nd Annual International Protease Society*. Freising, Germany.

**2002**

- *6th International Symposium on Predictive Oncology & Intervention Strategies*, Pasteur Institute, Paris, France
- *Dutch Cancer Society Annual Symposium*, Luntern, The Netherlands
- *Cancer: Genome, Signal & Environment, Takeda Genome Urology International*, Kyoto, Japan
- *Chemotherapy of Experimental & Clinical Cancer*, Gordon Research Conference, Colby Sawyer College, New London, NH, USA
- *Proteolytic Enzymes & their Inhibitors*, Gordon Research Conference, Colby Sawyer, New London, NH, USA
- *From the Cancer Cell to a Tumor - Tumors as Outlaw Organs,* Schilling Research Conference, The American Cancer Society, Aptos CA, USA
- *Cancer Intervention 2002*, Van Andel Research Institute, Grand Rapids, Michigan USA
- *Pathobiochemistry B Study Section Workshop,* Natl. Cancer Institute, Hilton Head, SC, USA

- *Proteases, Extracellular Matrix and Cancer*, AACR Special Conference, Hilton Head Island, SC, USA
- *ECM and Cancer*, Minisymposium, ASCB Annual Meeting, San Francisco, CA, USA

**2003**

- *2nd Annual International Symposium on Epithelial Biology*, Timberline, Oregon USA
- *Matrix Metalloproteinases*, Gordon Research Conference, Big Sky, Montana, USA
- *Angiogenesis & Microcirculation*, Gordon Research Conference, Salve Regina, Newport R.I., USA
- *Inflammatory Cells and Cancer,* Symposium, American Society of Hematology 2003 Annual Meeting, San Diego, CA, USA
- *Validation of a Causal Relationship: Criteria to Establish Etiology*, National Cancer Institute, Cancer Etiology Branch, Washington, DC, USA.
- *Functional Imaging of Proteolysis*, Special Session, ASCB Annual Meeting, San Francisco, CA, USA

**2004**

- 10th International Congress of the *Metastasis Research Society*, 'Progress Against Tumor Progression', Genoa Italy
- Scleroderma Research Foundation Annual Scientific Workshop, San Francisco, CA, USA
- *Systems Biology of Cancer: The Tumor as an Organ,* Symposium, 95th AACR Annual Meeting. Orlando, FL, USA
- *Inflammation and Cancer,* Symposium, 95th AACR Annual Meeting. Orlando, FL, USA
- *Remarkable Role of the Microenvironment in Development and Disease Pathogenesis*, Symposium; Experimental Biology 2004, Sponsored by: Assoc. of Anatomy, Cell Biology and Neurobiology, Washington, D.C., USA.
- *Molecular and Cellular Basis of Disease: Structure and Function of the Extracellular Matrix in Disease: Novel Roles and Regulation of MMPs and TIMPs in Disease,* Symposium; Experimental Biology 2004, Sponsored by: the Am. Society of Investigative Pathology, the American Society for Matrix Biology and the North American Vascular Biology organization. Washington, D.C., USA.
- Pacific Coast Protease Workshop, Half Moon Bay, CA, USA.
- 19th Aspen Cancer Conference: *Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy.* Aspen, CO, USA.

**2005**

- *International Consortium Meeting of the Children's Tumor Foundation: Molecular Biology of NF1, NF2 and Schwannomatosis,* Aspen, CO, USA
- *International Symposium on Systems Genome Medicine - Bench to Bedside,* Institute of Medical Sciences University of Tokyo, Tokyo, Japan
- *Immunotherapy of Cancer*, XI Annual Symposium of the Danish Cancer Society, Copenhagen, Denmark
- *4th General Meeting of the International Proteolysis Society*, Quebec City, Canada
- Keystone Symposia, *The Role of Microenvironment in Tumor Induction and Progression (J5),* Banff, Alberta CANADA
- Keystone Symposia, *Inflammation and Cancer (B8)*, Breckenridge, CO, USA
- *Symposium on Inflammation, Repair and Carcinogenesis in Liver, Pancreas and Colon*. UCSF Liver Center and the Program in Gastrointestinal Cancer of the UCSF Cancer Center, Rohnert Park, CA, USA
- *In the Forefront of Advances in Cancer Research*, Symposium, 96th AACR Annual Meeting. Anaheim, CA, USA
- *Macrophage Symposium*, AMGEN, Seattle, WA, USA
- *Immune Response to Cancer Symposium*, 41st Annual Meeting, American Society Clinical Oncology (ASCO), Orlando. FL. USA
- *Phagocyte*, Gordon Research Conference, New London, CT, USA
- *Mouse Models of Human Cancer Consortium*, Annual Steering Committee Meeting, New Brunswick, NJ USA
- *Matrix Metalloproteinases*, Gordon Research Conference, Big Sky, Montana, USA
- *Annual Buffalo Regional Conference on Immunology*, Buffalo, NY, USA
- Montagna Symposium on *'Tissue repair - molecular mechanisms and clinical challenges'*, Salishan

Lodge, OR, USA
- 4th Annual AACR Conference on *Frontiers in Cancer Prevention Research*, Baltimore MD, USA
- AACR Special Conference, *Cancer, Proteases and the Microenvironment*, Bonita Springs, Florida. USA

**2006**
- Centro Nacional de Investigaciones Oncológicas (CNIO) Cancer Conference: *Inflammation and Cancer*, Mardid SPAIN
- 18th Annual Pezcoller Symposium *'Tumor Microenvironment: Heterotypic Interactions'*, Trento ITALY
- European Association for Cancer Research (EACR) 1st Annual Meeting, Budapest HUNGARY
- XXXIVth Meeting of the International Society for Oncodevelopmental Biology and Medicine (ISOBM: Tumor Biology, Detection and Therapy, Pasadena, CA, USA
- 37th International Symposium of the Princess Takamatsu Cancer Research Fund '*Cancer Cells and Their Microenvironment*', Tokyo, JAPAN
- Timberline Annual Symposium on Epithelial Biology, *Intrinsic and Microenvironmental Regulation of Epithelial Cancer*', Timberline Lodge, Oregon, USA
- Keystone Symposium, *Molecular Targets for Cancer Prevention*, Granlibakken Resort, Tahoe City, CA, USA
- *Inflammation and Cancer,* Symposium, *97th AACR Annual Meeting*. Washington, D.C., USA
- Lineberger Cancer Center's *30th Annual Scientific Symposium*, University of North Carolina, Chapel Hill, North Carolina, USA
- *Vanderbilt-Ingram Cancer Center*, Vanderbilt University, Nashville TN, USA
- *Advances in Neuroblastoma Research 2006*, Los Angeles, CA, USA
- *Genetic, Cellular and Microenvironmental Determinants of Tumor Progression and Metastasis: A 'TPM' Workshop Honoring Martin L Padarathsingh, Ph.D.* TPM Study Section Workshop, Natl. Cancer Institute, Georgetown, VA, USA
- ASCO/Federation of European Societies Symposium: *Inflammation in Cancer Progression*, 2006 ASCO Annual Meeting, Atlanta, GA, USA
- AACR Special Conference, *Mouse Models of Cancer*, Cambridge, MA, USA
- AACR Special Conference, *Tumor Immunology: An Integrated Perspective.* Miami, FL, USA

**2007**
- *4th International Conference on Tumor Microenvironment*, Florence, ITALY
- *2nd International Symposium on Cancer Metastasis and the Lymphovascular System*: Basis for Rational Therapy, San Francisco CA USA
- CNIO – Nature Symposium on "*Oncogenes and Human Cancer*". The Next 25 Years", Madrid SPAIN
- *7th International Symposium on Hodgkin Lymphoma*, Cologne, GERMANY
- *Inflammation and Cancer: From molecular links to bed side*; Inaugural meeting for the *Istituto Clinico Humanitas*, Milan ITALY
- 7th AACR-Japanese Cancer Association Joint Conference: *In the Forefront of Basic and Translational Cancer Research*, Waikoloa, Hawaii, USA
- Keystone Symposium, *'Mouse Models at the Frontiers of Cancer Discovery'*, Whistler, British Columbia, CANADA
- Keystone Symposium '*Inflammation and Cancer'*, Santa Fe, NM, USA
- AAAS Annual Meeting, *Healthy Aging: Inflammation and Chronic Diseases'* Symposium, San Francisco, CA USA
- *Tumor Microenvironment and Tumor-Stromal Interactions* Workshop: Sponsored by Biogen Idec Inc., Oncology Discovery Research, San Diego CA USA
- American Thoracic Society Annual International Conference, *San Francisco Science: Inflammation, Immunity and Signaling*. San Francisco, CA USA
- 22nd Aspen Cancer Conference: Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy, Aspen CO, USA
- Gordon Research Conference, *Epithelial Differentiation & Keratinization*, Bryant University, Smithfield, RI, USA
- AACR, *Frontiers in Cancer Prevention Research Conference*, Philadelphia, PA, USA

- National Cancer Institute Workshop, '*Profiling of Immune Response to Guide Cancer Diagnosis, Prognosis and Prediction of Therapy'*, Bethesda, MD, USA

**2008**

- *7th Annual International Congress on the Future of Breast Cancer*, Kauai, Hawaii USA
- Cancer Research UK Cambridge Research Institute (CRI) Inaugural Annual Symposium, '*Unanswered Questions in the Tumour Microenvironment'*, Homerton College, Cambridge UK
- 5th International Kloster Seeon Meeting, *Angiogenesis: Molecular Mechanisms and Functional Interactions*. Kloster Seeon, GERMANY
- National Cancer Research Institute Annual Conference, Birmingham UNITED KINGDOM
- 47th Midwinter Conference of Immunologists, '*Meeting the challenge: Immunobiology in health and disease*', Asilomar, CA USA
- AACR-TREC-NCI Conference on *Energy Balance and Cancer: Mediators and Mechanisms*, Lansdowne, VA USA
- Keystone Joint Symposium, '*Cell Death in the Immune System / Cell Death and Cellular Senescence'*, Beaver Run Resort in Breckenridge, CO, USA
- Keystone Symposium, '*Inflammation, Microenvironment and Cancer'*, Snowbird Resort in Snowbird, Utah, USA
- *Tumor Microenvironment Symposium*, Stony Brook University, Stony Brook. NY. USA
- Fox Chase Cancer Center 13th Annual Postdoctoral Fellow and Graduate Student Symposium, Philadelphia, PA USA
- DOD BCRP Era of Hope Meeting, Symposium Session: *Immune and Inflammatory Contributions to Breast Cancer*, AND *Era of Hope Spotlight Session*, Baltimore MD, USA
- *AACR Centennial Conference: Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine;* Hyatt Regency Monterey in Monterey, CA USA
- University of Michigan Comprehensive Cancer Center 2008 Fall Symposium, Ann Arbor MI, USA
- *AACR Special Conference*, *Chemical and Biological Aspects of Inflammation and Cancer*, Ko Olina Hawaii, USA
- International Society for Biological Therapy of Cancer (iSBTc), Workshop on Inflammation in Cancer Development, Westin Horton Plaza San Diego, CA USA
- Skirball Symposium, New York University School of Medicine, New York, NY USA
- *AACR Special Conference in Cancer Research, Tumor Immunology: New Perspectives*; Miami FL, USA

**2009**

- 21ST Lorne Cancer Conference, Lorne AUSTRALIA
- 6th International Symposium on the Intraductal Approach to Breast Cancer, Santa Monica CA USA
- International Cancer Conference, *CANCER 2009*, Dublin IRELAND
- 19th Annual BioCity Symposium, *'Tumor Microenvironment in Cancer Progression*", Tirku FINLAND
- European Association of Cancer Research, Special Conference on *Inflammation and Cancer*, Berlin GERMANY
- 7th International Symposium on *Minimal Residual Cancer*, Athens, GREECE
- Tri-Society Annual Conference of the Society for Leukocyte Biology, International Cytokine Society, and the International Society for Interferon and Cytokine Research, Lisbon, Portugal
- 5th International Conference on Tumor Microenvironment, Versailles, FRANCE
- Italian Cancer Society Annual Meeting, Milano ITALY
- *1st Conference on Regulatory Myeloid Suppressor Cells*, Clearwater, FL USA
- Keystone Symposium, '*Extrinsic Control of Tumor Genesis*, Vancouver, British Columbia CANADA
- *Inflammation and Cancer: Novel Aspects of Protumor Immunity,* Major Symposium*,* 100th Annual Meeting AACR, Denver CO USA
- 2nd Annual Retreat of the CCR-NCI Cancer and Inflammation Program, Gettysburg, PA USA
- 24th Annual Aspen Cancer Conference, Aspen, CO, USA
- Geoffrey Beane Cancer Research Symposium: *Inflammation and Cancer*, Memorial-Sloane Kettering Cancer Center, New York NY USA
- AACR Special Conference, Advan*ces in Breast Cancer Research: Genetics, Biology, and Clinical*

*Applications*, San Diego CA USA
- NCI's National Tumor Microenvironment Network, Nashville TN USA

**2010**
- CHUV Research Day, University Hospital (CHUV) and the Faculty of Biology and Medicine, Lausanne, SWITZERLAND.
- *NATURE - CNIO Cancer Symposium* on *Frontiers in Tumour Progression*, Madrid SPAIN
- Joint Keystone Symposia, *Role of Inflammation in Oncogenesis/Molecular and Cellular Biology of Immune Escape in Cancer*, Keystone CO USA
- *3rd Annual Wyeth Discovery Frontiers in Human Disease Symposium*, New York, NY USA
- Annual Meeting of the American Association for Cancer Research, Washington DC USA
- *10th Annual Oncology Research Symposium at MIT's Koch Institute for Integrative Cancer Research*. Boston MA USA
- *Metastasis and the Tumor Microenvironment*, Short Course, Eppley Institute for Cancer Research, Univ of Nebraska, Omaha, NB USA
- *Cancer Cell Biology and Signaling Workshop*, ImClone Systems/Eli Lilly, New York NY, USA
- Center for Excellence in Immunology of the National Cancer Institute Symposium, Bethesda MD, USA
- *25th Annual Critical Issues in Tumor Microenvironment, Angiogenesis and Metastasis*, Boston MA, USA
- Metastasis Research Society-AACR Joint Conference on *Metastasis and the Tumor Microenvironment, Philadelphia, PA USA*
- University of Vermont Cancer Center Clinical and Translational Research Symposium, *Inflammation & Cancer*, Burlington VT, USA
- Saban Research Institute *Annual Symposium, Honoring Yves DeClerck*, University of Southern California and Children's Hospital Los Angeles, Los Angeles CA, USA
- American College of Veterinary Pathologists and American Society for Veterinary Clinical Pathology, Concurrent Annual Meetings, Baltimore MD, USA

**2011**
- Curie Institute Symposium, *Breast Cancer from Biology to Clinics*, Paris FRANCE
- EPFL Inaugural Symposium, *Hallmarks and Horizons in Cancer*, Lausanne SWITZERLAND
- Joint meeting of the International Cytokine Society and the International Society for Interferon and Cytokine Research, Florence, ITALY
- 41st Australian Society for Immunology (ASI), Adelaide, South AUSTRALIA
- 11th Annual Meeting of NANT Consortium Investigators. Biology and Therapy of High Risk Neuroblastoma, Redondo Beach CA, USA
- 2nd International Conference on *Immunochemotherapy: Correcting Immune Escape in Cancer*", Philadelphia PA USA
- *The Biology of Cancer: Microenvironment, Metastasis & Therapeutics*, Cold Spring Harbor Laboratory Meeting Series. Cold Spring Harbor, NY USA
- 2nd NCI Tumor Microenvironment Network Junior Investigator Meeting, Cambridge, MA USA
- AACR Special Conference: *Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy*, Orlando Florida USA
- San Antonio Breast Cancer Conference, San Antonio, Texas USA

**2012**
- International Symposium of the Collaborative Research Center (ISCRC), *Molecular Basis and Modulation of Cellular Interactions in the Tumor Microenvironment,* Cologne, Germany
- Keystone Symposium on *The Role of Inflammation During Carcinogenesis*, Dublin, IRELAND
- Federation of Clinical Immunology Societies (FOCIS) 2012, Improving Human Health Through Immunology, Vancouver, BC, CANADA
- Annual Meeting of the (French) National Institute of Cancer, Plenary session on "*Cancer Immunity and Inflammation*", Paris FRANCE
- 25th International IGB Workshop, organized by the Institute of Genetics and Biophysics "A. Buzzati-Traverso", CNR, Capri, ITALY
- 51st Midwinter Conference of Immunologists, Asilomar, CA USA

- *Tumor Heterogeneity: Challenges and Therapeutic Opportunities*, *103rd Annual Meeting of the AACR*, Chicago, IL USA
- 2012 Scientific Colloquium of the Cancer Immunotherapy Consortium. *Immune Signatures in the Tumor and Beyond: Toward Predictive and Prognostic Markers*. Baltimore Maryland, USA
- AACR Special Conference on Pancreatic Cancer, Lake Tahoe NV, USA
- CELL Symposium, *Hallmarks of Cancer*, San Francisco CA USA
- AACR Special Conference, *Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances*, Miami FL, USA
- Karmonas Cancer Institute, Wayne State University School of Medicine, Annual Symposium: Tumor & Microenvironment. Detroit, MI USA.

**2013**

- Cancer Research Center of Lyon (CRCL), First International CRCL Symposium: *A Focus on Tumor Escape*. Lyon FRANCE
- 9th AACR-Japanese Cancer Association International Conference; Maui, Hawaii. USA
- 3rd Meeting on Immunochemotherapy, Paris FRANCE
- UK National Cancer Research Institute Annual Conference, Liverpool, ENGLAND
- Society of Surgical Oncology Annual Meeting, Washington D.C., USA
- Phagocytes Gordon Research Conference, Waterville Valley, NH, USA
- Salk Institute, Mechanisms and Models of Cancer Annual Symposium, La Jolla CA USA
- Society of Leukocyte Biology, *Regulators of Innate Cell Plasticity Effects in Host Defense*" Newport RI, USA
- 3rd Annual Women's Cancer Research Center Retreat, University of Pittsburgh Cancer Institute, Pittsburgh PA USA
- Society for Immunotherapy of Cancer, 28th Annual Meeting, National Harbor, MD, USA
- San Antonio Breast Cancer Symposium, Discussant, General Session 1. San Antonio, TX USA

**2014**

- 26th Lorne Cancer Conference, Lorne, AUSTRALIA
- 15th International Biennial Congress of the Metastasis research Society, Heidelberg, GERMANY
- *3rd International Conference on Tumor Microenvironment and Cellular Stress: Signaling, Metabolism, Imaging and Therapeutic Targets*, Mykonos, GREECE
- Keystone Symposium, *Inflammatory Diseases: Recent Advances in Basic and Translational Research and Therapeutic Treatments*, Vancouver BC CANADA
- Breast Cancer Issues Conference, Portland, OR USA
- AACR Special Conference, *Cellular Heterogeneity in the Tumor Microenvironment*, San Diego, CA USA
- Keystone Symposium, *Immune Evolution in Cancer*, Whistler BC, CANADA
- AACR 105th Annual Meeting, Major Symposium: *Translating Preclinical Trials in Genetically Engineered Mouse Models toward Clinical Trial*s, San Diego, CA USA
- AACR Annual Meeting, Education Symposium: *Phenotyping Solid Tumor Stroma*, San Diego, CA USA
- PancWest Symposium, Portland, OR USA

**2015**

- Cell Symposia; *Cancer, Inflammation, and Immunity*, Sitges, SPAIN
- 1st International Cancer Immunotherapy Conference: "Translating Science into Survival." Sponsored by, Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR). New York NY USA
- AACR International Conference on Frontiers in Basic Cancer Research. Philadelphia PA USA
- National Cancer Institute Intramural Program Retreat, Washington DC, USA
- 17th Annual Symposium on Anti-Angiogenesis and Immune Therapies for Cancer, San Diego, CA USA
- Predictive Preclinical Models in Oncology conference, Molecular Medicine TriConference, San Francisco, CA USA
- Moores Cancer Center 11th Industry/Academia Translational Oncology Symposium, La Jolla, CA

USA
- Keystone Symposium on *Dendritic Cells and Macrophages Reunited,* Quebec CANADA
- Fundamental Immunology and its Therapeutic Potential, Cold Spring Harbor Laboratory, NY USA
- AACR 106th Annual Meeting, "*Oncology Meets Immunology: Not Just Another Hallmark"*, Philadelphia, PA USA
- New Horizons in Immunotherapy for Head and Neck Cancer, Newberg, OR USA
- NCI-sponsored workshop on Tumor Heterogeneity, Portland, OR USA
- 6th Annual Meeting of the American Pancreatic Association, San Diego CA USA

**2016**
- iMIG 2016, 13th International Conference of the International Mesothelioma Interest Group, Burmingham, UK
- Towards Predictive Cancer Models, ICREA and VHIO Symposium, Barcelona SPAIN
- International Association for Breast Cancer Research (IABCR), Portland OR USA
- NATURE – MSKCC conference "Cancer as an evolving and systemic disease". Memorial Sloan Kettering Cancer Center, New York, NY USA
- Keystone Symposia, "Cancer Pathophysiology: Integrating the Host and Tumor Environments", Breckenridge Co, USA
- AACR 107th Annual Meeting, Major Symposium "*Inflammation and Cancer: Targeting the Microenvironment"*, New Orleans, LA USA
- AAI IMMUNOLOGY 2016, SITC Guest Society Symposium, "Overcoming Failure of Immune Checkpoint Inhibition in Patients with Cancer", Seattle WA USA
- National Cancer Institute, Annual Symposium, '*From Metchnikov to Systems Biology: The Role of Inflammation and Phagocytic Cells in Cancer",* Bethesda, MD USA.
- SITC 31st Annual Meeting, National Harbor, Maryland, USA

**2017**
- BACR Tumour Microenvironment Meeting, Nottingham UNITED KINGDOM
- EACR-AACR-SIC Special Conference: Challenges of Optimizing Immuno and Targeted Therapies: From Cancer Biology to the Clinic. Florence ITALY
- 1st Crick Cancer Meeting, Francis Crick Institute, London UNITED KINGDOM
- Joint Meeting of Bioscience Societies, Buenos Aires, Argentina.
- Immunoterapia: La revolución en el tratemiento del cáncer. Aula Magna-Facultad de Ciencias Exactas y Naturales – University of Buenos Aires, Buenos Aires, ARGENTINA.
- National Cancer Institute, Division of Cancer Biology. Strategy Workshop on 'Tumor Immune Microenvironment (TIME), Rockville, MD USA
- Keystone Symposia, "*Inflammation Driven Cancer: Mechanisms to Therapy/Microbiome in Health and Disease*, Keystone, Colorado USA
- *Frontiers in Cancer Immunotherapy,* New York Academy of Sciences. New York, NY. USA
- Keystone Symposia, "*Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology",* Whistler, British Columbia, CANADA.
- Annual Meeting of the American Association for Cancer Research, Education Session & Major Symposium. Washington, DC, USA
- Cell Symposia: Cancer, Inflammation, and Immunity. San Diego CA, USA

**2018**
- Horizons of Cancer Biology and Therapy – 2018, Swiss Cancer Center, Lausanne, SWITZERLAND
- Keystone Symposium, "Cancer Immunotherapy: Combinations". Montreal, Quebec, CANADA
- 18th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2018). San Francisco, California USA
- Joint Montagna Symposium & Annual PanAmerican Society for Pigment Cell Research Conference, "Melanoma to Vitiligo: The Melanocyte in Biology & Medicine". Glenenden Beach, Oregon USA
- Forbeck Forum, Colorado Springs, CO USA
- AACR Special Conference: '*Tumor Immunology and Immunotherapy*". Miami, FL. USA.
- San Antonio Breast Cancer Conference, San Antonio, TX USA

**2019**

- TEFAF Oncology Symposia, Maastricht University, Maastricht, The Netherlands
- '*Stress and inflammation in Tumor Progression and Metastasis Conference*', Weizmann Institute of Science, Rehovot, ISRAEL
- 50th Princess Takamatsu International Cancer Symposium. Tokyo JAPAN
- Immunology LA Symposium, Los Angeles CA USA
- 2nd Triannual Symposium Highlighting Parnassus Campus Cancer Research in the HDFCCC, Univ., of California, San Francisco, CA., USA
- AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care. Boston MA, USA

**2020**

- 32nd Lorne Cancer Conference. Lorne AUSTRALIA
- EACR-AACR-ASPIC Basic and Translational Research Conference on *Tumor Microenvironment*. Lisbon, PORTUGAL
- Komen Scholar Annual Meeting, Dallas TX, USA
- 26th Congress of the European Association for Cancer Research, *Innovative Cancer Science: Better Outcomes Through Research*. Virtual meeting due to COVID-19.
- Keystone Symposium, *Myeloid Cells and Innate Immunity in Solid Tumors*. Virtual meeting due to COVID-19.
- CRUK Grand Challenge Key Concepts, *STORMing Cancer*. Virtual meeting due to COVID-19.

**2021**

- Tumor Myeloid Microenvironment Directed Therapeutics Summit. Virtual meeting due to COVID-19.
- Breast Cancer Workshop, *Tumor Microenvironment in Breast Cancer Progression*. Experimental Biology 2021. Virtual meeting due to COVID-19.
- **KEYNOTE ADDRESS***, 6th Meeting on the Biology of Cancer: Microenvironment & Metastasis,* Cold Spring Harbor Laboratory Symposium, New York USA
- **KEYNOTE ADDRESS,** *Moving Breast Cancer Treatments Forward*, Jayne Koskinas Ted Giovanis Foundation for Health and Policy, Bethesda MS USA
- **KEYNOTE ADDRESS,** Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting 2021, Washington DC, USA

**2022**

- Stanford Drug Discovery Symposium 2022, Palo Alto CA USA. *Virtual*
- 2022 Annual meeting of the National Foundation for Cancer Research, Washington DC, USA
- USCACA China-US Anti-Cancer Summit, *Virtual*
- HALLMARKS OF CANCER CELL SYMPOSIA, SAN DIEGO CA, USA

**2023**

- **PRESIDENTIAL ADDRESS**, 2023 AACR Annual Meeting, Orlando FL. USA
- **MARGARET L KRIPKE LEGEND AWARD LECTURE,** MD Anderson Cancer Center, Houston TX, USA

**UPCOMING**

**Academic, Biotechnology and Pharmaceutical: Invited Presentations**

**1997**

- Biologic Therapy Research Conference. Univ. of Pittsburgh Medical Center, Pittsburgh, PA, USA
- Immunology Seminar Series. Univ. of Pittsburgh Medical Center, Pittsburgh, PA, USA

**1999**

- Axys Pharmaceuticals, South San Francisco, CA, USA
- Berlex Pharmaceuticals, Emeryville, CA, USA
- Axys Pharmaceuticals, La Jolla, CA, USA
- 14th Annual Excalibur Round Table, American Cancer Society, San Francisco, CA, USA
- Colloquium in Microbiology, Cell and Molecular Biology. San Francisco State Univ., San Francisco, CA, USA

**2000**

- Medical Genome Center, Division of Molecular Medicine, Australian National University, Canberra, A.C.T. AUSTRALIA.

- Chiron Corporation, Emeryville, CA, USA
- Oral and Pharyngeal Cancer Branch/NIDCR, National Institutes of Health, Bethesda, MD, USA
- Fibrogen, Inc., South San Francisco, CA, USA
- Scios Inc., Sunnyvale, CA, USA
- Molecular Biology Department, University of Southern California, Los Angeles, CA, USA

**2001**

- German Cancer Center, Heidelberg, GERMANY.
- MERCK Pharmaceutical, Damstedt GERMANY.
- Dept. of Pediatric Hematology and Oncology, Children's Hospital Los Angeles, Univ. of Southern California, Los Angeles, CA, USA
- Jonnson Comprehensive Cancer Center, Univ. of Calif., Los Angeles, Los Angeles, CA, USA

**2002**

- Institute for Engineering and Medicine, Univ. of Pennsylvania, Philadelphia, PA, USA
- Oncology Grand Rounds, Univ. of Missouri, Columbia, MO.
- Cancer Center, Univ. of California, Davis, Davis CA, USA
- AstraZeneca, Waltham, MA USA
- Pharmacology Seminar Series, Dept. of Pharmacology, Wayne State Univ., Detroit, MI, USA

**2003**

- University of Toronto, Ontario Cancer Institute & Princess Margaret Hospital, Toronto, Ontario, CANADA
- Dept. of Biology, Univ. of Calif., San Diego, San Diego, CA USA
- Tularik, Inc., South San Francisco, CA USA
- Dept. of Cancer Biology's Cancer Metastasis Research Program Seminar Series, M.D. Anderson Cancer Center, Univ. of Texas, Houston, TX, USA
- Dept. of Cancer Biology, Stanford University, Stanford, CA, USA

**2004**

- Cancer Research UK, Barts & The London Queen Mary's School of Medicine & Dentistry, John Vane Science Center, Charterhouse Square, London, UNITED KINGDOM
- Cancer Research UK, London Research Institute, Lincoln's Inn Fields Laboratories, London, UNITED KINGDOM
- Burnham Cancer Institute, San Diego, CA, USA
- The Wistar Cancer Institute, Philadelphia, PA, USA
- Regeneron Pharmaceuticals, Inc. Tarrytown, New York, USA
- Dana Farber Cancer Center, Harvard Medical School, Boston MA, USA
- Indiana University, Herman B. Wells Center for Pediatric Research and Clinical Cancer Center, Indianapolis IN, USA
- Immunology Graduate Program Seminar, Stanford University, Stanford, CA, USA
- University of British Columbia, Department of Biochemistry and Molecular Biology, Vancouver, British Columbia, CANADA

**2005**

- Dept. of Nutritional Sciences & Toxicology, Univ. of Calif., Berkeley, Berkeley, CA USA
- Rigel, Inc., South San Francisco, CA USA
- Dept of Pathology & Lab Medicine, Univ. of California, Los Angeles, Los Angeles, CA USA

**2006**

- Division of Cancer Biology and Angiogenesis in the Department of Pathology at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA USA
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA USA

**2007**

- Angiogenesis and Tumor Targeting Research Unit & Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, Milan, ITALY
- *Lymphoma and Myeloma Conference*, M.D. Anderson Cancer Center, Houston, TX, USA
- University of Minnesota, Dept. of Lab Medicine and Pathology, Minneapolis, MN, USA

- Memorial-Sloan Kettering Cancer Center, Program in Cancer Biology and Aging, New York NY, USA
- Abramson Family Cancer Research Institute and Univ. of Pennsylvania, Division of Hematology-Oncology, Philadelphia, PA USA
- Albert Einstein College of Medicine, New York NY, USA
- Oncology Division Research, Biogen Idec Inc., San Diego, CA USA
- Genentech, Inc. Immunology Program. South San Francisco, CA USA
- University of Iowa Carver College of Medicine, Dept of Pathology, *Pathology Grand Rounds*, Iowa City, Iowa, USA
- Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
- University of Michigan, Program in Immunology and Cancer Research Series, Ann Arbor, MI USA

**2008**

- Institute of Cell Biology, ETH Zurich Switzerland
- Institute of Cancer and the CR-UK Clinical Centre, Barts & The London School of Medicine and Dentistry, London UNITED KINGDOM
- Department of Pathology/UCLA School of Medicine Seminar, Los Angeles CA USA
- University of Virginia, Charlottesville VA, USA
- Department of Cancer Biology, Meharry Medical College, Nashville, TN USA
- University of California, Davis Cancer Center, Sacramento, CA USA
- Department of Immunology, University of Pittsburgh School of Medicine. Pittsburgh, PA, USA
- Cancer Biology Series, Ben May Cancer Center, University of Chicago, Chicago, IL, USA
- National Cancer Institute Center for Cancer Research Grand Rounds Series in Clinical and Molecular Oncology. Bethesda MD, USA

**2009**

- University of South Hampton, UNITED KINGDOM
- The Netherlands Cancer Institute, Amsterdam, THE NETHERLANDS
- University of Michigan, Oral Health Sciences Program and Biomedical Engineering Seminar Series, Ann Arbor, MI USA
- Department of Pharmacology, Wayne State University, Detroit, MI USA
- Molecular Biology Seminar Series, Biochemistry and Molecular Genetics, University of Colorado Health Sciences Center, Aurora, CO USA
- National Institutes of Health/National Cancer Institute, Vascular Biology Seminar Series, Bethesda MD, USA
- Genentech, Inc., Molecular Oncology Program. South San Francisco, CA USA
- Breast Cancer Network of Strength, California Breast Cancer Organizations, Northern California Affiliate, David CA USA
- Fred Hutchinson Cancer Center, Seattle WA USA

**2010**

- Institute of Cancer, Barts & London School of Medicine. London UNITED KINGDOM
- Cold Spring Harbor Laboratory, CSH NY USA
- Albert Einstein College of Medicine, New York, NY USA
- Department of Cell Biology & Physiology Washington University, St Louis, MO USA
- Cancer Center Seminar Series at Burnham Institute for Medical Research, San Diego CA, USA
- Oncology Seminar Series, MedImmune, Gaithersburg, MD, USA
- Immunology Institute Seminar Series, Mt Sinai School of Medicine, NY, NY USA
- San Francisco State University, Fall Seminar Series, San Francisco CA USA

**2011**

- McArdle Seminar in Cancer Biology series, Univ of Wisconsin-Madison, USA
- Duke University Medical Center, Durham, North Carolina USA
- Immunology and Infectious Disease Program, Dept of Veterinary and Biomedical Sciences, Pennsylvania State Univ. University Park, PA USA
- The Huck Institute, University Park, Pennsylvania State Univ. University Park, PA USA
- Weill Cornell Medical College of Cornell University, Center for Vascular Biology, NY USA
- Dana-Farber Cancer Institute and the Dana-Farber Cancer Institute, Boston MA, USA

- Tulane Cancer Center, Hematology & Medical Oncology, Tulane Univ. School of Medicine, New Orleans, LA USA
- Northwestern University Breast Cancer Research Program and Breast Cancer Research Seminar Series, Northwestern University, Chisago IL, USA
- Novartis Institutes for Biomedical Research, Emeryville CA USA
- FivePrime Therapeutics, South San Francisco, CA USA
- Abbott Biotherapeutics, Redwood City CA USA

**2012**

- Excellence in Genetics and Immunology Lecture Series, Complex Traits Group at McGill University, Montreal, Qc, CANADA
- German Cancer Aid, and Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, GERMANY
- Cambridge Research Institute Distinguished Lecture, Cambridge UK.
- Brown Foundation Institute of Medicine, Univ. of Texas, Health Science Center at Houston, Houston TX USA
- Baylor College of Medicine, Houston TX USA
- Harvard Medical School's (HMS) Committee on Immunology Seminar Series
- Massachusetts General Hospital's (MGH) Seminar Series
- University of Rochester, Department of Microbiology and Immunology, Rochester, NY, USA
- Becton, Dickinson and Company, San Jose CA, USA
- Eisai, Inc. Andover MA, USA

**2013**

- University of Colorado, Denver-Anschutz Medical Campus, Cancer Biology Graduate Program Seminar. Denver, CO USA
- Earle A Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Center, Portland OR. USA
- University of Wisconsin, Milwaukee, WI USA

**2014**

- University of Western Australia, Harry Perkins Institute for Medical Research, Seminar Series. Perth, AUSTRALIA
- Netherlands Cancer Institute, Amsterdam, The NETHERLANDS
- Institute Suisse de Recherche Experenentale sur le Cancer (ISREC), Lausanne SWITZERLAND
- Center for Cancer Research, National Cancer Institute, Eminent Lecture Series, Bethesda MD USA
- Huntsman Cancer Center, Salt Lake City UT, USA
- Halozyme Inc., San Diego Ca, USA
- Moffit Cancer Center, Tampa FL, USA
- Stanford University, Departments of Cancer Biology and Immunology, Palo Alto, CA USA
- Infinity Pharmaceuticals, Cambridge MA, USA
- Koch Institute Cancer Center, Massachusetts Institute of Technology, Boston MA, USA

**2015**

- Centre for Cancer Research and Cell Biology, Queen's University, Belfast, N. Ireland
- Dept of Pharmacology, Univ. of Calif., San Diego, La Jolla CA, USA
- The Salk Institute, La Jolla, CA USA
- Helen Diller Family Comprehensive Cancer Center, Univ. of Calif., San Francisco. San Francisco, CA USA
- Fox Chase Cancer Center, Philadelphia PA, USA.
- Frontiers in Oncology series of University of Maryland Greenebaum Cancer Center, UM School of Medicine at Baltimore, Baltimore MD, USA
- Genentech, Inc., S. San Francisco, CA USA

**2016**

- Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas, Madrid SPAIN
- Columbia University Medical Center, Hematology/Oncology Division Grand Rounds. New York, NY USA

**2017**

- Barts Cancer Institute, London UK.
- Aduro Biotech, Berkeley, CA, USA
- Harvard Medical School Immunology Seminar Series. Harvard Medical School, Boston MA USA
- Massachusetts General Hospital, Immunology and Imaging Programs, Boston MA USA
- Cell Signaling Technology, Danvers MA USA
- Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH USA
- The Salk Institute, La Jolla CA, USA.

**2018**

- European Academy of Tumor Immunology (EATI), Centre de Recherche de Cordeliers, Paris, FRANCE.
- Div. of Hematology and Oncology Seminar, Weill Cornell Medicine Medical College, New Your NY USA

**2019**

- Kyoto Prefectural University of Medicine, Kyoto, JAPAN
- Simmons Cancer Center Distinguished Lecture Series, UT Southwestern, Dallas TX USA
- Seattle Genetics, Seattle WA USA
- Roswell Park Cancer Center, Buffalo NY. USA
- Cell Signaling Technologies, Danvers, MA USA
- Department of Cancer Research, Ben May Cancer Center, University of Chicago, Chicago IL. USA
- Perlmutter Cancer Center Research Seminar Series, NYU Langone Health NYU, NY USA

**2020**

- Department of Medical Biology, Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne. Melbourne AUSTRALIA
- AbbVie Oncology Discovery Group, Chicago IL USA. *virtual*
- Breast Disease Research Seminar Series, Baylor College of Medicine, TX USA*. virtual*

**2021**

- Biology of Cancer series, Johns Hopkins University, Baltimore MD USA. *Virtual*
- Breast Disease Research Seminar, Baylor College of Medicine, Houston TX USA *Virtual*

**2022**

- Cell Signaling Technologies, Immunology series. Danvers, MA USA. *Virtual*
- CRUK Manchester Cancer Institute, Manchester UK. *Virtual*
- 31st Annual Short Course on Experimental Models of Cancer, JAX, CT. *Virtual*
- 37th Annual Critical Issues in Tumor Microenvironment, Harvard University. *Virtual*

**2023**

- **KEYNOTE ADDRESS,** 2023 Internal Medicine Research Retreat, University of Texas, MD Anderson Comprehensive Cancer Center. *Virtual*

**UPCOMING**

**Invited Lectures/Seminars: OHSU**

**2012**

- OHSU Knight Cancer Biology Research Group Meeting, OHSU
- OHSU School of Medicine, TEDMED 2012 Live Simulcast
- **KEYNOTE**: OHSU PMCB Annual Retreat
- OHSU MD/PhD Annual Retreat, McMenamins Edgefield, Troutdale, OR.
- OHSU, Medical & Molecular Genetics Weekly Seminar Series; OHSU, Portland, OR, USA.

**2013**

- OCSSB and Dept. of Biomedical Engineering Weekly Seminar Series
- OHSU Knight Cancer Institute, Annual Retreat; OHSU, Portland, OR, USA.

**2014**

- Marquam Hill Lecture; OHSU, Portland, OR, USA.
- Department of Dermatology Grand Rounds, OHSU, Portland, OR, USA.

**2015**

- Department of Surgery Grand Rounds, OHSU, Portland OR USA

**2016**

- OHSU Knight Cancer Institute and Dept. of Surgical Oncology: *Metastatic Colorectal Cancer: Early Detection and Prediction of Recurrence. A State of the Science Symposium.*
- Knight Cancer Institute and Cancer Research UK: Sondland-Durant Early Detection of Cancer Conference, Portland, OR USA
- Mouse Models of Human Disease Research in Progress Forum. OHSU, Portland, OR, USA.

**2017**

- SMMART Retreat, OHSU, Portland, OR, USA.
- Knight Cancer Institute, Cancer Biology and Translational Oncology Program Retreat. OHSU, Portland, OR, USA.

**2018**

- Pancreas Research Meeting group; Brenden-Colson Center for Pancreatic Care. OHSU, Portland, OR, USA.

**2019**

- Pancreas Research Meeting group; Brenden-Colson Center for Pancreatic Care. OHSU, Portland, OR, USA.

**2020**

- Basic & Translational Sciences Seminar Series, OHSU Dept of CDCB and Knight Cancer Institute

**2022**

- Hematology & Oncology Grand Rounds, OHSU School of Medicine and Knight Cancer Institute

**2023**

- Hematology & Oncology Research Fellows, OHSU School of Medicine and Knight Cancer Institute
-

## Invited Lectures/Seminars: UCSF

**1997**

- Breast Cancer SPORE Seminar. UCSF

**1999**

- Cancer Research Institute Retreat, Tomales Bay, CA

**2000**

- Chemistry and Cancer: How Chemistry-Based Tools Are Helping Solve Today's Serious Health Problems, Dev. & Alumni Relations, UCSF
- Oncology Grand Rounds, Department of Hematology and Oncology, UCSF
- PIBS-Cell Biology Seminar Series, UCSF
- Pathology and Lab Medicine Grand Rounds, UCSF
- BMS Student Pizza Talk, UCSF
- Cell Cycle & Dysregulation Club, Comprehensive Cancer Center, UCSF
- Comprehensive Cancer Center Retreat, Granlibakken, Tahoe City, CA

**2001**

- BMS Student Pizza Talk, UCSF
- Pathology and Lab Medicine Grand Rounds, Departments of Medicine and Pathology, UCSF
- UCSF, Cell Biology Retreat, Wilbur Hot Springs, CA, USA
- UCSF TETRAD Retreat, Granlibakken, Lake Tahoe, CA, USA
- UCSF Cancer Research Institute/BMS Retreat, Granlibakken, Lake Tahoe, CA. USA

**2002**

- Current Topics in Medical Science, UCSF Medical Scientist Training Program (M170.09)
- Mouse Models of Human Cancer Program, Comprehensive Cancer Center, UCSF
- Cancer Research Institute Retreat, Santa Cruz, CA

**2003**

- PIBS Student Pizza Talk, UCSF
- Breast Oncology Program, Comprehensive Cancer Center, UCSF
- Comprehensive Cancer Center Faculty Retreat: *Identification and Functional Assessment of Cancer Effectors*, Golden Gate Club, San Francisco CA

**2004**

- BMS Graduate Program Retreat, Granlibakken Tahoe City, CA

**2005**

- BMS Student Pizza Talk, UCSF

**2006**

- *Introduction to Research,* Department of Pathology, UCSF

**2008**

- Division of Experimental Medicine, Divisional Seminar Series, UCSF

**2009**

- Immunology Program, UCSF
- Helen Diller Family Comprehensive Cancer Center *Research Symposium*; UCSF

**2010**

- Bay Area Workshop on Lung Development, Physiology and Cancer, San Francisco CA USA
- UCSF-GIVI Center for AIDS Research (CFAR) Scientific Symposium for 2010: *HIV Infection, Inflammation, and Premature Aging*, San Francisco, CA USA
- Breast Oncology Program Seminar, Helen Diller Family Comprehensive Cancer Center, UCSF

**2011**

- Breast Oncology Program Annual Retreat, Helen Diller Family Comprehensive Cancer Center, UCSF

**2012**

- Breast Oncology Program Annual Retreat, Helen Diller Family Comprehensive Cancer Center, UCSF